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In freshly isolated adult rat cardiac myocytes, adrenaline decreased AMPK activity 
and  Thrl72  phosphorylation  in  AMPK  a-subunits.  This  was  associated  with  a 
decrease in AMPK-driven phosphorylation of acetyl-CoA carboxylase. The effect of 
adrenaline  on AMPK was  rapid with  a half-time of approximately 4 minutes.  The 
inactivation of AMPK by adrenaline was not associated with detectable changes  in 
the  myocyte  contents  of ATP,  ADP,  AMP,  creatine,  and  creatine  phosphate.  The 
effect  of adrenaline  on  AMPK was  preserved under conditions  where  AMPK was 
activated by palmitate or sorbitol, but it was markedly diminished when AMPK was 
activated by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), oligomycin, 
or  phenformin.  The  effect  of adrenaline  was  partially  blocked  by  propranolol  (0- 
adrenergic  antagonist)  or  phentolamine  (ai-adrenergic  antagonist)  while  it  was 
essentially abolished  when  both  blockers  were  present,  suggesting  involvement  of 
both  p  and  ai  adrenergic  receptors.  Isoproterenol  (P-adrenergic  agonist)  and 
phenylephrine  (ai-adrenergic  agonist)  could  also  decrease  AMPK  activity  and 
Thrl72 phosphorylation. Adrenaline did not increase phosphorylation of Ser485/491 
in  the  AMPK a-subunit, but incubation  of a catalytically inactive AMPK complex 
(aipiyl)  with  a  cell  lysate  from  adrenaline-treated  myocytes  increased 
phosphorylation  of  the  AMPK  pi  subunit.  The  effect  of  adrenaline  was  not 
mimicked by conditions that activated cAMP-pathways and was not blocked by an 
inhibitor of calcium/calmodulin-dependent kinase II. However, a phorbol ester could 
mimic  the  effect  of adrenaline  on  AMPK,  suggesting  the  possible  involvement  of 
PKC isoforms.
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13Chapter 1: Introduction
1.1  The physiological roles of cardiac adrenergic receptors
The  stimulation  of cardiac  adrenergic  receptors,  which  occurs  following  increased
sympathetic activity and the increased release of adrenaline from the adrenal medulla
(e.g.  during  exercise  and  fight-or-flight  response),  causes  an  acute  increase  in  the
cardiac  output as  a result of the  increased heart rate (positive  chronotropic  effect),
relaxation rate (positive lusitropic effect), and force of contraction (positive inotropic
effect).  During exercise,  the adrenergic  stimulation of cardiac output, together with
skeletal  muscle  vasodilation,  increases  blood  flow  to  the  active  muscles.  The
sympathetic  activity  is  also  increased  during  conditions  which  cause  a  fall  in  the
arterial  blood  pressure  (e.g.  hemorrhage  and  heart  failure)  and  the  adrenergic
stimulation  of cardiac  output  is  an  important  part  of the  hemodynamic  defence
reaction  which  attempts  to  restore  the  blood  pressure.  The  stimulation  of cardiac
adrenergic  receptors also causes  alterations  in the  cardiac  fuel  metabolism to meet
the increased demand for energy that accompanies the increased contractile function.
The heart contractile activity requires a continuous supply of energy in the form of
ATP. The heart is an omnivorous organ which can utilise a wide range of substrates
including fatty acids,  glucose,  lactate, ketone bodies and amino acids.  However,  in
the  normal-well  oxygenated heart,  approximately 70%  of ATP  is  generated by the
oxidation of fatty acids  and the rest mainly comes  from carbohydrate (glucose and
lactate)  oxidation.  Adrenergic  stimulation  causes  a  rapid  burst  of glycogenolysis
followed  by  stimulation  of exogenous  glucose  uptake,  as  well  as  stimulation  of
14intracellular triacylglycerol  (TAG) turnover and peripheral  lipolysis,  increasing the 
fatty acid supply to the heart (Goodwin et al 1998 a and b; Collins-Nakai et al 1994; 
Williamson 1964; Gold et al 1965; Crass et al 1975). During adrenergic stimulation, 
both  fatty  acid  and  glucose  oxidation  and  glycolysis  are  stimulated,  but  glucose 
utilisation is preferentially increased over fatty acid oxidation, increasing the relative 
contribution of carbohydrate to the overall ATP production (Goodwin et al  1998b; 
Collins-Nakai  et  al  1994).  The  selective  utilisation  of  glucose  is  thought  to  be 
advantageous  in the  situations of increased cardiac workload  as the  ATP  yield per 
oxygen consumed is higher for the oxidation of carbohydrate than that of fatty acids 
(Goodwin et al 1998b).
Plasma  catecholamines  are  elevated  in  the  patients  with  chronic  heart  failure 
(Rundqvist et al 1997) and prolonged stimulation of adrenergic receptors is thought 
to be a factor contributing to the development of pathological hypertrophy.  This  is 
supported  by  numerous  studies  done  with  the  whole  animals  or  isolated 
heart/myocytes (Scheuer  1999) and by the observation that transgenic mice lacking 
endogenous adrenaline and noradrenaline developed less hypertrophy in response to 
pressure overload by aortic constriction (Esposito et al 2002). Cardiac hypertrophy is 
an adaptive response to increased workload and is characterised by increased protein 
synthesis and cardiac myocyte size, and in the case of pathological hypertrophy, it is 
also  associated  with  the  expression  of genes  that are  normally  expressed  in  foetal 
cardiac myocytes, and with structural and metabolic abnormalities including reduced 
fatty  acid  oxidation  and  energy  starvation  (Sugden  and  Clerk  1998a;  Allard  et  al 
2006). Pathological hypertrophy is often associated with myocardial cell death (Dorn 
II and Brown  1999). This effect may be secondary to the metabolic abnormalities in 
the hypertrophied heart but it may also be partly due to direct activation of apoptotic 
signalling by adrenergic receptor stimulation (Krishna Singh et al 2001).
1.2  The adrenergic receptors
The  adrenergic  receptors  are  a  subfamily  of  the  G  protein  coupled  receptors 
(GPCRs),  which  trigger  intracellular  signalling  by  activating  heterotrimeric  G 
proteins  upon  stimulation.  Based  on  the  pharmacological  properties  and  the
15downstream signalling pathways they activate, the adrenergic receptors are classified 
into three types; p, aj and 0.2, each of which is further divided into several genetically 
distinct  subtypes  (Pj,  P2,  P3,  (*ia,  aie,  aio,  a2A,  012B,  and  a2c).  In addition to these, 
there are the aiL receptor,  which  is  a putative a\  subtype  (Muramatsu  et al  1990); 
four splice variants of ajA  (1 a-i to  lA-4) (Hirasawa et al 1995; Chang et al 1998); and 
a putative  ‘P4 receptor’  which is probably the  Pi  receptor (Brodde et al 2001).  The 
cardiac  expression  of the  adrenergic  receptor  types  and  subtypes  depends  on  the 
species and the developmental stage. The heart expresses both p and ai receptors.  012 
receptors do not appear to be expressed in the heart in many species including human 
(Xiang and Kobilka 2003;  Brodde  et al 2001).  In the human heart  a receptors  are 
much less abundant than p receptors (the ratio of p receptors to a receptors is about 
ten  to  one)  (Hoffman  and  Lefkowitz  2002).  However,  the  rat  heart  expresses 
relatively high levels of oil receptors (Michelotti et al 2000). All three ai subtypes are 
expressed in rodent cardiac myocytes with aiB being the most abundant (Yang et al 
1998; Price et al 1994a; Wolff et al 1998). In contrast, the mRNA for aiA (1A-4 and 
1  A-l) predominates in the human heart (Chang et al 1998; Price et al 1994b). In both 
rodents and human, aio is minimally expressed in the heart (Tanoue et al 2002; Yang 
et  al  1999,  Price  et  al  1994a).  Both  pi  and  p2  receptors  are  expressed  in  the  rat 
(Morisco  et al 2001b)  and human heart (Brodde et al 2001).  In both species,  Pi  is 
more abundant than P2 in the adult heart (Brodde et al 2001; Morisco et al 2001b). 
However, the opposite pattern is seen in the neonatal rat heart (Morisco et al 2001b). 
The P3 receptor is also expressed in the human heart (Gauthier et al 1996 and 1998).
All  adrenergic  receptors  have  similar overall  structures  which  are  characterised by
seven  transmembrane  helices  linked  by  three  intracellular  and  three  extracellular
loops (Strosberg et al 1993; Graham et al 1996; Yarden et al 1986). The N-terminal
region,  which  contains  a  number of N-linked  glycosylation  sites,  is  located  at  the
extracellular  side  of the  plasma  membrane  while  the  C-terminal  tail  is  cytosolic.
Mutagenesis and chimeric receptor studies have shown that the amino acid sequence
at  the  intracellular  loop  connecting  the  5th  and  6th  transmembrane  regions  is
important for the interaction of the receptor with G proteins and for the specificity of
the receptor - G protein coupling (Wu et al 1995; Xiao 2001). The C-terminal tail has
a number of important  functions.  It  contains  phosphorylation  sites  for PKA,  PKC,
and  GRK  which  are  involved  in  the  desensitisation  of the  adrenergic  receptors
16(Garcia-Sainz  et  al  2000).  The  P2  receptor  can  be  palmitoylated  at  a  C-terminal 
cysteine  (O'Dowd  et  al  1989).  The  palmitoylation  at  this  site  may  regulate  the 
desensitisation  by  inhibiting  PKA  phosphorylation  of the  receptor  (Moffett  et  al
1996)  or  it  may  be  involved  in  the  association  of hydrophobic  proteins  with  the 
receptor  (Morris  and  Malbon  1999).  The  C-terminal  tail  of the  (3   receptor  also 
contains  a  PDZ  domain-binding  motif (Hall  and  Lefkowitz  2002).  Several  PDZ- 
domain-containing  proteins  including  PSD-95  and  MAGI-2  have  been  shown  to 
associate with the Pi receptor (Hall and Lefkowitz 2002). The P2 receptor associates 
with NHERFP-1  and NHERFP-2 through PDZ domain (Hall and Lefkowitz 2002). 
However, the role of the PDZ domain-binding motif in cardiac adrenergic signalling 
is  not  clear.  The  C-terminus  of the  p2  receptor  also  interacts  with  the  A-kinase 
anchoring proteins (Section  1.5.1) such as AKAP220 (gravin) (Fan et al 2001) and 
AKAP79 (Cong et al 2001).
1.3  GTP-binding protein (G protein) signalling
Adrenoreceptor stimulation causes the activation of G protein signalling through the 
following sequence of events.
1)  In the  absence of agonists,  the adrenoreceptors resonate between the basal  state 
(R)  and  the activated  state  (R*).  Only R*  can  interact with  G protein  and  activate 
downstream  signalling.  This  concept of spontaneous  activation  is  supported by the 
observation that overexpression of some adrenoreceptors (e.g.  P2) (Bond et al  1995) 
can activate downstream pathway in the absence of agonist.  However this does not 
appear  to  be  the  universal  property  seen  in  all  adrenoreceptor  subtypes  as  over­
expression of the Pi receptor does not activate downstream pathway in the absence of 
the agonist (Zhou et al 2000).  The agonist preferentially binds to R*  and locks the 
receptor  in  the  activated  state,  while  the  antagonist  binds  to  both  R  and  R*  with 
similar affinity and blocks agonist binding. A negative agonist preferentially binds to 
R and locks the receptor in the inactive state. In addition to this simplified scheme, 
the  existence  of multiple  R*  states,  which  are  coupled  to  different  downstream 
signalling  events  have been  suggested  for aie  (Perez  et al  1996)  and  p2  receptors
17(Peleg  et al 2001;  Ghanouni  et al 2001).  Adrenergic  receptors  may  also  dimerise 
upon activation (Hebert and Bouvier 1998).
2) The heterotrimeric G proteins are composed of the Ga subunit, which is bound to 
GDP in the basal state,  Gp,  and Gy.  Gp and Gy are tightly associated.  The activated 
receptor acts as a guanine nucleotide exchange factor (GEF) for the heterotrimeric G 
proteins and stimulates the exchange of GDP bound to Ga for GTP. The GTP binding 
lowers the affinity of Ga to Gpy and the receptor, resulting in the dissociation of the 
active  Ga  from  the  complex  and  the  release  of Gpy  dimer.  Both  Ga  and  Gpy  then 
interact and modulate a number of downstream signalling components.
3) Hydrolysis of GTP by the intrinsic GTPase activity of Ga causes re-association of 
Ga with Gpy, terminating Ga and Gpy signalling.
There are four classes of Ga (Gs, Gj, Gq, and G 12/13) which activate distinct signalling 
pathways (Morris and Malbon  1999;  Eschenhagen  1993). The Gs  class includes Gs, 
which  is widely expressed  including the heart, and  G0if,  which is only found in the 
brain and olfactory epithelium. The Gs class of G proteins activates adenylate cyclase
2t (AC), which catalyses the formation of the second messenger cAMP from Mg  ATP. 
cAMP activates PKA which mediates many biological effects of adrenergic receptor 
stimulation. There are nine classes of AC with splice variants (Houslay and Milligan
1997). They are all activated by Gs but they differ in the regulation by other factors 
such as  Ca2+,  PKC and PKA.  The predominant isoforms expressed in the heart are 
ACV and VI (Espinasse et al  1995). ACV and VI are phosphorylated and inhibited 
by PKA (Iwami et al 1995; Chen et al 1997). This may serve as a negative feedback 
mechanism for cAMP and PKA signalling (Bauman et al 2006).  PKC has different 
effects  on ACV and ACVI;  it inhibits ACVI (Lai et al  1997) but it activates ACV 
(Kawabe  et  al  1994).  ACV  and  VI  have  been  reported  to  be  insensitive  to 
Ca2+/calmodulin  (Tanssig  and  Gilman  1985;  Katsushita  et  al  1992),  although  the 
study by Cooper et al suggests  ACV  and  VI  are  inhibited by  Ca2+  (Cooper et al
1994).  Apart  from  activating  AC,  Gs  has  been  suggested  to  directly modulate  the 
activity of the L-type Ca2+ channel (Section  1.5.3) and Na+ channel (Schubert et al 
1989).
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widely  expressed  but  the  heart  does  not  express  Gj_i  (Jones  and  Reed  1987).  The 
predominant Gj expressed in the heart is Gj.2 (Bohm et al 1994). G0 and Gt are found 
in the brain and retina, but a low level of G0 mRNA is also found in the human and 
rat heart (Eschenhagen et al  1993). Gj is inhibitory to ACV/VI (Taussig et al 1994; 
Ran et al 2003).
The  Gq  class  includes  Gq,  Gn,  G 14,  G 15,  and  Gi6.  Gq  and  Gn  are  ubiquitously 
expressed. All members of the Gq class activate phospholipase Cp (PLCP) (Wu et al 
1992). There are four isoforms of PLCp (PLCpi-4). The mRNA for PLCpi and 3 are 
found  in  the  heart  (Schnabel  et  al  1996  and  2000).  PLC  hydrolyses 
phosphatidylinositol-4,5-bisphopsphate  (PtdIns(4 ,5 )P2)  to  generate  diacylglycerol
I
(DAG)  and  inositol-1,4,5-trisphosphate  (IP3).  IP3  causes  Ca  release  from  the  SR 
through  the  IP3  receptor (Section  1.5.3).  DAG  is  an  activator of conventional  and 
novel PKC isoforms (Section 1.5.7).
The G 12/13 class  is widely expressed,  but their function is not well understood.  The 
suggested  downstream  signalling  of  these  G  proteins  includes  Rho  and  PYK2 
(Kurose 2003).
In  addition  to  differences  in  their  downstream  pathways,  these  four  classes  of G 
proteins show differences in their susceptibility to ADP-ribosylation by cholera and 
pertussis toxins and this property is useful for identifying which class of G protein is 
involved  in  a  given  cellular response.  Gs  proteins  are  ADP-ribosylated  by  cholera 
toxin  (CTX),  which  inhibits  the  intrinsic  GTPase  activity.  This  causes  the 
constitutive activation of AC and cAMP generation.  The members of the Gj family, 
except  for  Gz,  are  irreversibly  ADP-ribosylated  by  pertussis  toxin  (PTX)  which 
uncouples  the  G  protein  from the  receptor and  inhibits  signalling through these  G 
proteins.  The  members  of Gq  and  G 12/13 families  are  insensitive  to  both  CTX  and 
PTX.
In  addition to the  four classes  of G proteins  described  above,  a  G protein with an
unusually  high  molecular  weight  (78  kDa)  termed  Gh  has  been  isolated  from  the
bovine heart (Baek et al 1993). This G protein has been shown to associate with the
19ai  receptor and PLC and mediate the activation of PLC by ai  agonists in vitro (Das 
et al 1993; Baek et al 1993).
Like  Ga,  Gpy  regulates  activity  of a number of effectors  including  class  IB  PI3K 
(Section  1.5.5),  AC  isoforms  (Taussig and  Gilman  1995),  and  PLCp  (Smrcka and 
Stemweis  1993). The effect of Gby on ACV/VI is controversial. Bayewitch et al have 
reported  that  ACV  and  VI  are  inhibited  by  Gpy  (Bayewitch  et al  1998),  although 
others  found  no  effect  of  Gpy  on  ACV  and  VI  (Taussig  and  Gilman  1995).  In 
contrast, Gao et al have recently reported that Gpy enhances activity of ACV and VI 
in  the  presence  of Gas  or  forskolin  (Gao  et al 2006).  PLCp  isoforms,  particularly 
PLCp2  and  3  are  activated  by  Gpy  (Park  et  al  1993).  Gpy  also  plays  a  role  in 
desensitisation by recruiting PARK to the membrane (Pitcher et al 1995).
Both pi and p2 receptors are coupled to Gs and the stimulation of both receptors cause 
activation of AC  and cAMP accumulation (Chesley et al 2000;  Bartel  et al 2003). 
Several  lines of evidence suggest that the  P2 receptor is additionally coupled to  Gj. 
Some  downstream  effects  of selective  P2  stimulation,  such  as  activation  of PI3K 
(Chesley et al 2000) and PLA2 (Pavoine et al 1999), are PTX sensitive. PTX has also 
been shown to enhance the stimulation of contraction by the P2 receptor (Xiao et al
1995). Lastly, in mouse cardiac myocytes, association of the p2 receptor and Gj (Gj-2 
and  Gi.3)  has  been  demonstrated  by  photoaffinity  labelling  and  by 
immunoprecepitation  using  a  Gj  specific  antibody  (Xiao  et  al  1999).  Like  the  P2 
receptor,  the  P3  receptor also  appears  to  dually couple  to  both  Gs  and  Gj  (Section 
1.4.1).
The  ai  receptors  are  coupled  to  multiple  G  proteins.  A  transient  transfection
experiment with COS-7 cells showed that all three ai  subtypes can couple to Gq and
G 11  to activate PLCpl  in response to noradrenaline (Wu et al  1992).  However, the
three  subtypes  showed  a difference  in the coupling to  G 14  and Gi6;  die coupled to
both G ]4 and Gi6, aiA  only coupled to G 14, and dm did not couple to G 14 or Gi6 (Wu
et  al  1992).  The  four  splice  variants  of aiA   all  couple  to  the  PLC-Ca2+  pathway
(Hirasawa et al  1995;  Chang et al  1998).  The heart ai  receptor may also associate
with  Gh  (Baek et al  1993).  Some downstream effects  of cardiac  ai  stimulation are
PTX sensitive (Steinberg et al 1985) or blocked by inhibitors of G 12/B (Maruyama et
20al 2002), indicating G; and G 12/13 are also downstream of ai  receptors. Gallego et al 
observed that stimulation of the cardiac ai receptor (aiA  and aie) caused a P receptor- 
independent  (but  Gs-  and  AC-dependent)  increase  in  cAMP  and  PKA  activity 
(Gallego  et al 2005).  This  effect  was  only  seen  in  intact  cells,  and the  effect was 
inhibited  by  disrupting  the  cytoskeleton  by  colchicine,  indicating 
compartmentalisation of this  effect  (Gallego  et al 2005).  It  was  also  demonstrated 
that phenylephrine increased physical association of Gs with the ai receptor (Gallego 
et al 2005).
G protein signalling is regulated by a number of mechanisms. Prolonged stimulation 
of  adrenergic  receptors  reduces  the  responsiveness  of  the  receptors  to  activate 
downstream signalling pathways by the process termed desensitisation. This process 
involves  phosphorylation  of the  receptors  by  PKA,  PKC  and  a  group  of kinases 
called the G protein receptor kinases (GRKs) (Benovic et al 1985; Diviani et al 1996 
and  1997;  Guimond  et al 2005;  Lattion et al  1994).  Phosphorylation of adrenergic 
receptors  by  PKA,  PKC,  and  GRKs  inhibits  interaction  of the  receptors  with  G 
proteins and inhibits stimulation of G protein signalling (Benovic et al 1985; Diviani 
et  al  1996,  Guimond  et  al  2005).  The  phosphorylation  by  GRKs  causes  agonist- 
specific (homologous) desensitisation, while PKA and PKC phosphorylations cause 
non-agonist  specific  (heterologous)  desensitisation  (Lattion  et  al  1994).  Several 
isoforms  of GRK are expressed  in the rat heart including GRK2  (also known  as  P 
adrenergic  receptor kinase (PARK)),  3,  5,  and  6  (Inglese  et al  1993).  Studies with 
mice over-expressing different GRKs suggested that distinct GRKs may be involved 
in desensitisation of the different adrenoreceptor subtypes  in vivo.  The aie receptor 
appears  to  be  phosphorylated  mainly  by  GRK3  in  vivo  (Eckhart  et  al  2000). 
However,  the  over-expression  of GRK3  did  not  affect  p  signalling  (Eckhart  et al
2000), which was attenuated by over-expression of GRK5 (Rockman et al 1996). In 
addition  to  inhibiting  G  protein  coupling,  the  phosphorylation  of the  receptors  by 
GRKs and possibly PKC (Fonseca et al 1995) also leads to the internalisation of the 
receptors  by  recruiting  P-arrestin,  which  binds  a  number  of proteins  involved  in 
endocytosis including clathrin, clathrin adaptor AP-2, NSF, and ARF6 (Laporte et al 
1999 and 2000; McDonald et al 1999; Claing et al 2001).
21Another key regulatory step in G protein signalling is the hydrolysis of GTP bound 
to the active Ga by the intrinsic GTPase activity of Ga. This process is accelerated by 
the  GTPase  activator  proteins  (GAPs)  which,  by  doing  so,  negatively  regulate  G 
protein  signalling.  PLCp  appears  to  act as  a GAP  for Gq  (Berstein et al  1992).  A 
class  of GAPs  called the regulators  of G-protein  signalling  (RGS)  are  a family of 
proteins that share a conserved RGS domain that can accelerate the GTPase activity 
of Ga(Wieland and Mittmann 2003). In the mammalian heart, at least 13 members of 
the  RGS  protein  family  are  expressed  including  the  most-well  studied  RGS4 
(Wieland  and  Mittmann  2003).  The  majority  of RGS  proteins  identified  to  date, 
including RGS4, enhance the GTPase activity of Gj/0 and Gq/i i  and inhibit signalling 
downstream of these G proteins (Wieland and Mittmann 2003).  Some RGS proteins 
including RGS3, which is expressed in the heart, also inhibit signalling mediated by 
Gpy  by binding and  sequestering these  subunits  (Shi et al 2001).  GRK2  contains  a 
domain  similar to  the  RGS  domain  which binds  Gq/n  and  it  seems  to  regulate  Gq 
signalling  by  sequestering  the  activated  Gq  (Kozasa  2001).  RGS-PX1  is  another 
protein containing a RGS-like domain. This protein acts as a GAP for Gs and inhibits 
isoproterenol-induced  AC  activation  in  neonatal  rat  cardiomyocytes  (Zheng  et  al 
2001).  Another  RGS-like  domain-containing  protein  pll5-Rho-GEF  is  a  specific 
GAP for G 12 and Gn (Kozasa et al 2001).
G protein signalling may also be regulated by direct post-translational modifications 
of the G proteins.  The palmitoylation of Ga  has been shown to protect Gz and  Gj_i 
from GAP activity and RGS4, respectively (Tu et al  1997).  The phosphorylation of 
Gj.2  by  PKC  may  block  the  effect  of Gj_2  to  inhibit  AC  (Bushfield  et  al  1990; 
Strassheim and Malbon  1994). Gq/n  has been reported to be tyrosine phosphorylated 
by an unidentified tyrosine kinase upon receptor activation and this phosphorylation 
promotes the interaction of Gq/n with the receptor (Umemori et al 1997).
1.4. An overview of cardiac adrenergic signalling
This section briefly outlines signalling pathways involved in the different biological 
effects of cardiac adrenergic receptor stimulation.
221.4.1  Contraction
The adrenergic stimulation of contractile function is predominantly regulated by the 
pi  receptor  through  an  increase  in  cAMP  and  activation  of  PKA,  which
94-
phosphorylates key proteins involved in Ca  homeostasis and contraction including 
the L-type Ca2+ channel, the ryanodine receptor, phospholamban (PLB), and troponin 
I and C proteins.  Phosphorylation of the L-type Ca2+ channel  increases Ca2+ influx 
across the sarcolemma which triggers Ca2+-induced Ca2+ release from the SR through 
the ryanodine receptor,  leading to an increase in the cytosolic  Ca2+  and contractile 
amplitude.  PKA  may  also  contribute  to  this  process  by  increasing  the  open 
probability of the ryanodine receptor (Bers 2002).  The lusitropic  effect  is due to a 
PKA phosphorylation of PLB (at PKA site, Seri6) and troponin I which accelerates
9+
Ca  sequestration  into  the  SR  and  reduces  the  sensitivity of the  myofilament  for
94-
Ca  , respectively.  Some of these PKA targets are also phosphorylated by CAMKII. 
CAMKII  has  been  shown  to  increase  the  Ca2+  current  through  the  L-type  Ca2+ 
channel and the relaxation rate through the phosphorylation of PLB at the CAMKII 
site,  Thrl7  (Wang  et  al  2004).  While  the  cAMP  level  declines  quickly  after 
adrenergic stimulation, CAMKII activity is sustained for longer (Wang et al 2004). 
Thus,  CAMKII  has  been  suggested  to  be  the  primary  regulator  of  excitation- 
contraction coupling during prolonged Pi stimulation (Wang et al 2004).
Stimulation of the p2 receptor also causes an increase in cAMP through the activation
of Gs. However, unlike stimulation of the Pi  receptor, which causes a global increase
2+
in cAMP and leads to PKA phosphorylation of membrane targets (e.g. Ca  channel) 
as well as intracellular targets (e.g. PLB), stimulation of the p2 receptor in adult rat 
cardiac myocytes has been shown to cause a compartmentalised increase in cAMP
9_i_
which increases PKA phosphorylation of the L-type Ca  channel without affecting 
PLB phosphorylation (Jo et al 2000). Consistent with the lack of phosphorylation of
2_j_
PLB,  the  p2  receptor  stimulation  increased  the  Ca  transient  and  contraction 
amplitude without increasing the relaxation rate  in these myocytes  (Jo et al 2002). 
The  exact  mechanism  responsible  for  the  compartmentalisation  of the  P2  cAMP 
signalling is unknown, but the activation of Gj and PI3K, which is downstream of Gj, 
are essential for this effect (Jo et al 2000). Both the p2 receptor and Gj are primarily
23found in calveoli (Rybin et al 2000),  suggesting the cAMP accumulation by the  p2 
receptor  is  confined  to  the  calveoli.  However  this  compartmentalised  cAMP 
signalling  apparently  does  not  exist  in  human  cardiac  myocytes  which  showed 
phosphorylation  of PLB  by  PKA  after  0 2  stimulation  (Kaumann  et  al  1996).  In 
contrast to  rat and human cardiac  myocytes,  stimulation  of the mouse  p2  receptor 
does not cause an inotropic response despite a dual coupling of the  0 2 receptor with 
Gs  and  Gj  (Xiao  et  al  1999).  Thus,  in  mouse  cardiac  myocytes,  a  P2-mediated 
increase in cAMP appears to be completely negated by simultaneous activation of Gj.
The signalling of the cardiac p3 receptor and its role in contractile activity and other 
processes are not well-understood.  However several studies have demonstrated that 
selective  stimulation  of  the  cardiac  p3  receptor  causes  a  small  decrease  in 
contractility  (Devic  et  al  2001;  Gauthier  et  al  1996  and  1998).  This  effect  is 
attributed  to  the  Gj-dependent  activation  of nitric  oxide  synthase  (Gauthier  et  al
1996). The p3 receptor also appears to be coupled to the Gs-cAMP pathway because 
selective stimulation of the P3 receptor in the presence of PTX increased contractility, 
although this effect would be masked by the inhibitory effect through Gj during the 
normal  stimulation  of  the  receptor  (Devic  et  al  2001).  The  P3  regulation  of 
contraction may play a role  in the  deterioration of heart contractile activity during 
chronic  adrenergic  stimulation because,  unlike  pi  and  p2  receptors,  the  p3  receptor 
lacks the recognition motif for PARK and PKA which is involved in desensitisation 
(Strosberg et al 1993).
In  addition  to  Pi  receptors,  ai  receptors  also  contribute  to  contractile  activity  by 
increasing Ca2+ and activating PKC, which has been implicated in the regulation of 
Ca2+ homeostasis (Kamp et al 2000),  in modulation of properties of the contractile 
proteins (Takeishi et al 1998), and in ionic balance (Gambassi et al 1998 and 1992). 
However,  ai  receptors  are  generally  considered  to  play  a  minor  role  in  the 
stimulation of contractile activity.  The effect of ai  receptors on contractile function 
also  appears  to  depend  on  the  species  and  the  developmental  stage  (Tanoue  et al 
2003).
241.4.2  Fuel catabolism
Adrenergic  receptor  stimulation  increases  fuel  catabolism  via  both  ai  and  p 
receptors. Key regulators of this process are PKA and Ca2+. PKA phosphorylates and 
activates  key  enzymes  in  catabolism  including  phosphorylase  kinase  (Hayes  and 
Mayer  1981),  phosphofructokinase  2  (PFK2)  (Depre  et  al  1998)  and  TAG  lipase 
(Small  et al  1989).  PKA has also been shown to phosphorylate and inactivate the 
cardiac isoform of acetyl-CoA carboxylase (ACC) (ACC2/ACC280) in vitro (Boone 
et al 1999). ACC2 plays an important role in the regulation of the p-oxidation of long 
chain  fatty  acids  in  muscles  by  synthesising  malonyl-CoA,  a  metabolite  which 
inhibits  the  translocation  of  long  chain  fatty  acids  into  the  mitochondria  for  p- 
oxidation  by  allosterically  inhibiting  carnitine  palmitoyltransferase  1   (Kemer  and 
Hoppel  2000).  A  decrease  in  malonyl-CoA  has  been  observed  during  adrenergic 
stimulation,  consistent  with  a  stimulation  of  fatty  acid  oxidation  (Goodwin  and 
Taegtmeyer  1999).  However,  whether ACC2  is  inactivated by PKA  in  vivo  is not 
clear. Although Boone et al observed phosphorylation of ACC2 in cardiac myocytes 
in response to isoproterenol, partially purified ACC from isoproterenol-treated cells 
did  not  show  a  change  in  catalytic  activity  (Boone  et  al  1999).  Goodwin  and 
Taegtmeyer also did not observe any change in ACC activity despite a decrease in 
malonyl-CoA  during  adrenergic  stimulation  in  the  perfused  heart  (Goodwin  and 
Taegtmeyer 1999). These investigators attributed the decrease in malonyl CoA to the 
activation of malonyl-CoA decarboxylase (MCD) (Goodwin and Taegtmeyer  1999). 
However, how MCD is activated during adrenergic stimulation was not investigated 
in  this  study.  The  increase  in  Ca2+  which  occurs  after  p  receptor  or  ai  receptor 
stimulation  activates  a  number  of  metabolic  enzymes  including  phosphorylase 
kinase,  pyruvate  dehydrogenase  (through  pyruvate  dehydrogenase  phosphatase), 
NAD+-isocitrate  dehydrogenase,  and  2-oxoglutarate  dehydrogenase  (Werth  et  al 
1982;  McCormack and Denton  1979;  Denton et al  1978;  McCormack and England 
1983;  Denton  et  al  1996).  The  ai  receptor  has  been  reported  to  activate  PFK  in 
perfused hearts by Ca2+-dependent process, although PFK was not directly activated
by Ca2+ (Patten et al  1982). The ai  receptor may also contribute to the activation of
2+ mitochondrial  enzymes  by activating the mitochondrial  Ca  uniporter (Kesser and 
Crompton  1981). The mechanism of the adrenergic stimulation of glucose uptake is
25not completely understood.  Both ai  and p receptors are likely to be involved in the 
stimulation of Glut4 translocation and glucose uptake (Rattigan et al 1986; Fischer et 
al 1996a and 1996b; Clark and Patten 1984). The proposed downstream pathways for 
both  receptors  include  Ca2+  (Clark  and  Patten  1984;  Rattigan  et  al  1986)  and 
PI3K/PKB (Doenst and Taegtmeyer  1999;  Morisco et al 2005).  PKC has also been 
implicated in the stimulation of glucose and fatty acid uptake in the heart (Luiken et 
al 2004).
1.4.3  Hypertrophy
The role of the ai  receptor and Gq signalling in the development of hypertrophy is 
well-documented  (reviewed  by Dorn  II  and Brown  1999).  Although the  signalling 
pathways  downstream  of Gq  are  complex  and  incompletely  understood,  PKC  and 
MAPKs (ERK, p38, and JNK) have been identified as key regulators of Gq-mediated 
hypertrophy (Dorn II and Force 2005;  Michel et al 2001;  Steinberg 2002).  MAPKs 
regulate  a  wide  range  of transcription  factors  (Michel  et al 2001).  PKC  regulates 
activities of transcription factors such NFATc3  (through inhibition of GSK3) (Dorn 
II  and  Force  2005),  class  II  histone  deacetylase  (Vega  et  al  2004),  and  MAPKs 
(Section  1.5.9).  There  has  been  interest  in  the  identification  of the  ai  receptor 
subtypes responsible for hypertrophic growth. Although aiA, am, and a )D, all couple 
to Gq, a number of studies suggest that the signalling by these subtypes are distinct. 
Transfection  experiments  using  PC 12  cells  showed  the  three  subtypes  display
2_j_
differences in the efficiency of inositol phosphate production and Ca  release, with 
efficacy  in  the  order;  aiA>am>aiD  (Zhong  and  Minneman  1999).  In  the  same 
experiments, the three subtypes also showed differences in the coupling to MAPKs. 
While ERK,  JNK,  and P38  were all  activated by aiA,  am  only activated ERK and 
P38  (Zhong  and  Minneman  1999).  The  am  receptor  did  not  cause  significant 
activation of MAPKs (Zhong and Minneman 1999). In the rat heart, phospholipase D 
(PLD), the enzyme though to be important for the sustained activity of PKC (Section 
1.5.7), was activated by aiA  and am receptors, but not by am (Mier et al 2002). The 
three subtypes also show distinct subcellular localisations; ajA  is localised at both the 
plasma  and  intracellular  membranes;  am  is  localised  primarily  at  the  plasma 
membrane; and am is confined to intracellular membranes (Plascik and Perez 2001).
26Of the three  subtypes,  am  is  generally not thought to play a major role  in cardiac 
adrenergic  signalling  due  to  its  low  abundance  and  poor  coupling  to  downstream 
signalling pathways. In neonatal cardiac myocytes, the selective activation of aiA has 
been shown to be sufficient to cause hypertrophy (Autelitano and Woodcock  1998). 
There  is  a  controversy  over  the  relative  importance  of  the  am  receptor  in 
hypertrophy.  Transgenic  mice  over-expressing  constitutively  active  am  developed 
cardiac hypertrophy (Milano et al  1994b), but over-expression of the wild type am 
was found to be insufficient to cause hypertrophy (Akhter et al 1997). Moreover, in 
neonatal  rat  cardiac  myocytes,  the  phenylephrine-induced  increase  in  protein 
synthesis  was  inhibited  by  an  aiA  antagonist  but  it  was  potentiated  by  am 
antagonists, suggesting that am signalling may inhibit hypertrophic signalling by the 
a ^  receptor (Deng et al 1998).
In addition to the ai receptors, stimulation of the P receptors by the general p agonist 
isoproterenol has also been demonstrated to cause hypertrophy in  vitro and  in vivo 
(Stein et al  1996; Morisco et al 2001b).  This effect seems to be mediated primarily 
via the pi receptor as the stimulation of hypertrophy by isoproterenol was unaffected 
by P2 antagonists and over-expression of the p2 receptor did not cause hypertrophy in 
mice  (Morisco  et al 2001b;  Milano et al  1994;  Liggett et al 2000).  The  Pi  and  ai 
receptors  appear  to  promote  hypertrophy  via  distinct  pathways.  The  Pi  effect  is 
primarily  mediated  by  the  Ca2+-activated  phosphatase  calcineurin  (PP2B),  which 
increases  nuclear  translocation  of  NFAT,  by  CAMKII,  which  regulates  MEF2 
through  class  II  histone  deacetylase,  and  by  PKB,  which  regulates  transcription 
factors  such  as  GATA4  and  NFAT3  (Morisco  et  al  2000;  Morisco  et  al  2001a; 
Sucharov  et  al  2006).  PKB  is  also  an  activator  of mTOR  signalling  and  protein 
translation (Proud 2004).
1.4.4  Apoptosis
The  stimulation  of apoptosis  by  prolonged  adrenergic  stimulation  appears  to  be 
mediated mainly by the  Pi  receptor (Zhu et al 2003).  The pathways  linking the  Pi 
receptor  to  apoptosis  is  not  well-understood.  The  involvement  of PKA  has  been 
demonstrated by some investigators (Iwai-Kanai et al  1999), but this is disputed by
27Zhu et al who showed that pi receptor-mediated apoptosis was insensitive to specific 
PKA inhibitors but was blocked by chelating Ca2+ or by inhibiting CAMKII (Zhu et 
al 2003). The involvement of calcineurin in (3  receptor-mediated apoptosis has also 
been reported (Saito et al 2000).  Stimulation of the P2 receptor has been reported to 
protect  cardiac  myocytes  from  apoptosis  caused  by  the  Pi  stimulation  or  H2O2 
(Chesley et al 2000; Zhu et al 2001). The anti-apoptotic effect of the P2 receptor was 
attributed to the P2 specific activation of Gj/PI3K/PKB pathway (Chesley et al 2000; 
Zhu et al 2001). However a later study showed that PI3K was activated as effectively 
by  the  Pi  receptor  (Leblais  et  al  2004),  suggesting  that  some  other  factors  are 
involved in this effect or that different isoforms of PI3K are activated by the Pi  and 
P2  receptors.  Although over-expression of Gq in the heart causes  apoptosis in mice 
(Adams et al  1998), in isolated myocytes the ai  receptor has been reported to have 
either  no  effect  on  apoptosis  (Communal  et  al  1998)  or  even  to  have  an  anti- 
apoptotic effect (Iwai-Kanai et al  1999). Although MAPKs are known as regulators 
of apoptosis, the precise roles of MAPKs in the adrenergic regulation of apoptosis in 
cardiac  myocytes  are  not  well-understood  (Bishopric  et  al;  Krishna  Singh  et  al
2001). However, the observations that the anti-apoptotic effect of the ai receptor was 
blocked  by  ERK  inhibition  (Iwai-Kanai  et  al  1999)  and  that  p  receptor-mediated 
apoptosis was potentiated by p38  inhibition (Communal et al 2000) have suggested 
anti-apoptotic roles of ERK and p38 in cardiac myocytes.
1.5 Signalling components
1.5.1  Protein kinase A (PKA)
At the unstimulated level of cAMP, PKA exists as a holoenzyme consisting of two 
catalytic  (C)  and  two  regulatory  (R)  subunits.  The  C  subunit  is  a 40  kDa  Ser/Thr 
kinase  that  transfers  y  phosphate  of  ATP  to  substrates  containing  -RRXSX- 
consensus  sequence.  Three  isoforms  of the  C  subunit  encoded  by  different  genes 
have been characterised; Ca, Cp, and Cy (Francis and Corbin 1994). Ca and Cp show 
a  high  sequence  similarity  and  are  ubiquitously  expressed  while  Cy  shows  less 
similarity  and  is  only  expressed  in  the  testis  (Francis  and  Corbin  1994).  In  the 
holoenzyme,  the  C  subunits  are  inactivated  by  interaction  with  the  autoinhibitory
28region of R subunits.  Each of the R subunits has two cAMP binding sites, and the 
binding  of cAMP  to  these  sites  decreases  the  affinity  of the  R  subunit  for the  C 
subunit, releasing the free R subunits and the active C subunits. Four isoforms of the 
R subunit have been identified and they are divided into two types; RI (43 KDa) and 
RII (25 kDa) (Francis and Corbin 1994). RIa and Rlla are the predominant isoforms 
and  are  ubiquitously  expressed,  while  Rip  and  RIip  are  expressed  in  the  central 
nervous  system and reproductive tissue (Francis and Corbin  1994).  The R subunits 
form  homodimers  through  the  amino  terminal  dimerisation  domain.  An  important 
difference between RI and RII is that RI is predominantly found in cytosol whereas 
RII is associated with the membrane (Scott  1991). This difference in the subcellular 
localisation  is  attributed  to  the  preferential  interaction  of RII  with  the  A-kinase 
anchoring proteins  (AKAPs).  Apart from regulation by the  R subunits  and  cAMP, 
PKA activity is known to be regulated by several other factors including the nuclear 
protein  kinase  inhibitors  (PKIs)  a,  p,  and  y,  which  bind  to  PKA  and  inhibit  its 
activity  (Koppemd  et  al  2003).  PKIs  also  assist  nuclear  export  of the  C  subunit 
(Koppemd et al 2003). The C subunit can be inactivated by glutathionylation of Cys 
199 which may occur during oxidative stress (Humphries et al 2002). .
AKAPs play a key role  in  PKA  signalling by giving  specificity to  the very broad
action of PKA (Ruchr et al 2004). PKA is tethered to discrete subcellular locations,
usually its targets, by interaction with different AKAPs containing unique subcellular
targeting  domains  (Ruchr  et  al  2004).  For  example,  AKAP15/18,  Yotiao,  and
AKAP79/150 tether PKA to L-type Ca2+ channel, potassium channel KCNQlIk, and
ACV/VI, respectively (Marx et al 2002; Fraser et al 1998; Gray et al 1997; Bauman
et al 2006). Most AKAPs bind the RII homodimer by interaction of the amphipathic
helix with the amino terminal domain of RII (Dodge Kafka et al 2006). As well as
anchoring  PKA  to  its  targets,  AKAPs  also  act  as  signalling  processing  units  by
binding  other  signalling  enzymes  such  as  phosphodiesterases  (PDEs)  and
phosphatases.  Localised clustering of PDEs and PKA allows differential control  of
PKA activity in different subcellular locations.  Similarly, clustering of phosphatases
and  PKA  targets  by  AKAP  allows  localised  control  of the  duration  of the  effect
initiated by PKA.  The activity of PDEs or phosphatases in a given AKAP complex
may be regulated by AKAP, PKA or some other proteins present in the complex. For
example,  AKAP220, which binds PKA and PP1,  is a competitive inhibitor for PP1
29(Schillace  et  al  2001).  Muscle-selective  AKAP  (mAKAP),  which  is  found  at  the 
nuclear envelope  and  SR of cardiac  myocytes  forms  a  complex  with  a number of 
proteins  including PKA,  ryanodine receptor,  PDE4D3,  PP1,  PP2A,  PP2B, nesprin- 
la, Epac, MEK5 and ERK5 (Kapiloff et al 2001; Marx et al 2000; Dodge et al 2001; 
Dodge Kafka et al 2005). PDE4D3 is phosphorylated at two sites by PKA, resulting 
in  increased  activity and  increased binding affinity for mAKAP  (Sette  et al  1996; 
Carlisle  Michel  et  al  2004).  PDE4D3  is  also  under  control  of  ERK5  which 
phosphorylates and inhibits it (Dodge Kafka et al 2005).  In addition to providing a 
scaffold for assembly of the PKA signalling complex, some AKAPs also play a more 
direct signalling role. For example, AKAP-lymphoblastoma crisis (Lbc), which binds 
PKA and Gai2, is a Rho selective guanine nucleotide exchange factor (Diviani et al
2001).
1.5.2 Exchange Protein Directly Activated by cAMP (Epac)
Epac is a relatively recently discovered downstream effector of cAMP (de Rooji et al
1998).  It  is  the  broadly  expressed  cAMP-sensitive  guanine  nucleotide  exchange 
factor for Rapl  and Rap2, which are small Ras-like GTPases (Kitayama et al 1989). 
The  sequence  of the  putative  cAMP  binding  site  of Epac  is  similar to  the  cAMP 
binding site of the regulatory subunits of PKA (de Rooji et al 1998). The binding of 
cAMP relieves the inhibition of the guanine nucleotide exchange factor activity by 
the cAMP-binding domain, (de Rooji et al 1998). The downstream effects of cAMP 
mediated  by Epac  can  be  discriminated  from  PKA-mediated  effects  by the  use  of 
cAMP analogues which selectively activate Epac (Koppemd et al 2003). The role of 
Epac  in the  heart  is  still  not well-understood.  A  recent  study suggested  Epac  may 
activate Ca2+ and Rho signalling in neonatal cardiac myocytes (Morel et al 2005).
1.5.3 Ca2+
Ca2+ is a common signalling component for both ai  and p receptor signalling. In the 
beating  heart  or  electrically  paced  cardiac  myocytes,  the  p  receptor-mediated 
increase  in  intracellular  Ca2+  is  attributable  to  phosphorylation  of the  L-type  Ca2+ 
channel  at  the  sarcolemma by PKA,  which  increases  the  mean channel  open  time
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and/or opening probability (van der Heyden et al 2005). The L-type Ca  channel has 
also been reported to be activated directly by Gas (Lader et al 1998; Hamilton et al
i
1991; Imoto et al 1988). Because the opening of the L-type Ca  channel is regulated 
by the action potential, p receptor stimulation in quiescent cardiac myocytes does not
9+
cause a rapid increase in intracellular Ca  , as seen for the contracting heart or for 
contracting  myocytes  (Saini  et  al  2006).  However,  it  appears  that  the  p  receptor
94-  9+
stimulation still causes a slow accumulation of Ca  through the L-type Ca  channel 
even in the absence of the action potential, since prolonged Pi  stimulation increased
9_i
Ca  in quiescent cardiac myocytes and this effect was inhibited by nifedipine (Zhu
2+
et al 2003).  The  ai  receptor-mediated  increase in Ca  is  due to production of IP3
9_i
which  releases  Ca  from the  SR through the  IP3  receptor,  ai  stimulation has  also
2+  2+ 
been reported to increase Ca  influx through the L-type Ca  channel, but this effect
is controversial (Liu et al 1994; Gaughan et al 1998).
1.5.4  Calcium/calmodulin-dependent protein kinase II (CAMKII)
Of  the  three  CAMK  types  (CAMKI,  II,  and  IV),  which  are  all  activated  by 
Ca2+/calmodulin,  CAMKII  is  most  abundant  in  the  heart  and  most  well-studied 
(Colomer et al 2003).  The heart also expresses CAMKI but its  function is unclear. 
CAMKIV  is  only  present  in  low  abundance  (Colomer  et  al  2003).  CAMKII  is  a 
homo or heteromultimer of 8-12 CAMKII monomers bound to each other by the C- 
terminal domain (Anderson 2005). The binding of Ca2+/calmodulin to the N-terminal 
regulatory  region  releases  the  inhibition  of  the  catalytic  activity  by  the 
pseudosubstrate sequence.  Once a CAMKII monomer is activated it phosphorylates 
adjacent  monomers  in  the  holoenzyme  at  Thr287  (Anderson  2005).  This 
autophosphorylation  has  two  effects;  it  increases  the  affinity  of the  monomer  for 
Ca2+/calmodulin,  and  it also  makes  CAMKII  active  even  in  the  absence  of bound 
Ca2+/clamodulin  after  the  return  of the  cellular  Ca2+  to  the  basal  level  (Anderson 
2005). There are four isoforms of CAMKII encoded by separate genes; a, p, y, and 5, 
with splice variants for each isoform (Mayer et al 1995). In the heart the predominant 
CAMKII  isoform  is  CAMK5, which is  further divided into two splice variants,  5C 
(62) and 5B (63) (Edman and Shulman  1994).  CAMK5B, which is the predominant 
isoform,  is  found  in  the  nucleus  whereas  CAMK8C  is  cytosolic  (Edman  and
31Shulman  1994;  Zhu  et al 2003).  CAMK5B  and  CAMK5C  appear to have  distinct 
roles; CAMK5C is implicated in the regulation of contraction and apoptosis while 5B 
is implicated in hypertrophy (Zhang et al 2002; Maier et al 2003; Zhu et al 2003).
Pi  receptor  stimulation  has  been  reported  to  activate  CAMKII  via  a  PKA- 
independent activation of the L-type Ca2+ channel in adult rat cardiac myocytes (Zhu 
et al 2003; Wang et al 2004). In the perfused heart only pi  receptor stimulation and 
not  p2  stimulation  caused  phosphorylation  of  PLB  at  Thrl7  (CAMKII  site), 
suggesting CAMKII is not a downstream target of the p2 receptor (Bartel et al 2003). 
CAMKII has also been shown to be activated by ai  stimulation in cardiac myocytes 
(O-Uchi  et  al  2005;  Wang  et  al  2001a).  In  adult  rat  cardiac  myocytes,  the 
phenylephrine-induced activation of CAMKII was inhibited by a PKC inhibitor (O- 
Uchi et al 2005). The role of PKC in the activation of CAMKII is unknown. In the 
same  study,  CAMKII  was  also  shown  to  translocate  from  the  plasmalemma  to 
transverse  tubules  (O-Uchi  et al 2005).  The  authors  suggested  that  like  PKC,  the 
translocation may be important for the regulation of CAMKII activity .
1.5.5  Phosphoinositide-3-kinase (PI3K)
PI3Ks  are  lipid kinases that phosphorylate the  inositol  ring of phosphatidylinositol 
(Ptdlns)  and  various  phosphatidylinositol  phosphates  at  the  3  position.  PI3Ks  are 
grouped into three classes; classes I, II, and III. In vivo, class I PI3Ks predominantly 
phosphorylate  PtdIns(4 ,5)P2  to  generate  PtdIns(3 ,4 ,5)P3,  whereas  class  II  and  III 
mainly phosphorylate Ptdlns to generate PtdIns(3)P (Oudit et al 2004).  The class  I 
PI3Ks  are  heterodimeric  enzymes  consisting  of catalytic  and  regulatory  adaptor 
subunits, and they are further divided into class IA and IB. There are three isoforms 
for class IA catalytic subunits; pi 10a, pi 10p, and pi 105, and three isoforms for the 
adaptor subunit; p85a, p85p, and p55y.  The class IB  PI3K (PI3Ky) is composed of 
the catalytic subunit pi lOy tightly bound to the regulatory subunit plOl. The adaptor 
subunits  for the  class  IA  PI3Ks  contain  a  SH2  domain  as  well  as  a pi 10  binding 
domain, and they recruit the catalytic subunit to the plasma membrane upon tyrosine 
phosphorylation  following,  for  example,  receptor  tyrosine  kinase  activation  by 
insulin. In contrast, the regulatory subunit of PI3Ky lacks the SH2 domain.  Instead,
32both the catalytic and regulatory subunits of PI3Ky contain the binding sites for Gpy 
(Wymann et al 2003). PI3Ky is recruited and activated by Gpy following activation of 
GPCRs  (Stephens  et al  1997;  Alloatti  et al 2004;  Naga Prasad  et al 2000).  Both 
class IA PI3Ks and PI3Ky catalytic subunits also contain the C2 domain involved in 
phospholipid binding,  the  PIK domain involved  in protein-protein  interaction,  and 
the  Ras-binding  domain.  Ras-GTP  binding  enhances  the  catalytic  activity of both 
class IA PI3K and PI3Ky (Wymann et al 2003).
The  class  IA  PI3Ka  and  PI3K(3  enzymes  are  expressed  in  cardiac  myocytes 
(Crackower 2002).  The  physiological  importance  of PI3Ky  in  cardiac  myocytes  is 
questioned by some investigators because it is only weakly expressed (Alloati et al
2004).  However  deletion  of  PI3Ky  causes  significant  differences  in  the  cardiac 
phenotype including altered  contractile function in response to  catecholamines  and 
the  loss  of  downstream  effects  of  some  GPCRs,  suggesting  the  physiological 
importance  of this  protein  (Alloatti  et  al 2004).  The  signalling  and  physiological 
function of class IA PI3Ks  and PI3Ky appear to be distinct.  While class  IA PI3Ks 
seem to be involved in adaptive hypertrophy without cardiac dysfunction, PI3Ky is 
associated with pathological hypertrophy (Shioi et al 2000; Naga Prassad et al 2003). 
Moreover,  only  PI3Ky  appears  to  be  involved  in  the  regulation  of  contraction 
(Alloatti et al 2004).
Several studies have reported the activation of PI3K after p2 receptor stimulation in
neonatal rat cardiac myocytes or in adult rat or mouse cardiac myocytes (Chesley et
al 2000; Jo et al 2002; Zhu et al 2001).  The stimulation of the pi  receptor has also
been reported to  activate  PI3K in  adult rat cardiac  myocytes  (Leblais et al 2004).
However, the isoforms of PI3K activated in these studies were not determined, and
the  pathways  by  which  p  receptors  activate  PI3K  are  not  completely understood.
Figure 1.1  summarises the putative pathways by which the P receptor activates PI3K
in cardiac myocytes. For the P2 receptor, the observations that the activation of PI3K
or its downstream effects were inhibited by PTX or pARK-ct peptide (an inhibitor of
Gpy  signalling)  suggest  the  activation  of PI3Ky through  Gj  and  Gpy  (Chesley  et al
2000; Jo et al 2002). In contrast, the downstream effects of PI3K activation by the pi
receptor were unaffected by PTX, although they were inhibited by PARK-ct (Leblais
et al 2004). The lack of involvement of Gj is consistent with the exclusive coupling
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Figure  1.1  Putative  signalling  pathways  linking  the  p  adrenergic 
receptor to PI3K and PKB
Dotted lines indicate pathways which have been suggested in cardiac mycocytes but 
have not been completely elucidated, or pathways which have been observed in non­
cardiac myocytes but yet to be confirmed in cardiac myocytes.
34of the Pi  receptor with Gs.  It is possible that the Pi-mediated activation of PI3K is 
due to activation of PI3Ky by GP y derived from Gs. However, the involvement of GP y 
does not necessarily prove the  selective  activation  of PI3Ky.  As  well  as  being the 
direct activator of PI3Ky, GP y has also been reported to be upstream of non-receptor 
tyrosine  kinases  such  as  Src  family  tyrosine  kinases,  and  an  increase  in  tyrosine 
kinase  activity  after  p  receptor  stimulation  has  been  demonstrated  in  cardiac 
myocytes (Zou et al  1999). Thus, the possibility of activation of the class IA PI3Ks 
by p receptors through a GPy-mediated increase in tyrosine phosphorylation cannot be 
ruled out (Morisco et al 2000).
In adult cardiac myocytes, forskolin has also been shown to activate PI3K (Leblais et 
al 2004), suggesting cAMP signalling may also contribute to the PI3K activation by 
P  receptors.  The  activation  of PI3K by  forskolin has  been  indirectly  shown  to  be 
inhibited  by  pARK-ct,  suggesting  the  involvement  of GPy.  How  cAMP  signalling 
affects  GP y  signalling and  activates  PI3K is  not clear,  but it may be related to  the 
effect of PKA to phosphorylate the  p2 receptor and increase the coupling of the  P2 
receptor to Gj (Section 1.5.9). It has been shown in HEK293 cells that the expression 
of Epac  activates  PI3K  via  Rapl  (Mei  et al 2002).  Whether PI3K  is  activated  by 
cAMP through Epac in cardiac myocytes is unknown.
Till et al have reported the possibility of contraction-dependent activation of PI3K in 
cardiac  myocytes  (Till  et  al  2000).  These  investigators  observed  that  electrical 
contraction of adult rat cardiac myocytes  increased the PI3K activity present in the 
cell  lysate  (Till  et  al  2000).  This  activation  of PI3K  was  not  associated  with  the 
tyrosine phosphorylation of the insulin receptor and insulin receptor substrates (IRS) 
1/2 or the recruitment of PI3K to IRS 1/2 (Till et al 2000). However, they observed 
increased  association  of  p85a  with  unidentified  protein  which  is  tyrosine- 
phosphorylated following the myocyte contraction (Till et al 2000). This contraction- 
mediated  activation of PI3K may be relevant to  the  adrenergic  regulation of PI3K 
activity in the beating heart/myocytes or in the in vivo heart.
Compared  to  the  p  receptor,  the  information  regarding  activation  of PI3K  by  ai
receptor stimulation in the heart is limited. Doenst and Taegtmeyer reported that the
effects of the ai receptor and insulin to increase glucose uptake in the perfused heart
35were  additive  but  both  effects  were  inhibited  by  wortmannin  (Doenst  and 
Taegtmeyer  1999).  This  suggests  that  the  cardiac  ai  receptor  activates  a  PI3K 
isoform, possibly PI3Ky, which is different from those activated by insulin.
1.5.6  Protein kinase B (PKB) / Akt
The  activation  of PKB  by  PI3K  involves  the  recruitment  of PKB  to  the  plasma 
membrane  through  the  interaction  of  PtdIns(3 ,4 ,5)P3  with  the  PH  domain,  and 
phosphorylation by the phosphoinositide-dependent  kinase  1   (PDK1), which is also 
recruited to the membrane by the PH domain. PDK1  phosphorylates PKB at Thr308 
in the catalytic domain (Mora et al 2004). Ptdlns (3 ,4 ,5)P3 is thought to promote the 
phosphorylation  of PKB  by  PDK1  by  causing  a  conformational  change  of PKB 
which exposes Thr308 and by bringing constitutively active PDK1  to the proximity 
of PKB (Alessi et al 1997 and 1998; Stokoe et al 1997; Anderson et al 1998). PKB is 
additionally phosphorylated  at  Ser473  in  the  C-terminal  hydrophobic  region  (‘the 
PDK2 site’). The identity of the kinase(s) that phosphorylate(s) Ser478 is the subject 
of intense investigation (Dong and Liu 2005).  Several candidate kinases,  including 
mTOR/rictor  complex,  have  been  reported  (Dong  and  Liu  2005).  The  Thr308 
phosphorylation is essential for PKB activity. The role of Ser473  is less clear but it 
may  stabilise  the  active  configuration  and/or  it  may  assist  the  phosphorylation  of 
Thr308 by PDK1  (Dong and Liu 2005). However, Thr308 phosphorylation has been 
seen in the absence of Ser473 (Morisco et al 2005).
In neonatal  and adult rat cardiac myocytes,  isoproterenol or  (32 receptor stimulation 
has been shown to increase PKB activity (as measured by GSK3a phosphorylation) 
and/or phosphorylation of Ser478 (Morisco et al 2000; Zhu et al 2001). It has been 
reported that phenylephrine does not affect Ser478 phosphorylation of PKB in adult 
rat  cardiac  myocytes,  suggesting  PKB  may not  be  downstream  of the  ai  receptor 
(Wang  et al 2001b).  This  apparently  contradicts  the  activation  of PI3K  by the  ai 
receptor (Section 1.5.5). However, the lack of PKB phosphorylation under conditions 
that increase PI3K activity has been reported by several other studies (Till et al 2000; 
Zou et al 2002 and 2003) and it may be due to compartmentation of PI3K signalling. 
The activation of PKB by the p receptor is sensitive to inhibitors of PI3K (Morisco et
36al 2000; Zhu et al 2001). However, several observations suggest that PKB may also 
be activated by PI3K-independent pathways (Figure  1.1).  It has been shown in 293 
cells  that  cAMP-raising  agents  activate  PKB  by  a  PKA-dependent  but  PI3K- 
independent pathway (Fillippa et al 1999). The activation of PKB by cAMP-raising 
agents was associated with increased phosphorylation of Thr308 but it was seen in 
the absence of Ser473 phosphorylation (Fillippa et al 1999). This is in contrast to the 
activation of PKB by insulin, which required phosphorylation of both Thr308  and 
Ser473  (Fillippa et al  1999).  It appears that the increase in Thr308 phosphorylation 
by cAMP-raising treatments  is  not due to  direct phosphorylation of PKB  by PKA 
(Fillippa et al 1999). The possibility that PKB is also activated by the PKA pathway 
in cardiac myocytes is supported by the recent study by Morisco et al (Morisco et al 
2005). These investigators showed that isoproterenol caused phosphorylation of PKB 
at  Thr308  and  Ser473  with  different  time-courses;  the  phosphorylation  of Thr308 
could be detected within  1  minute of stimulation and  it returned to  the basal  level 
after 60 minutes, whereas the phosphorylation of Ser473  increased after  10 minutes 
and  was  sustained  for  2  hours  (Morisco  et al  2005).  They  showed  that  the  early 
phosphorylation of Thr308 (10 minutes), but not the later phosphorylation of Ser473 
(60  minutes),  was  insensitive  to  wortmannin  (Morisco  et  al  2005).  The 
phosphorylation of Thr308 was blocked by H89, nifidepine, or KN93, suggesting the 
possibility that PKA regulates PKB phosphorylation through activation of the L-type 
Ca2+  channel  and  CAMKII  (Morisco  et  al  2005).  How  Ca2+/CAMKII  might  be 
linked to PKB is not clear.
1.5.7  Protein kinase C (PKC)
There are at least ten different isoforms of PKC, which are grouped into conventional 
(cPKC) (a, pi, pil, y), novel (nPKC) (5, s, rj, 0), and atypical (aPKC) (£, X) PKCs. All 
PKC isoforms share conserved C-terminal catalytic domains termed C3  and C4 but 
display differences  in the N-terminal regulatory domain.  The regulatory domain of 
the  cPKCs  contains  two  tandem  repeats  of a  cysteine-rich  zinc  finger-like  motif 
termed  Cl  which  binds  DAG,  and  the  region  termed  C2  which  binds  membrane
phospholipids in a Ca2+ dependent manner. Both Ca2+ and DAG are required for the
•   2 1   activation  of the  cPKC  isoforms.  DAG  increases  the  affinity  of cPKCs  for  Ca
37(Nishizuka 1984). The nPKCs also contain the Cl region but they lack the C2 region. 
These isoforms require DAG for activation but are insensitive to Ca2+. Both cPKCs 
and  nPKCs  are  also  activated  by  phorbol  esters,  which  are  DAG  analogues.  The 
aPKCs, which lack the C2 region and contain only one cysteine-rich zinc finger-like 
motif,  are  insensitive  to  DAG  or  Ca  .  All  PKC  isoforms,  however,  require 
phosphatidylserine  (PS)  for activity.  The  activation  of PKC  isoforms  is  associated 
with  translocation  from  the  cytosolic  to  a  particulate  subcellular  fraction.  For  the 
cPKCs and nPKCs, the translocation to the membrane and the interaction with DAG 
and PS provides the energy to release the inhibitory pseudosubstrate from the active 
site.  Differential  centrifugation  followed  by  detection  with  PKC  isoform-specific 
antibodies has been most commonly used to show the activation of particular PKC 
isoforms.  Anchoring  proteins  called  Receptors  for  Activated  C-kinases  (RACKs) 
target activated PKC isoforms to a specific subcellular location (Mochly-Rosen and 
Gordon  1998).  In  neonatal  cardiac  myocytes  RACK1  selectively targets  activated 
PKCpiI  to  the  perinuclear  structure  (Ron  et  al  1995).  RACKII  (beta'-COP) 
selectively  targets  activated  PKCe  to  the  Golgi  membrane  in  cardiac  myocytes 
(Csukai  et al  1997).  It has been  suggested  some  of the  inactive  PKC  isoforms  are 
also  selectively  targeted  to  different  subcellular  sites  by  Receptor  for  Inactive  C- 
kinases (RICKs) (Mochly-Rosen and Gordon 1998).
DAG, which is required  for cPKCs and nPKCs activation, initially comes from the 
hydrolysis of PtdIns(4 ,5)P2 by PLCp upon Gq-coupled receptor activation (Nishizuka
1995).  However,  DAG  derived  from  PLCp  is  quickly  degraded  by the  actions  of 
DAG  kinase  and  DAG  lipase  (Nishizuka  1995).  The  sustained  increase  in  DAG, 
which  is  required  for  some  of  the  long  term  effects  of  Gq  signalling  such  as 
proliferation,  is  thought  to  be  due  to  the  hydrolysis  of phosphatidylcholine  (PC) 
(Nishizuka  1995).  This  is  because  the  fatty  acid  composition  of DAG,  which  is 
sustained,  corresponds with that of PC,  and DAG derived  from PC  is more  slowly 
degraded than DAG derived from PtdIns(4 ,5)P2 (Nishizuka 1995). DAG is produced 
from PC by the action of phospholipase D (PLD) which hydrolyses PC to generate 
phosphatidic  acid  (PA),  which  is  dephosphorylated  by  phosphatidate 
phosphohydrolase to DAG. PA is also known to be an activator of aPKCs (Farese et 
al 2002). PLD has been shown to be activated by ai  receptor stimulation in the rat 
heart (Weismuller et al 2004).
38In addition to DAG and Ca2+, the activity of PKC is also regulated by cis-unsaturated 
fatty acids (Nishizuka 1995). These fatty acids are incapable of activating cPKCs on 
their own but they increase the affinity of cPKCs for Ca  synergistically with DAG, 
causing  the  activation  of the  PKCs  at  basal  Ca2+  level  (Shinomura  et  al  1991; 
Yoshida  et  al  1992).  The  cis-unsaturated  fatty  acids  including  arachidonic  acid 
activate some nPKCs (s and 5) either in a DAG-dependent manner or independently 
of DAG  (Koide et al  1992;  Ogita et al  1992).  PKC^ has  also been reported to be 
activated by arachidonic acid (Kochs et al  1993). Phospholipase A2 (PLA2) appears 
to  play  a  role  in  PKC  signalling  by  hydrolysing  the  sn-2-fatty  acyl  ester  bonds 
thereby releasing  free  fatty acids  and  lysophospholipids.  Lysophosphatidylcholine, 
produced  by the  hydrolysis  of PC  by PLA2,  is  also  known  to  enhance  the  DAG- 
dependent  activation  of cPKC  (Sasaki  et  al  1993).  There  are  several  PLA2  types 
which  display  differences  in  their  preference  for  the  sn-2 -fatty  acids,  subcellular 
localisation,  and  Ca2+ requirement (Pavoine  and Defer 2005).  The  cytosolic  PLA2, 
which selectively releases arachidonic acid, has been shown to be activated by ai  or 
P2 receptors (Pavoine et al 2003; Ait-Mamar et al 2005; Debetto et al 1999).
Some members of nPKCs (8 , s, and rj) and aPKCs are also known to be activated by 
PtdIns(3 ,4 )P2  and  PtdIns(3 ,4 ,5)P3  (Farese  et  al  2002;  Rameh  and  Cantley  1999; 
Toker et al  1994; Nakanishi et al  1993). The activation by PtdIns(3 ,4 ,5)P3  is partly 
mediated by the phosphorylation of nPKCs and aPKCs by PDK1  (below).
All PKC isoforms are phosphorylated at the threonine residue in the activation loop 
and at one (aPKCs) or two (cPKCs and nPKCs) residues at the C-terminus (Malhotra 
et  al  2001b).  The  activation  loop  threonine  of  all  three  groups  of  PKCs  is 
phosphorylated by PDK1  (Dutil  et al  1998,  Le  Good  et al  1998).  For cPKCs,  the 
phosphorylation  of  the  activation  loop  by  PDK1  and  subsequent  stimulation  of 
autophosphorylation at the two C-terminal residues are required for the maturation of 
newly  synthesised  cPKCs  (Dutil  et  al  1998).  cPKCs  phosphorylated  at  the  C-
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terminal are still inactive but are now capable of being activated by Ca  and DAG
(Dutil  et al  1998).  Once  cPKCs are in the mature form,  the activation loop can be
2_|_
dephosphorylated without affecting the activation of cPKCs by Ca  and DAG (Dutil
et al  1998).  The re-phosphorylation of the activation loop of the mature cPKCs by
2 +  ,
PDK1  does not change the basal activity or DAG- and Ca  -induced activity (Dutil et
39al  1998).  In  contrast  to  cPKCs,  PDK1  phosphorylation  of  the  activation  loop 
increases the activity of aPKCs in the presence of PS or the activity of nPKCs in the 
presence of PS and DAG (Le Good et al 1998). This activation of aPKCs and nPKCs 
is  stimulated  in  the  presence  of PtdIns(3 ,4 ,5)P3  (Le  Good  et  al  1998).  However, 
phosphorylation of aPKCs by PDK1  is not an essential mechanism for the activation 
of  aPKCs  because  PA  appears  to  activate  aPKCs  without  this  phosphorylation 
(Farese et al 2002).
The  nature  of the  PKC  isoforms  expressed  in  cardiac  myocytes  is  controversial. 
Adult  rat  cardiac  myocytes  have  been  reported  to  express  a,  pi,  p2,  5,  s,  and  £ 
(Malhotra et al 2001a).  However studies by another group  found that adult cardiac 
myocytes express PKCs and £ but they do not express a, pi, y, or 5 (Bogoyevitch et 
al  1993).  In  cultured  neonatal  rat  myocytes,  PKCa,  5,  s,  and  £  were  detected but 
PKCp  was  not  detected  (Puceat  et  al  1994).  A  number  of  studies  done  with 
transgenic  mice  and  isolated  cardiac  myocytes  have  shown  that  ai  receptor/Gq 
stimulation selectively increases the translocation of PKCs to the membrane without 
affecting the translocation of PKCa and PKC^ (D’Angelo  et al  1997;  Puceat et al 
1994;  Clerk  et  al  1994;  Wang  et  al  2003;  Deng  et  al  1998).  Whether  PKC5  is 
activated by ai receptor stimulation is controversial. The translocation of PKC5 upon 
ai  stimulation has  been  observed  by  some  groups  (Puceat  et al  1994;  Wang  et al 
2003; Deng et al 1998), but not by others (Clerk et al 1994). There have been studies 
suggesting that p receptor stimulation can also activate PKC. The signalling linking 
the P receptor to PKC is unknown but it appears to involve Ca  .  In the perfused rat 
heart, isoproterenol pre-treatment ( 1 0 min) provided ischemic preconditioning which 
was inhibited by a L-type Ca2+ channel blocker or by PKC inhibitors (Miyawaki and 
Ashraf  1997).  In  adult  rat  cardiac  myocytes  isoproterenol  (lh)  increased 
translocation of PKCe to the membrane without affecting PKCa and  5 (Shizukuda 
and Buttrick 2001).
1.5.8  Protein kinase D (PKD)
PKD  is  a  family of serine/threonine  kinases  that  includes  PKD,  PKD2  and  PKD3 
(Wang  2006).  Although  PKD  and  PKD3  are  also  known  as  PKCp  and  PKCv,
40respectively,  PKDs  show different  substrate  specificities  from PKCs  and  are more 
closely  related  to  CAMKs  (Wang  2006).  PKD  contains  a  PH  domain  and  the  N- 
terminal  Cl  domain  (Cl a/C lb)  which  binds  DAG  and  phorbol  esters.  Like 
conventional and novel PKCs, PKD is activated by DAG or phorbol ester (van Lint
1995).  PKDs  are also activated by phosphorylation by PKC  (particularly the novel 
PKCs) which relieves the autoinhibitory effect of the PH domain (Wang 2006). PKD 
is expressed  in rat ventricular myocytes  and  is  activated by GPCR (Haworth et al 
2000) but the cardiac function of PKDs is still not well-understood.  PKD has been 
suggested to mediate the effect of PKC to phosphorylate class II histone deacetylase 
(Vega  et  al  2004).  Cardiac  troponin  I  and  myosin-binding  protein  C  have  been 
identified as possible PKD targets (Haworth et al 2004), indicating a possible role of 
PKD in the regulation of contraction.
1.5.9  Mitogen-activated protein kinases (MAPKs)
MAPKs are classified into 5 groups (Michel et al 2001);
1. The extracellular signal-regulated kinase (ERK) 1  and 2
2. p38 a, (3, y, and 5
3. The c-Jun N-terminal kinase (JNK) 1, 2, and 3
4. ERK 5
5. ERK 3 and 4
The  regulation  and  function  of the  first three  groups  are  most  extensively  studied 
whereas the functional  information for the last two groups is relatively scarce.  The 
heart  predominantly  expresses  ERK1/2,  p38a/p,  and  JNK1/2  (Magne  et  al  2001; 
Lemke  et  al  2001;  Stein  et  al  1997;  Clerk  et al  1998).  MAPKs  are  activated  by 
phosphorylation of threonine and tyrosine in the Thr-X-Tyr motif in the activation 
loop  by  one  or  more  of  the  upstream  dual  specificity  kinases,  MAPK  kinases 
(MKKs) which selectively activate each group of MAPKs. Thus, MEK1  and MEK2 
activate  ERKs,  MKK3  and  MKK6  activate  p38s,  and  MEK4  and  MEK7  activate 
JNKs. MAPKs are inactivated by specific MAPK dual phosphatases. The activity of 
MKKs  is  under the  control  of the  upstream  ser/thr kinase,  MAPK kinase  kinases
41(MKKKs).  The  Raf MKKK  family  (Rafl,  A-Raf,  and  B-Raf)  and  MEKK1  are 
upstream components  of the ERK MAPK cascade.  MKKKs  for p38  include JAK1 
and  PAK,  and  those  for  JNK  include  MEKK4,  MUK,  and  MST.  MKKKs  often 
activate more than one group of MAPKs by activating several MKKs. Thus, MEKK2 
and MEKK3  can activate both ERK and JNK via their respective MKKs.  Similarly 
ASK1, SPRK, TAK1 can activate both p38 and JNK.
In cardiac myocytes, both ai and p receptors have been reported to activate all three 
of ERK, p38, and JNK (Markou and Lazou 2002; Yamazaki et al  1997; Communal 
et  al  2000;  Wang  and  Proud  2002;  Maruyama  et  al  2002).  However,  there  is 
considerable  controversy  over the  activation  of individual  MAPKs  (ERK,  p38,  or 
JNK)  by  different  adrenergic  receptor  types  and  subtypes,  and  the  relative 
importance  of  each  MAPK  on  the  development  of  hypertrophy  and  apoptosis 
(Michel  et  al  2001).  This  is  at  least  partly  due  to  diversity  of the  experimental 
systems employed (transgenic animals, freshly isolated/cultured myocytes, perfused 
hearts)  and the  age  (adult vs.  neonatal  myocytes)  and  species  (e.g.  rat vs.  mouse) 
specificity of the adrenergic signalling.
The adrenergic receptors activate MAPKs through multiple pathways which are not 
completely understood. Figure  1.2 summarises some of the pathways that have been 
suggested to be involved in MAPK activation. Many studies have identified PKC as 
a  key  signalling  component  mediating  the  activation  of ERK  and  possibly  other 
MAPKs by the ai receptor (Sugden and Clerk 1998b; Zou et al 1999; Yamazaki et al 
1997;  Bogoyevitch  et al  1996;  Wang et al 2003).  The activation of ERK by PKC 
appears  to  involve  Raf  (Sugden  and  Clerk  1997).  In  addition,  the  activation  of 
MAPK by the ai receptor has been suggested to involve the small G proteins Ras and 
Rho  (Thorbum  1994;  Sugden  and  Clerk  2000).  Rho  has  been  shown  to  be 
downstream of G 12 and G 13, and it seems to be involved in the activation of JNK by 
the ai receptor (Maruyama et al 2002). G 12 and G 13 may activate Rho by stimulating 
the GEF activity of AKAP-Lbc (Kurose 2003; Diviani et al 2001) and pi 15RhoGEF 
(Hart et al 1998), respectively.
In contrast to the ai receptor, the activation of ERK by the |3 receptor is insensitive to
PKC  inhibition  (Zou  et  al  1999;  Bogoyevitch  et al  1996;  Yamazaki  et al  1997).
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Figure 1.2 Signalling pathways linking cardiac adrenergic receptors 
to MAPKs
43Instead, the activation of MAPK by the (3  receptor appears to involve PKA, Gj/0, and 
Gpy signalling (Zou et al 1999; Yamazaki et al 1997; Zheng et al 2000; Chesley et al 
2000; Communal et al 2000), although the pathways linking these to MAPK are not 
well-understood.  Gpy  has  been  suggested  to  activate  MAPK  via  PI3Ky  (Lopez- 
Ilasaca et al  1997).  It has also been reported that Gj-derived Gpy activates ERK via 
the Src-Ras-Rafl pathway, and phosphorylation of the 02 receptor by PKA stimulates 
this  pathway by  increasing  the  coupling  of the  receptor with  Gj  (Zou  et al  1999; 
Daaka  et  al  1997).  However,  how  Gpy  activates  the  Src  pathway  is  not  clear. 
Possibly,  it could involve the activation of 0ARK and the recruitment of 0-arrestin, 
which  has  been  postulated  to  activate  MAPK  by  binding  Src  as  well  as  the 
components of ERK and JNK MAPK cascades (Rockman et al 2002). The activation 
of p38 by the  02 receptor has been shown to be dependent on PKA but independent 
of Gj/Gpy (Zheng et al 2000), suggesting PKA also activates MAPK via mechanisms 
other than the stimulation of the Gi pathway.  One likely pathway is the increase in 
intracellular Ca2+  through activation of the  L-type  Ca2+  channel.  The activation of
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ERK by  isoproterenol  or phenylephrine has  been reported  to  be  inhibited by Ca
i
chelation  or  nifedipine,  suggesting  Ca  is  a  common  mechanism  mediating  the 
activation of MAPK by both ai  and 0 receptors (Yamazaki et al  1997; Bogoyevitch 
et  al  1996).  The  mechanisms  by  which  Ca2+  activates  MAPK  are  not  clear.  The 
possible  downstream  pathways  include  the  activation  of  tyrosine  kinase  PYK2 
(Sugden and Clerk 1997) or CAMKII, which appears to be upstream of the apoptosis 
signal-regulated kinase 1  (ASK1) (Kashiwase et al 2005).
1.6  AMP-activated protein kinase (AMPK)
1.6.1  Introduction
The  AMP-activated  protein  kinase  is  a  broadly  expressed  serine/threonine  kinase 
consisting  of catalytic  a  subunit  and  regulatory  0  and  y  subunits.  AMPK  and  its 
orthologues  are present  in all  eukaryotes.  The  earlier studies  with purified  AMPK 
from the rat liver (much of the earlier in vitro studies were done with AMPK from 
this tissue) showed AMPK was activated by AMP and by phosphorylation of Thrl72 
at  the  catalytic  loop  of the  a  subunit  by upstream  kinases,  collectively  called  the
44AMPK kinases (AMPKKs), which cause a dramatic increase in the AMPK activity 
(Hawley et al  1996).  AMP  activates AMPK by several mechanisms;  1.  It binds to 
AMPK and allosterically activates AMPK (Sullivan et al  1994).  2.  It enhances the 
phosphorylation of Thrl72 by AMPKKs (Hawley et al  1995).  3.  It protects AMPK 
against  the  dephosphorylation  of  Thrl72  by  PP2C  and  PP2A,  the  phosphatases 
identified to dephosphorylate Thrl72 in vitro (Davis et al 1995). 4.  It allosterically 
activates AMPKK (Hawley et al 1995). The last effect was observed with a partially 
purified  liver  AMPKK  but  it  is  questioned  following  the  recent  discoveries  that 
LKB1  and  CAMKK(3 phosphorylate  Thrl72  and  act  as  AMPKKs  (Section  1.6.3). 
Both LKB1, which is the main AMPKK in the liver, and CAMKK(3 are not directly 
activated by AMP (Section  1.6.3).  All four effects of AMP have been shown to be 
antagonised by ATP (Carling et al 1989; Davis et al 1995; Hawley et al 1996). Thus, 
the activity of AMPK in vivo is likely to be regulated by changes in the AMP/ATP 
ratio  rather  than  AMP per se.  A  number  of conditions  that  increase  the  cellular 
AMP/ATP ratio (e.g. skeletal muscle contraction and H2O2) have been demonstrated 
to  increase  Thrl72  phosphorylation  and  the  AMPK  activity  in  isolated  or  in  vivo 
tissues/cells. In the heart, AMPK has been shown to be activated by ischemia and by 
metabolic inhibitors which impede ATP production (Kudo et al 1995; Pelletier et al
2005).  AMPK  is  also  activated  in  many  cell  types  including  cardiac  myocytes 
(Chabowski  et  al  2006)  by  5-aminoimidazole-4-carboxamide  ribonucleoside 
(AICAR)  (Corton  et  al  1995),  which  is  converted  in  the  cell  to  ZMP,  an  AMP 
analogue which has also been shown to activate AMPK in vitro (Sullivan et al 1994). 
AICAR  is  the  most  commonly used  experimental  tool  for  activating  AMPK,  and 
many downstream effects of AMPK have been studied using this compound.
In  the  heart  AMPK  is  emerging  as  a  key regulator of many metabolic  pathways.
AMPK has been  shown to phosphorylate and  inactivate cardiac ACC2  (Dyck et al
1999).  AMPK  has  also  been  shown  by  some  investigators  to  phosphorylate  and
activate  MCD  in  skeletal  muscle  (Saha  et  al  2000)  but  this  effect  has  not  been
confirmed  by  others  (Habinowski  et  al  2001).  The  activation  of  AMPK  during
ischemia/reperfusion  is  associated  with  phosphorylation  of  ACC,  a  decrease  in
malonyl  CoA,  and  an  increased  rate  of fatty  acid  oxidation  (Kudo  et al  1995  and
1996). AMPK activation is also associated with increased lipoprotein lipase activity
(An et al 2005) and translocation of the fatty acid translocase CD36 to the plasma
45membrane  (Luiken et al 2003).  Recently, prolonged activation of AMPK has been 
shown to increase the expression of fatty acid transporters FABPpm and FAT/CD36 
in  cardiac  myocytes  and  perfused  heart  (Chabouski  et  al  2006).  In  addition  to 
stimulating fatty acid utilisation, AMPK also regulates glucose metabolism.  Several 
studies have shown that the activation of AMPK increases the translocation of Glut4 
to the plasma membrane (Russell et al 2004;  Li  et al 2005).  AMPK has also been 
shown  to  phosphorylate  and  activate  PFK2  in  vitro  and  this  is  implicated  in  the 
stimulation of glycolysis during ischemia (Marsin et al 2000). Results from skeletal 
muscle  suggest  that  AMPK  may  also  regulate  cardiac  glycogen  metabolism  by 
inhibiting glycogen synthase (Wojtaszewski et al 2002). AMPK possibly stimulates 
glycogen phosphorylase (by phosphorylating phosphorylase kinase) but this effect is 
controversial (Carling and Hardie  1989; Young et al 1996; Beyer et al 2000). These 
effects  of  AMPK  to  stimulate  energy  producing  pathways,  together  with  the 
activation of AMPK by an increase in the AMP/ATP ratio, have led to the notion that 
the main physiological function of this enzyme is to protect the cells against the loss 
of ATP during metabolically stressful conditions. For this reason AMPK is described 
as  the  energy  or  stress  sensor  (Hardie  et  al  2006).  This  role  of AMPK  has  been 
supported by the recent  study with hearts  from transgenic mice  lacking a2 AMPK 
(the  major  isoform),  which  showed  a  much  higher  increase  in  AMP/ATP  during 
ischemia than wild type hearts (Zarrinpashneh et al 2006).
In  addition  to  stimulating  energy producing pathways,  the  maintenance  of cellular
ATP by AMPK is also  likely to involve inhibition of energy consuming pathways.
Liver ACC and HMG CoA reductase, which are involved in the biosynthesis of fatty
acids and cholesterol, respectively, are inactivated by AMPK (Carling et al 1987). In
the  heart,  which  is  not  lipogenic,  one  relevant  biosynthetic  pathway  which  is
inhibited  by  AMPK  activation  is  protein  synthesis  (Chan  and  Dyck  2005).  The
activation  of AMPK  in cardiac  myocytes  causes  inhibition of protein  synthesis  by
phosphorylation and activation of the eukaryotic elongation factor 2  (eEF2) kinase,
which phosphorylates  and  inhibits  eEF2  (Horman  et al 2003;  Browne  et al 2004;
Macleod et al 2002;  Chan et al 2004;  Browne and Proud 2004).  Studies in cardiac
myocytes  and  other  cell  types  have  suggested  that  AMPK  also  regulates  protein
synthesis  by  inhibiting  the  mTOR-p70  S6  kinase  pathway  (Bolster  et  al  2002;
Kimura  et  al  2003).  AMPK  may  inhibit  this  pathway  either  by  direct  inhibitory
46phosphorylation of mTOR (Cheng et al 2004), or by phosphorylation and activation 
of TSC2, which is a negative regulator of mTOR (Inoki et al 2003).
Recently,  there  have  been  an  increasing  number  of studies  reporting  AMP/ATP- 
independent  modulation  of  AMPK  activity  and  Thrl72  phosphorylation  state. 
AMPK  has  been  demonstrated  to  be  activated  by  hyperosmotic  stress  (Section 
1.6.5.d) and metformin (Section  1.6.5.f) via AMP/ATP-independent mechanisms.  It 
has  also  been  reported  that  AMPK  is  inactivated  by  glucose  in  skeletal  muscle 
(Section  1.6.5.1) and is activated by long chain fatty acids  in the heart and  skeletal 
muscle (Section  1.6.5.m) through an AMP/ATP-independent change in the Thrl72 
phosphorylation  state.  These  findings  suggest  that,  in  addition  to  protecting  cells 
from ATP depletion, AMPK may have other roles. For example, AMPK may act as a 
fuel sensor which regulates fuel metabolism in response to the change in the type of 
fuel  supplied.  Moreover,  recent  studies  have  also  shown  that  the  activity  and  the 
Thrl72 phosphorylation state of AMPK can be modulated by a number of hormonal 
or other extracellular signals through the stimulation of cell surface receptors. These 
include  insulin  (Section  1.6.5.e),  adiponectin  (Section  1.6.5.i),  leptin  (Section 
1.6.5.i),  ghrelin (Section  1.6.5.j),  resistin (Section  1.6.5.i),  extracellular nucleotides 
(Section  1.6.5.h),  fibronectin (Han et al 2006),  angiotensin  II  (Nagata et al 2004), 
histamine  (Section  1.6.5.h),  thrombin  (Section  1.6.5.h),  interleukin- 6  (Kelly  et  al
2004)  and  adrenergic  agonists  (Section  1.6.5.p).  These  observations  suggest  that 
AMPK may additionally mediate some of the biological effects of these signals.
1.6.2  AMPK structure
AMPK purified from rat liver exists as a heterotrimer of a, p, and y subunits (Davies 
et al 1994). In vitro expression of the three subunits showed that the formation of the 
ternary complex is not dependent on phosphorylation or the catalytic activity of the a 
subunit (Woods et al 1996; Dyck et al 1996). The p subunit interacts with both a and 
y subunits, but the a subunit does not interact (Woods et al  1996) or interacts very 
weakly with the y subunit (Dyck et al 1996). Transfection of the AMPK subunits in 
COS-7  cells  has  shown  that  co-expression  of either the  p  or y  subunit  with  the  a 
subunit has a small stimulatory effect on AMPK activity but the full activity requires
47the expression of all three subunits (Dyck et al 1996). This may be partly due to the 
stabilisation  of the  a  subunit  by  the  (3   and  y  subunits  (Dyck  et  al  1996).  The 
homologues of all three  subunits are found in S.cerevisiae.  The AMPK a,  (3,  and y 
subunits  are  genetically  and  functionally  related  to  the  yeast  Snflp, 
Siplp/Sip2p/Gal83p, and Snf4p, respectively (Stapleton et al 1994; Yang et al 1994; 
Woods et al 1996; Carling et al 1994; Woods et al 1994).
The catalytic a subunit (Carling et al 1989) transfers y phosphate of ATP to serine or 
threonine residues in the consensus sequence (0(X,P)XXS/T*XXX0, where O and (3  
indicate hydrophobic  and basic residues,  respectively;  X indicates  any amino acid; 
the order of the amino acids within the parenthesis is not important) (Weekes et al 
1993;  Dale  et  al  1994;  Salt  et  al  1998).  However,  a  structural  modelling  of the 
interaction  between  the  catalytic  domain  of AMPK  and  the  region  around  Ser79 
(AMPK  phosphorylation  site)  of ACC1  has  suggested  that  residues  over  a  much 
longer  region  than  the  above  recognition  motif are  important  for  the  interaction 
(Scott  et  al  2002).  There  are  two  isoforms  of the  a  subunit;  al  (548  residues) 
encoded  by  the  gene  on  chromosome  5p 11  (Stapleton  et  al  1997)  and  a2  (552 
residues) encoded by the gene on chromosome lp31 (Beri et al 1994) (Stapleton et al
1996).  Both  isoforms  migrate  on  SDS-PAGE  at  approximately  63kDa  and  are 
activated by AMP and by the phosphorylation of Thrl72 by AMPKK (Stapleton et al
1996).  They show high  sequence  similarity at the N-terminal  catalytic  domain but 
less  similarity  at  the  C-terminal  region  (Stapleton  et  al  1996).  Truncation  studies 
have  shown  that  the  C-terminal  region  (313-473)  of the  a  subunit  is  required  for 
association with the p and y subunits (Figure  1.3) (Crute et al 1998; Iseli et al 2005). 
A truncated al  lacking the C-terminal region (al  (312)) is constitutively active and 
the presence of an autoinhibitory domain has been suggested in the region between 
residues  312-392  (Crute  et  al  1998).  The  al  mRNA  and  protein  are  generally 
expressed but a2 mRNA and protein are most abundant in heart, skeletal muscle and 
liver  (Stapleton  et  al  1996).  In  terms  of  the  activity,  a2  AMPK  activity  is 
predominant  in  the  heart  and  skeletal  muscle,  while  al  AMPK  activity  is 
predominant in lung, kidney, testis, brain and pancreas (Cheung et al 2000). Both al 
and a2 AMPK contribute equally in the liver (Cheung et al 2000).  In the heart, al 
AMPK contributes to about 30% of the total AMPK activity (Cheung et al 2000).
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Figure  1.3  AMPK subunit domain  structures  and  phosphorylation 
sites
The domain structure and the phosphorylation sites  for the al,  pi,  and yl  subunits 
are  shown.  The  phosphorylation  sites  in  parentheses  represent  the  corresponding 
phosphorylation sites in the a2 and p2 subunits.
49The  al  and  a2  isoforms  display  a  number  of  differences.  The  a2  activity  is 
stimulated by AMP to a greater extent than al  in vitro (Salt et al 1998). This effect 
was seen for both the allosteric effect of AMP and for the stimulation of the Thrl72 
phosphorylation by an upstream kinase.  This  difference  in the  sensitivity to  AMP 
may  explain  the  greater  activation  of a2  AMPK  than  al  AMPK  during  cardiac 
ischemia (Li  et al 2006) and the isoform-specific AMPK activation during skeletal 
muscle contraction. Low or moderate skeletal muscle contraction has been generally 
found to selectively activate a2 AMPK while al  activation is only seen during high 
intensity contraction  (Vavvas  et al  1997;  Stephens  et al 2002;  Wojtaszewski  et al 
2000;  Chen  et  al  2000),  although  a  recent  study  by  Toyoda  et  al  has  shown  a 
selective  activation of al  AMPK by low intensity contraction  in the epitrochlearis 
muscle (Toyoda et al 2006). Both isoforms are deactivated similarly by PP2C but a2 
is deactivated by PP2A to a much greater extent than al  (Salt et al 1998). al and a2 
AMPK may  also have distinct physiological  functions.  It has been shown only a2 
AMPK  co-purifies  with  heart  ACC  (Dyck  et  al  1999)  suggesting  a  role  for  this 
isoform in the regulation of cardiac ACC. a2 AMPK has also been suggested to be 
the isoform involved in the regulation of glucose homeostasis (Jorgensen et al 2004). 
A selective activation of a2 has been also observed in skeletal muscle in response to 
leptin  (Section  1.6.5.i).  Both  al  and  a2  AMPK  are  found  in  the  cytosol  but  a2 
AMPK is also found in the nucleus in INS-1  cells and CCL13 cells (Salt et al 1998). 
This localisation is not dependent on the activation state of a2 or association with the 
(3  and y subunits (Salt et al 1998).
The P subunit binds both a and y subunits and is thought to act as a scaffold protein.
There are two isofoms of the p subunit; pi  (38kDa) and p2 (34kDa) (Thornton et al
1998).  The  two  isoforms  display  similar  C-terminal  sequence  but  show  less
similarity  at  the  N-terminal  sequence  (Thornton  et  al  1998).  AMPK  complexes
containing different  p  subunits  do  not show differences  in activity and there  is  no
evidence of preferential association of the two p isoforms with different a isoforms
in  vitro  (Thornton et al  1998).  Both  isoforms  are  generally distributed.  The  liver
expresses mainly pi  and a small amount of p2 , while the opposite pattern is seen in
skeletal muscle (Thornton et al  1998).  The heart expresses both isoforms but p2 is
slightly more abundant than pi  (Thornton et al 1998). The yeast homologues of the p
subunit contain conserved domains termed KIS and ASC, which are involved in the
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1997). Putative KIS and ASC domains are also found in the AMPK P subunits at the 
internal region and the C-terminal region, respectively (Gao et al 1996; Woods et al 
1996;  Thornton et al  1998).  However,  in  contrast to  SNF1,  a truncation study has 
revealed that the  P  subunit binds both a and y  subunits via a C-terminal  sequence 
(residues  186-270 for pi) (Iseli et al 2005).  The C-terminal residues 241-270 have 
also been shown to be sufficient to bind the y subunit, but not the a subunit (Iseli et 
al 2005). The KIS domain in the p subunit is not required for the association with the 
a or y subunit (Hudson et al 2003). The internal region (amino acids 68-163) of the p 
subunits  which  overlaps  with  the  putative  KIS  domain  has  been  identified  as  the 
glycogen binding domain (GBD) closely related to the isoamylase domain found in 
glycogen and starch branching enzymes (Polenkhina et al 2003). The association of 
AMPK  with  glycogen  in  vivo  has  been  suggested  by the  co-localisation  of the  p 
subunits with glycogen phosphorylase and synthase (Polenkhina et al 2003; Hudson 
et al 2003). The GBD domain is likely to be important for the regulation of glycogen 
metabolism by AMPK (Section  1.6.5.k).  The P subunits are myristoylated at the N- 
terminus  (Thornton  et  al  1998).  The  myristoylation  is  involved  in  the  membrane 
association of AMPK (Mitchelhill et al  1997;  Warden et al 2001).  The removal of 
the myristoylation has been also shown to increase AMPK activity by a mechanism 
independent of a change in the Thrl72 phosphorylation (Warden et al 2001).
The y subunit contains two pairs of CBS (cystathione-P-synthase) domains (CBS 1/2
and CBS3/4) called the Bateman modules which are proposed to bind AMP and ATP
(Kemp  2004;  Adams  et al 2004).  The  involvement  of the  CBS  domains  in  AMP
binding is supported by the observations that some point mutations in these domains
make  AMPK  insensitive  to  AMP  (Hamilton  et  al  2001;  Adams  et  al  2004).
Moreover,  several naturally occurring mutations  in the human y2  subunit  (R302Q,
H383R,  and  R531G),  which  are  associated  with  the  development  of the  Wolff-
Parkinson-White syndrome, are found within the CBS domains, and these mutations
have been shown to decrease the sensitivity of AMPK to AMP (Daniel and Carling
2002a).  The  inhibition  of the  stimulatory  effect  of AMP  on  AMPK  by  ATP  is
thought  to  be  due  to  the  competitive  binding  of ATP  to  the  Bateman  modules
(Adams et al 2004). There are three isoforms of the y subunit; yl, y2, and y3. The y2
gene  has  two  transcriptional  start  sites  and  two  forms  (short  and  long)  of y2  are
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(Cheung  et al 2000).  The  AMPK complexes  containing different y  subunits  show 
differences in the dependence for AMP for activation. The AMPK with y2 shows the 
highest AMP dependence followed by yl and y3 (Cheung et al 2000). There has been 
no conclusive evidence of selective association between the three y isoforms and the 
a isoforms (Cheung et al 2000), although the possibility of preferential association of 
y3 with a2 and (32 in the skeletal muscle has been reported (Mahlapuu et al 2004). In 
most  tissues,  except  for  the  brain  and  testis,  the  AMPK  complex  containing  yl 
accounts for the majority of the AMPK activity, and the remainder is accounted for 
by the  y2-containing  complex  (Cheung  et al 2000).  The  heart  expresses  both  yl, 
which  is  the  predominant  form,  and  y2  (Li  et  al  2006).  The  expression  of y3  is 
confined to the skeletal muscle (Cheung et al 2000; Yu et al 2004).
1.6.3  AMPK kinases (AMPKKs)
AMPK is activated by the phosphorylation of Thrl72 of the a subunit by AMPKK. 
The mutation of Thrl72 to alanine completely abolishes the activation of AMPK by 
partially purified AMPKK (Stein et al 2000). The identity of the upstream kinase(s) 
that phosphorylate(s) Thrl72 was elusive for a long time. Earlier studies on AMPKK 
mostly used a partially purified AMPKK fraction from rat liver. Recently, three yeast 
AMPKKs have been identified (Paklp, Tos3p and Elmlp) which can phosphorylate 
the residue equivalent to Thrl72  in the activation loop of Snflp (Hong et al 2003; 
Sutherland  et  al  2003).  Subsequently,  LKB1  in  mammals,  which  has  a  catalytic 
domain related to these three yeast kinases, has been shown to phosphorylate Thrl72 
and activate AMPK in vitro (Hong et al 2003; Hawley et al 2003; Woods et al 2003; 
Shaw et al 2003). LKB1  is known as a serine/threonine kinase which has a tumour 
suppressor role. Mutation of LKB1  causes the Peutz-Jeghers syndrome (Boudeau et 
al 2003).  LKB1  (~50kDa) purified  from rat  liver is associated with two accessory 
proteins;  STRADa  (~45/48kDa)  and  M025a  (~40kDa)  (Hawley et al  2003).  The 
heterotrimeric  complex  of LKB1  is  required  for  its  full  activity  towards  AMPK 
(Hawley et al 2003). LKB1  seems to equally activate AMPK complexes containing 
different subunit isoforms (Woods et al 2003). The role of LKB1  as an AMPKK in 
vivo is supported by several observations. First, an anti-LKBl antibody could remove
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(Hawley et al 2003; Woods et al 2003). Second, in cultured cell lines, the inhibition 
of LKB1  by  expression  of catalytically  inactive  LKB1  inhibited  the  increase  in 
Thrl72 phosphorylation induced by AICAR and H2O2 (Woods et al 2003; Shaw et al 
2003). Third, in HeLa cells, which lack endogenous LKB1, and in MEF cells from a 
LKB1  knock out mouse, AICAR or H2O2 failed to increase Thrl72 phosphorylation 
(Hawley et al 2003; Shaw et al 2003). Lastly, in transgenic mice, deletion of LKB1 
in the  liver or skeletal muscle  greatly decreased the basal  Thrl72  phosphorylation 
and almost completely abolished the increase in the Thrl72 phosphorylation caused 
by metformin, AICAR, or skeletal muscle contraction (Shaw et al 2005; Sakamoto et 
al 2005).  The heart  from the transgenic mice lacking cardiac  expression of LKB1  
also  showed  almost  complete  abolition  of the  basal  activity  of a2  AMPK  and  a 
moderate  reduction  in  the  activity  of al  AMPK,  indicating  a  significant  role  of 
LKB1  in cardiac AMPK regulation (Sakamoto et al 2006).
Despite the lack of LKB1, a small amount of Thrl72 phosphorylation could still be
detected  in  HeLa  cells  and  MEF  cells  from  LKB1  knock-out mice  (Hawley et al
2003). This was not due to non-phospho specific binding of the anti-Thrl72 antibody
as it was almost completely abolished by incubation with PP2A (Hawley et al 2005).
Moreover,  a  Ca2+  inophore  was  shown  to  increase  Thrl72  phosphorylation  and
AMPK activity in HeLa cells. These observations prompted the search for AMPKK
other than  LKB1.  The  AMPKK  activity towards  recombinant AMPK present  in  a
HeLa  cell  lysate  could  be  completely  abolished  by  STO-609,  an  inhibitor  of
CAMKKa  and  p  (Hurley  et  al  2005).  The  effect  of a  Ca2+  inophore  to  activate
AMPK in the HeLa cells was also inhibited by STO-609 or by small interfering RNA
(siRNA)  against  CAMKKa  or  p,  although  the  inhibitory  effect  of siRNA  against
CAMKKp was much greater than that for CAMKKa (Hurley et al 2005; Hawley et
al 2005;  Woods et al 2005).  Both CAMKKa and  p can phosphorylate Thrl72  and
activate recombinant AMPK in vitro, but CAMKKp activates AMPKK more readily
than CAMKKa (Hawley et al 2005; Woods et al 2005). These observations strongly
suggest  that  in  addition  to  LKB1,  CAMKKp  and  possibly  CAMKKa  also  act  as
AMPKKs  in vivo.  In brain slices, the activation of AMPK by depolarlisation or an
increase  in  Ca2+  induced  by  increasing  K+  concentration  has  been  shown  to  be
inhibited by STO-609, suggesting a role for CAMKKs in the regulation of AMPK in
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expressed  in the  brain,  they are poorly expressed  in  other tissues  (Anderson  et al
1998).  The heart has been reported to express CAMKKP but not CAMKKa (Allard 
et al 2006). The role of CAMKKp in the regulation of cardiac AMPK remains to be 
determined.
There  still  remains the possibility of AMPKKs different from LKB1  or CAMKKs. 
The possibility of a yet unidentified AMPKK that is activated during ischemia has 
been reported in the heart (Section  1.6.5.o).  Suzuki et al have demonstrated that in 
several cultured cell lines, including the human pancreatic cancer cell line (PANC-1), 
HeLa and human fibroblast cell  lines, AMPK Thrl72 phosphorylation is increased 
by incubation with growth factors such as IGF-1  (Suzuki et al 2004).  The tyrosine 
phosphorylation  of ATM  (ataxia telangiectasia mutated)  appears  to be  involved  in 
this effect as the activation of AMPK was blocked by genistein or antisense mRNA 
for  ATM  (Suzuki  et  al  2004).  The  ATM  immunoprecipitated  from  the  IGF-1- 
stimulated  cells phosphorylated the  AMPK a catalytic  domain  in  vitro,  suggesting 
ATM may be directly upstream of AMPK (Suzuki et al 2004).
1.6.4  Phosphorylation sites other than Thrl72
In addition to Thrl72, AMPK is known to be phosphorylated at several sites on the a 
and p subunits (Figure  1.3).  The a subunit has been shown to be phosphorylated at 
two  other  sites,  Thr258,  and  Ser485  (al)/Ser491  (a2)  (Woods  et  al  2003).  The 
mutation of Thr258 or Ser485/491 to asparatic acid to mimic phosphorylation did not 
affect the kinase activity or sensitivity of AMPK to AMP (Woods et al 2003). Using 
constitutively active  and  catalyticaliy inactive  mutants  of AMPK,  these  sites  were 
shown to be phosphorylated by both autophosphorylation and by a partially purified 
AMPKK  (Woods  et  al  2003).  However,  the  upstream  kinases  that  phosphorylate 
Thr258 and Ser485/491 were thought to be different from that which phosphorylates 
Thrl72 because the sequences surrounding the Thr258 and Ser485/491  were similar 
to each other but different from the sequence surrounding the Thrl72 (Woods et al 
2003).  Unlike Thrl72,  the  Ser485  phosphorylation was  also resistant to  incubation 
with  PP2C,  PP1  or  PP2A  (Woods  et  al  2003).  Recently,  Horman  et  al  have
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phosphorylated by LKB1  (Horman et al 2006). Moreover, PKB has been shown to 
phosphorylate recombinant alplyl  and a2plyl  AMPK in vitro at Ser485/491.  The 
phosphorylation  of Ser485  did  not  directly  affect  the  kinase  activity  but  in  vitro 
preincubation  of AMPK  with  PKB  and  phosphorylation  of Ser485  decreased  the 
Thrl72  phosphorylation  and  the  activation  of  AMPK  by  LKB1,  suggesting  a 
hierarchical  mechanism  where  the  prior  phosphorylation  of  Ser485  inhibits  the 
subsequent phosphorylation at Thrl72 (Horman et al 2006).
The  pi  subunit  has  been  reported  to  be  phosphorylated  at  Ser24,  Ser25,  Ser96, 
SerlOl,  Serl08,  and  Serl82  (Mitchelhill et al  1997;  Woods et al 2003;  Chen et al
1999).  The  phosphorylations  of Ser24/25  are mutually exclusive  (Mitchelhill  et al
1997).  The  only reported phosphorylation on the  p2  subunit  is  Seri 82  (Chen  et al
1999).  Phosphorylation of these residues may regulate the AMPK activity,  cellular 
localisation,  or  interaction  with  substrate.  Warden  et  al  showed  that  mutation  of 
Serl08 to  alanine decreased  AMPK activity while mutation of Ser24/25  or Seri82 
did not affect the activity but increased the nuclear localisation (Warden et al 2001). 
Seri08  is  within  the  GBD  and  mutating  it  to  glutamic  acid  has  been  shown  to 
partially inhibit the association of GBD with glycogen (Polekhina et al 2003). Most 
of the p phosphorylation sites identified are autophosphorylation sites (Mitchelhill et 
al  1997;  Woods  et al 2003).  However Seri 82  and some of the other sites  are  also 
likely  to  be  phosphorylated  by  separate  kinases  (Mitchelhill  et  al  1997).  The 
catalytically inactive mutant of AMPK has been reported to be phosphorylated at the 
P subunit by a partially purified AMPKK (Mitchelhill et al  1997;  Stein et al 2000) 
although  this  was  not  observed  by  other  investigators  (Woods  et  al  2003).  This 
discrepancy is likely to be due to the difference  in the composition of the partially 
purified AMPKK used in these studies. Recently, incubation of recombinant AMPK 
with PKB has been shown to increase phosphate incorporation into the pi but not p2 
subunit  (Horman  et  al  2006).  The  significance  of PKB  phosphorylation  of the  p 
subunit in the regulation of AMPK remains to be determined.
551.6.5  The regulation of AMPK by AMP/ATP and other factors
(a) AMP/ATP
In vitro, AMP activates AMPK by a direct allosteric mechanism and by increasing 
the phosphorylation of AMPK at Thrl72  by AMPKK.  This phosphorylation is the 
key  event  which  accounts  for most  of the  activation  of AMPK  by AMP.  Recent 
studies  in  cultured  cells  and  in  skeletal  muscle  lacking  LKB1  expression  have 
suggested that LKB1 is required for the phosphorylation of AMPK by treatments that 
increase the AMP/ATP ratio (Section  1.6.3). However, it has been shown that AMP 
does not directly activate LKB1, although the phosphorylation of AMPK by LKB1 is 
stimulated in the presence of AMP (Hawley et al 2003; Woods et al 2003; Shaw et al 
2003).  The  activity of LKB1  purified  from  cultured  cells  or  from  skeletal  muscle 
treated  with  agents  that  increase  AMP/ATP  is  also  not  different  from  that  in 
untreated cells (Woods et al 2003; Shaw et al 2003; Sakamoto et al 2004). LKB1  is 
known to be phosphorylated at up to eight residues (Boudeau et al 2003), and LKB1 
immunoprecipitated  from  a  liver AMPKK  fraction exists  as  several  species  which 
seem  to  represent  different  phosphorylation  states  of LKB1  (Woods  et  al  2003). 
However, none of the phosphorylations of LKB1   appear to regulate LKB1   catalytic 
activity (Sapkota et al 2001  and 2002). Consistent with this, preincubation of LKB1 
with PP1,  PP2A  or PP2C  does not affect the phosphorylation of AMPK by LKB1 
(Woods et al 2003).  These observations  suggest that LKB1  is constitutively active 
and AMP stimulates the Thrl72 phosphorylation by making AMPK a better substrate 
for LKB1. The exact molecular mechanism for this effect is unknown. According to 
the  model  suggested  by  Cheung  et  al,  AMP  binding  to  both  a  and  y  subunits 
stabilises  the  conformation  where  the  autoinhibitory  region  of  the  a  subunit  is 
removed from the catalytic site, exposing Thrl72 (Cheung et al 2000). Alternatively, 
Adams  et al has proposed that ATP binding to  the  CBS  domains  of the y  subunit 
positions a part of the ATP molecule in the activation loop region of the a subunit 
and  blocks  the phosphorylation  of Thrl72  (Adams  et al 2004).  AMP  binding has 
been  suggested  to  stimulate  the  Thrl72  phosphorylation  by  displacing  ATP  and 
removing this inhibitory interaction (Adams et al 2004). The constitutive activity and 
insensitivity of LKB 1  to AMP is consistent with the observations made with the total
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earlier study by Hawley et al showed that AMPKK partially purified from the liver 
was directly activated by AMP (Hawley et al  1995). Although LKB1  appears to be 
the  predominant  AMPKK  in  the  liver,  the  possibility  of  as  yet  unidentified 
AMPKK(s) which is/are activated by AMP can not be ruled out.
Whether CAMKK is  involved  in the phosphorylation of AMPK in response to  an 
increase in AMP/ATP is not clear. CAMKKa and (3  are activated by Ca2+/calmodulin 
but they are not directly activated by AMP (Hawley et al 2005; Woods et al 2005). 
This  observation  alone  does  not  rule  out  the  possibility  that  AMP  facilitates  the 
phosphorylation  of Thrl72  by  CAMKKp  which  has  been  reported  to  have  some 
activity  in  the  absence  of stimulation  by  Ca  /calmodulin  (Anderson  et  al  1998). 
However,  unlike  LKB1,  AMP  has  been  shown  to  have  no  effect  on  the  in  vitro 
phosphorylation  of  AMPK  by  CAMKKs  (Hawley  et  al  2005).  Although  this 
observation  contradicts  the  earlier  study  by  the  same  group  which  showed  a 
stimulatory  effect  of AMP  (Hawley  et  al  1995),  it  raises  the  possibility  that  the 
AMP-induced  facilitation  of  Thrl72  phosphorylation  by  LKB1  may  involve  a 
specific interaction between LKB1  and AMPK.  Several  other observations  suggest 
that  CAMKKs  specifically mediate  the  phosphorylation  of Thrl72  in  response  to
Ca2+. In HeLa cells, which lack LKB1, AMPK is not activated by AICAR or H2O2
2+ but it is activated by a Ca  inophore (Hurley et al 2005; Hawley et al 2005). In brain
slices,  STO-609 inhibited the activation of AMPK by Ca2+ but it did not affect the
activation of AMPK by phenformin, which increased cellular AMP/ATP (Hawley et
al  2005).  In  contrast  to  these  studies,  Woods  et  al  showed  that  Thrl72
phosphorylation  could be  increased by H2O2  in HeLa cells  and  in  LKB 1-deficient
MEF  cells  (Woods  et al 2005).  Moreover,  transfection of HeLa cells  with  siRNA
against CAMKKp decreased the basal AMPK activity and both H2O2 and inomycin
stimulated AMPK activity (Woods  et al 2005).  They also  showed that in NIH3T3
cells,  which  express  both  LKB1  and  CAMKKs,  the  activation  of  AMPK  by
inomycin,  AICAR and  H2O2  were only partially inhibited by STO-609  whereas  in
the  LKB 1-deficient  MEF  cells,  their  effects  were  completely  inhibited  by  the
inhibitor,  suggesting  that  Ca2+  and  AMP  activate  AMPK  via  both  LKB1  and
CAMKKp (Woods et al 2005).  Offering a possible explanation for the discrepancy
between this study and those by Hurley et al and Hawley et al described above, these
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the activation of AMPK by AMP and Ca2+ signalling, respectively, the distinction is 
likely to be blurred in vivo because an increase in Ca2+ is often associated with an 
increase in AMP and vice versa, possibly due to the action of the Ca2+ pump (Woods 
et al 2005).
(b) Creatine/Creatine phosphate (Cr/CrP)
AMPK has been reported to be inhibited in vitro by physiological concentrations of 
creatine  phosphate  (CrP)  (5-40mM),  and  this  effect  has  been  shown  to  be 
antagonised by creatine (Cr) (Ponticos et al 1998). The regulation of AMPK activity 
by Cr/CrP is consistent with the energy sensing role of AMPK. The effect of Cr/CrP 
on AMPK is not affected by the presence of AMP, suggesting Cr/CrP bind to a site 
distinct from the AMP binding site (Ponticos et al 1998). Whether Cr/CrP affects the 
phosphorylation of Thrl72 by AMPKKs remained unknown. Recently, Taylor et al 
showed  that  physiological  concentrations  of  CrP  (5-50  mM)  did  not  affect  the 
activation of recombinant aipiyl  or a2p2y2 by the recombinant LKB1  complex or 
the activation of AMPK purified from the liver by recombinant LKB1  (Taylor et al
2005). Moreover, the activity of aipiyl or a2p2y2 were not inhibited by CrP, and Cr 
did not activate a2p2y2 or the activation of a2p2y2 by recombinant LKB1  (Taylor et 
al 2005).  However,  they did  observe  an  inhibitory effect of CrP  on crude  AMPK 
purified from rat liver and skeletal muscle by PEG precipitation. However, this effect 
was not specific for CrP (glucose-6 -phosphate also inhibited crude AMPK), and the 
inhibitory effect by CrP or glucose-6 -phosphate was not seen in the purer preparation 
of AMPK obtained by immunoprecipitation, suggesting that the inhibitory effect of 
CrP seen in the crude AMPK preparation and possibly that observed by Ponticos et 
al  may be  an  artefact  due  to  contaminating  enzymes  such  as  creatine  kinase  and 
phosphatases that act on CrP or other small phosphomolecules and possibly perturb 
the concentrations of free phosphate, ATP or AMP (Taylor et al 2005).
(c) NAD+ /NADH
The recombinant  AMPK  heterotrimer  has  been  shown  to be activated by (3-NAD+
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on  the  concentrations  of  AMP  and  ATP;  increasing  the  concentration  of  AMP 
increased  the  potency  of NADH  to  inhibit  AMPK  and  slightly  increased  that  of 
NAD+  to  activate  AMPK  (Rafaeloff-Phail  et  al  2004).  The  ability  of NADH  to 
inhibit  AMPK  is  decreased  with  the  increasing  concentration  of ATP  (Rafaeloff- 
Phail et al 2004).The physiological significance of this effect is not clear. The effect 
of NAD+/NADH on covalent modification of AMPK is unknown.
(d) Hyperosmotic stress
In  H-2Kb  muscle  cells,  sorbitol  caused  activation  of both  al  and  a2  AMPK  and 
increased the Thrl72 phosphorylation (Fryer et al 2002). The effect of sorbitol on the 
AMPK activity was independent of changes in the AMP/ATP ratio and was additive 
to the effects of AICAR and DNP, suggesting hyperosmotic stress activates AMPK 
by a distinct pathway (Fryer et al 2002). This is supported by the study by Daniel and 
Carling  who  showed  that  the  al  chimeric  protein  containing  the  C-terminal 
regulatory region of snflp coexpressed with the SNF1  regulatory subunits in CCL13 
cells was not activated by an increase in the AMP/ATP  ratio but was  activated by 
sorbitol (Daniel and Carling 2002b).  LKB1  was shown to be required for the effect 
of sorbitol  to  increase the Thrl72  phosphorylation (Woods  et al 2003,  Shaw et al 
2003). However, like AMP/ATP-raising treatments, sorbitol did not affect the LKB1 
activity in cultured cells (Woods et al 2003,  Shaw et al 2003).  Thus, how sorbitol, 
which  does  not  increase  AMP/ATP,  increases  the  LKBl-mediated  Thrl72 
phosphorylation is unknown. Hyperosmotic stress is known to activate a number of 
kinases including PKA, MLTK, PI3K, PKC, and p38 MAPK (Mao et al 2004; van 
der  Kaay  et  al  1999;  Schaffler  et al  2000).  It  appears  that  PI3K,  PKC,  and  p38 
MAPKa/p  are  not  involved  in  the  sorbitol  induced  AMPK  activation  (Fryer  et  al
2002).
(e) Insulin
Insulin  has  been  known  to  inhibit  AMPK  activity  in  the  heart  (Gamble  and 
Lopaschuk  1997;  Clark  et  al 2004).  This  effect  was  shown  to  be  independent  of
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decreased the extent of the AMPK activation and Thrl72 phosphorylation increased 
by ischemia or anoxia by a mechanism which was again independent of AMP/ATP 
and Cr/CrP but was  sensitive to wortmannin (Beauloye  et al 2001).  Subsequently, 
Kovacic  et al demonstrated that the  Thrl72 phosphorylation was  decreased  in  the 
heart  of  transgenic  mice  and  neonatal  cardiac  myocytes  over-expressing 
constitutively  active  PKB  (Kovacic  et al  2003).  A  possible  mechanism  by  which 
insulin inhibits AMPK activity has been recently described by Horman et al, who 
showed  that  PKB  phosphorylates  the  a  subunit  of AMPK  at  Ser485/491  in  vitro 
(Horman et al 2006) (Section 1.6.4). They also showed in the perfused heart that the 
phosphorylation  of  Ser485/491  was  increased  by  insulin  and  by  ischemia.  The 
phosphorylation  of  Ser485/491  by  ischemia  is  consistent  with  the 
autophosphorylation  of this  site.  It  may be  possible  that  this  autophosphorylation 
serves  as  a negative  feedback  mechanism.  Similar to  the  in  vitro  observation,  the 
prior phosphorylation of Ser485/491  by insulin in the perfused heart prevented the 
phosphorylation  of  Thrl72  by  ischemia  (Horman  et  al  2006).  Consistent  with 
Horman et al, Soltys et al showed that adenoviral expression of constitutively active 
PKB in neonatal cardiac myocytes prevented the increase in the phosphorylation of 
Thrl72 and ACC2 Ser227 (ACC1  Ser79) induced by adenoviral expression of LKB 1  
or chemical hypoxia (Soltys et al 2006).
(f)  Metformin
The  anti-diabetic  drug  metformin  decreases  plasma  glucose  by  inhibiting  hepatic 
glucose  production  and  by  stimulating  peripheral  glucose  utilisation.  Metformin 
increases Thrl72 phosphorylation and activates AMPK in various tissues including 
the liver (Zhou et al 2001),  skeletal muscle (Musi et al 2002), heart (Kovacic et al 
2003),  adipocyte  (Huypens  et  al  2005b)  and  endothelial  cells  (Zou  et  al  2004). 
Metformin  has  been  shown  to  inhibit  complex  1   of the  mitochondrial  respiratory 
chain  (El  Mir  et  al  2000;  Owen  et  al  2000)  and  the  activation  of AMPK  by 
metformin is associated with decreased ATP and CrP in skeletal muscle (Musi et al
2002).  However,  AMP/ATP-independent  increases  in  Thrl72  phosphorylation  and 
AMPK  activity  have  been  reported  in  CHO  fibroblasts,  a  rat  hepatoma  cell  line
60(H4IIE), and in cultured muscle cells (H-2Kb) (Hawley et al 2002; Fryer et al 2002). 
Metformin did not directly stimulate the activation of purified AMPK by a partially 
purified AMPKK in vitro and it did not protect AMPK from dephosphorylation by 
PP2C (Hawley et al 2002).  However, the AMPKK activity present in the lysate of 
metformin-treated  H4IIE  cells  was  increased  compared  to  that  in  untreated  cells 
(Hawley  et  al  2002),  raising  the  possibility  that  metformin  activates  AMPKK 
through a covalent modification.
(g)  Peroxynitrite
A  series  of studies by Zou et al primarily done  in endothelial cells  suggested that 
some  of  the  reported  AMP/ATP-independent  activation  of  AMPK,  including 
metformin and hypoxia (Section  1.6.5.o), may be mediated by peroxynitrite (Zou et 
al 2002, 2003,  and 2004;  Xie et al 2006).  In endothelial cells, both metformin and 
peroxynitrite  increased  Thrl72  phosphorylation  and  activated  AMPK  without 
changing AMP/ATP (Zou et al 2003 and 2004). Peroxynitrite has been shown to be 
increased  by metformin  in  endothelial  cells  in  vitro  or in  the heart  of metformin- 
administered  mice  (Zou  et  al  2004).  The  involvement  of  peroxynitrite  in  the 
activation  of  AMPK  by  metformin  in  endothelial  cells  is  suggested  by  the 
observation that the activation of AMPK by metformin was abolished by inhibiting 
the two precursors of peroxynitrite, superoxide and nitric oxide, by over-expression 
of superoxide dismutase  and by an eNOS  inhibitor,  respectively (Zou  et al 2004). 
Metformin is likely to increase superoxide by inhibiting the mitochondrial complex I 
as  functional  mitochondria  were  required  for  the  effect  of metformin  to  produce 
superoxide,  and  rotenone,  another  inhibitor  of  the  complex  I,  also  increased 
superoxide  (Zou  et  al  2004).  In  endothelial  cells,  hypoxia  or  reoxygenation  after 
hypoxia  caused  the  activation  of  AMPK  and  this  effect  was  inhibited  by 
overexpression  of  superoxide  dismutase  or  a  NOS  inhibitor,  indicating  that 
peroxynitrite is also involved in the regulation of AMPK during hypoxia (Zou et al
2003).  Further  limited  studies  by  the  same  investigators  have  shown  that 
peroxynitrite activates AMPK in other cell types including cardiac myocytes, retinal 
pericytes,  cultured  rat  vascular  smooth  muscle  cells  and  mouse  3T3-L1  pre­
adipocytes, suggesting the possibility that the regulation of AMPK by metformin and
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2006).  Supporting  this  possibility,  the  effect  of  metformin  to  increase  Thrl72 
phosphorylation in the cardiac myocytes was inhibited by superoxide dismutase and 
by a NOS inhibitor (Zou et al 2004).
These investigators have also provided evidence that peroxynitrite activates AMPK 
by increasing the association of LKB1  with the AMPK a subunit (Xie et al 2006). 
This  is  a novel  mechanism  for regulating the  ‘effective  activity’  of LKB1,  which 
appears to be constitutively active.  They have demonstrated that PKC^,  which has 
been shown to be activated by peroxynitrite, is required for the association of LKB 1  
with AMPK (Xie  et al 2006).  Moreover,  PKC^  has  been  shown  to  phosphorylate 
LKB1  at Ser428  (Ser431  in the human sequence)  in vitro, and the mutation of this 
residue  to  alanine  inhibited  the  peroxynitrite-induced  activation  of  AMPK, 
suggesting that Ser428  may be  important for the  interaction of LKB1  with AMPK 
(Xie et al 2006). Previously, the phosphorylation of Ser428 has been reported to have 
no effect on the catalytic activity of LKB1 (Sapkota et al 2001). The possible role of 
Ser428  in the  regulation of the  interaction  of LKB1  with AMPK may explain the 
previous  observation reported by Sapkota et al that mutating Ser428 prevented the 
suppression of cell growth by LKB1  in G361  melanoma cells despite the lack of the 
effect of the Ser428 mutation on the catalytic activity of LKB1  (Sapkota et al 2001). 
It may also  explain the observation made by Kimball  et al that the increase  in the 
AMPK Thrl72 phosphorylation in response to glucagon in the liver was associated 
with the increased PKA phosphorylation of LKB1  at Ser428 (Kimball et al 2004). In 
the  heart,  ischemia  has  been  reported  to  activate  AMPK  by  a  PKC-dependent 
mechanism (Nishino et al 2004). Although the activation of PKCe by ischemia was 
demonstrated, the activation of PKC^ was not determined in this study (Nishino et al
2004).  Whether,  PKC  isoforms  other than PKC^  can phosphorylate  LKB1  Ser428 
and regulate AMPK is unknown.
PKC^  was  suggested  to  be  activated  by peroxynitrite  through  a  cSrc-PI3K-PDKl 
pathway in endothelial  cells because the activation of AMPK by peroxynitrite was 
inhibited by wortmannin or by expression of dominant negative cSrc or PDK1  (Zou 
et al 2003). The activation of PI3K by peroxynitrite contradicts the observation that 
insulin  inhibits  AMPK  via  the  PI3K-PKB  pathway  (Section  1.6.5.e).  However,  it
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PI3K.
(h) Ca2+
In addition to the aforementioned activation of AMPK by Ca  in brain  slices  and 
cultured cells (Section 1.6.5.a), stimulation of several cell surface receptors have also 
been reported to activate AMPK by increasing intracellular Ca2+. The stimulation of 
the  thrombin  receptor  or  P2Y  purinergic  receptor  in  the  human  umbilical  vein 
endothelial  cells  (HUVEC)  and  triggering  of  the  T  cell  antigen  receptor  in  T 
lymphocytes  have  all  been  shown  to  increase  Thrl72  phosphorylation  via
9+
AMP/ATP-independent and Ca  -dependent mechanisms  (Stahmann et al 2006;  da 
Silva et al 2006; Tamas et al 2006). The increase in Ca2+ was likely to be mediated 
by  Gq  and  PLC  (Stahmann  et  al  2006).  The  effects  of all  three  receptors  on  the 
AMPK  activation  were  abolished  by  STO-609,  indicating  the  involvement  of 
CAMKKs  (Stahmann  et al 2006;  da  Silva  et al 2006;  Tamas  et al 2006).  LKB1, 
which is also expressed in HUVEC, does not seem to be involved in the activation of 
AMPK by thrombin as the effect was insensitive to siRNA against LKB1  (Stahmann 
et  al  2006).  In  contrast,  the  activation  of  AMPK  in  HUVEC  by  AICAR  was 
insensitive  to  CAMKKp  inhibition  but  it  was  inhibited  by  siRNA  against  LKB1 
(Stahmann  et al 2006).  These  observations  provide  additional  support  for  distinct 
roles of LKB1 and CAMKKs. Histamine in HUVEC has also been shown to activate 
AMPK  via  Ca  -dependent  mechanism  (Thors  et  al  2004).  Stimulation  of  ai 
adrenergic  receptor  in  skeletal  muscle  also  appears  to  activate  AMPK  by  a  Ca2+- 
dependent mechanism (Hutchinson and Bengtsson 2006; Section 1.6.5.p).
(i) Adipokines
An  adipocyte-derived  hormone  leptin has  been  shown to  have  different  effects  on 
AMPK  in  different  tissues.  Leptin  activates  a2  but  not  al  AMPK  in  the  skeletal 
muscle (Minokoshi et al 2002). However, leptin inhibits AMPK in the hypothalamus 
(Andersson et al 2004;  Minokoshi et al 2004), while it seems to have no effect on 
AMPK in the perfused heart (Atkinson et al 2002). In vivo administration of leptin
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effect  of  leptin  on  the  skeletal  muscle  and  indirect  slower  effect  through  the 
hypothalamic-sympathetic nervous system (Minokoshi et al 2002). The direct effect 
of  leptin  seems  to  be  mediated  by  the  AMP-dependent  pathway  as  a  transient 
increase in AMP was observed immediately after leptin administration (Minokoshi et 
al  2002).  However,  the  delayed  indirect  effect  is  likely  to  be  mediated  via  an 
AMP/ATP-independent mechanism through the ai adrenergic receptor as the in vivo 
effect was sensitive to phentolamine and phenylephrine activated AMPK in isolated 
skeletal muscle (Minokoshi et al 2002).
Another adipocyte-derived hormone adiponectin activates AMPK in skeletal muscle, 
liver,  and  pancreatic  p  cells  (Yamauchi  et  al  2002;  Huypens  et  al  2005a). 
Adiponectin receptors  are also expressed in the cardiac myocytes, which also have 
been  shown  to  secrete  adiponectin  (Pineiro  et  al  2005).  Adiponectin  increased 
AMPK Thrl72 phosphorylation in the HL-1  atrial cardiac myocyte cells (Pineiro et 
al  2005).  The  mechanism  by  which  adiponectin  activates  AMPK  is  not  clear. 
However adiponectin increased AMP in skeletal muscle, suggesting the involvement 
of the AMP-dependent pathway (Yamauchi et al 2002). In bovine aortic endothelial 
cells,  the  adiponectin-induced  increase  in  AMPK  Thrl72  phosphorylation  was 
inhibited  by  wortmannin,  suggesting  that the  adiponectin  effect  may  also  involve 
PI3K (Chen et al 2003).
Another adipocyte-derived hormone resistin inhibits AMPK in the liver and skeletal 
muscle by an unknown mechanism (Banerjee et al 2004; Muse et al 2004; Palanivel 
and Sweeney 2005).
(j) Ghrelin
Ghrelin is produced in the stomach and it stimulates food intake. Like leptin, ghrelin 
has  different  effects  on  AMPK  in  different  tissues.  Ghrelin  increases  Thrl72 
phosphorylation or AMPK activity in the hypothalamus and heart (Andersson et al 
2004;  Kola et al 2005).  However, ghrelin decreases the Thrl72 phosphorylation or 
AMPK  activity  in  the  liver  and  adipose  tissue,  while  it  has  no  effect  in  skeletal
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specificity is unknown.
(k) Glycogen
There appears to be a complex relationship between AMPK activity and the cellular 
glycogen content. High cellular glycogen was shown to be associated with decreased 
basal and AICAR-stimulated a2 AMPK activity in skeletal muscle (Wojtaszewski et 
al 2002). Moreover, the activation of AMPK in skeletal muscle induced by AICAR 
or by glucose withdrawal was accompanied by a decrease in the glycogen synthase 
activity (Wojtaszewski  et al 2002;  Halse et al 2003).  These observations  suggest a 
reciprocal  relationship  between  AMPK  and  the  cellular  glycogen  level.  The 
inactivation of glycogen  synthase  is probably due to the  direct phosphorylation  of 
glycogen synthase by AMPK,  which has  been  shown in  vitro  (Carling and Hardie 
1989).  The mechanism by which glycogen inhibits AMPK is not clear.  It has been 
shown that glycogen does not directly inhibit AMPK activity (Polekhina et al 2003). 
The  inhibitory  effect  may  involve  glycogen-associated  phosphatases  or  other 
glycogen-associated enzymes. However, this reciprocal relationship between AMPK 
and  glycogen  has  not  been  observed  under  some  conditions.  Aschenbach  et  al 
demonstrated  that  in  vivo  AICAR  administration  increased  glycogen  in  skeletal 
muscle despite the activation of a2 AMPK (Aschenbach et al 2002). These authors 
attributed the glycogen accumulation to increased glucose uptake because no change 
in the activity of glycogen synthase or phosphorylase was observed (Aschenbach et 
al  2002).  Several  naturally  occurring  mutations  in  the  human  y2  gene  have  been 
shown to cause excessive glycogen accumulation the heart. The myocardial glycogen 
accumulation  causes  ventricular  pre-excitation,  the  condition  called  Wolff- 
Parkinson-White  syndrome,  which  is  associated  with  the  development  of cardiac 
hypertrophy.  Transgenic mice expressing some of these mutations (N488I, R302Q, 
R531G) have been generated (Arad et al 2003; Davies et al 2006; Sidhu et al 2005). 
All  of  these  mice  showed  glycogen  accumulation  in  the  heart  and  cardiac 
hypertrophy  (Arad  et al 2003;  Davies  et al 2006;  Sidhu  et al 2005).  The  AMPK 
activity  is  decreased  in  the  heart  of R302Q-expressing  mice  (Sidhu  et  al  2005), 
consistent with the reciprocal relationship between AMPK and glycogen. The cardiac
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different at  1  week of age and there was also no glycogen accumulation at this age 
(Davies et al 2005). However, glycogen accumulation was seen at four week of age 
and this was  associated with the decreased AMPK activity (Davies et al 2005).  In 
contrast to these mutations, the N488I mutation is associated with accumulation of 
glycogen  despite  increased  AMPK  activity  (Arad  et  al  2003).  Thus,  the  precise 
relationship between AMPK and glycogen is not clear and requires further research.
(1) Glucose
Glucose has been shown to decrease Thrl72 phosphorylation and AMPK activiy in 
the pancreatic p-cells and skeletal muscle (da Silva Xavier et al 2000 and 2003; Itani 
et al 2003;  Halse  et al 2003).  While  glucose  caused  the  expected  decrease  in the 
AMP/ATP ratio in the P-cells (this is implicated in the 'glucose sensing1 function of 
the  P-cells  and  the  regulation  of insulin  release)  (da  Silva  Xavier  et  al  2003)), 
glucose did not affect the total adenine nucleotides and CrP in skeletal muscle (Itani 
et al 2003). The mechanism by which glucose inhibits AMPK in the skeletal muscle 
is unknown.  However, the possibility of a localised change in free AMP and ATP 
cannot  be  ruled  out.  The  effect  of glucose  does  not  appear  to  involve  glycogen, 
because inhibiting glycogen phosphorylase inhibited the decrease in glycogen caused 
by low glucose but it did not inhibit the activation of AMPK by low glucose (Halse 
et al 2003). Gimeno-Alcaniz and Sazz have demonstrated using the yeast two-hybrid 
system  that  the  interaction  of  AMPK  a2  and  yl  increased  when  the  glucose 
concentration  was  lowered  (Gimeno-Alcaniz  and  Sazz  2003).  The  significance  of 
this  effect  is  unclear  but  it  may  be  possible  that  glucose  or  a  glucose  metabolite 
causes a conformational modification of the AMPK complex which may affect the 
regulation by AMPKK or phosphatases.
(m) Long chain fatty acids
The physiological concentrations of long chain fatty acids (LCFA) such as palmitate 
have been  shown to  increase Thrl72 phosphorylation  and activate AMPK in heart 
and skeletal muscle (Hickson-Bick et al 2000;  Clark et al 2004;  Fediuc et al 2006;
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(Olsen and Hansen 2002; Dobrzyn et al 2005; Crozier et al 2005; Folmes et al 2006). 
Apart from the observation that fatty acids increase Thrl72 phosphorylation without 
a detectable change in AMP/ATP, CrP, or glycogen content (Clark et al 2004; Watt 
et  al  2006),  the  mechanism  of  the  fatty  acid-induced  activation  of  AMPK  is 
unknown.  Watt  et  al  reported  that  paradoxically,  the  activity  of LKB1  towards 
recombinant AMPK was lower in cells treated with fatty acids than in untreated cells 
(Watt  et al 2006).  However,  they found that palmitate  or  oleate  stimulated  the  in 
vitro activation of AMPK by LKB1  by a mechanism dependent on the presence of 
the (3  and y subunits of AMPK (Watt et al 2006). In contrast to Watt et al, Taylor et 
al did not observe a stimulatory effect of palmitate on the activation of AMPK by 
LKB1  in vitro (Taylor et al 2005). Moreover, they showed that the phosphorylation 
and activation of AMPK by LKB 1  or AMPKK purified from the liver were inhibited 
by long chain acyl  CoA esters  such as palmitoyl CoA in vitro  (Taylor et al 2005). 
Whether these in vitro observations are involved in the regulation of AMPK by fatty 
acids in intact cells is unknown.
(n) Contraction
The activation of AMPK seen during skeletal muscle contraction has been attributed 
to the increase in AMP/ATP associated with contraction (Hutber et al 1997; Park et 
al 2002). However, Toyoda et al recently demonstrated that low intensity contraction 
of skeletal muscle caused an increase in the Thrl72 phosphorylation and activation 
of al  AMPK without any changes in the total AMP/ATP (Toyoda et al 2006). This 
could be due to the activation of AMPK by a small or localised change in the free 
AMP concentration which would not be detected by total cellular adenine nucleotide 
measurements by HPLC. However, the authors argue that this possibility is unlikely 
because they did not observe an activation of a2 AMPK, which is more sensitive to 
AMP than al AMPK (Section 1.6.2) during the low intensity contraction. Thus there 
is the possibility that in addition to AMP/ATP, some other factor is also involved in 
the activation of AMPK during muscle contraction (Toyoda et al 2006). Compared to 
skeletal muscle, in the heart, the AMP/ATP ratio remains relatively constant during 
increased  contractile  activity.  However,  an  increase  in  the  AMP/ATP  ratio  during
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observations  suggesting that increased cardiac  contractile activity activates  AMPK 
by increasing the AMP/ATP ratio under some conditions (Section  1.7). Beauloye et 
al have shown that an acute increase in contraction induced by increasing afterload in 
perfused hearts does not increase AMP or AMPK activity, suggesting cardiac muscle 
contraction alone (without an increase in AMP) does not activate AMPK (Beauloye 
et al 2002).  However,  these  authors  also  demonstrated that  PKB  was  activated by 
increased  contraction  (Beauloye  et  al  2002).  These  observations  apparently 
contradict the inhibition of cardiac AMPK by PKB.
(o) Myocardial ischemia
Cardiac  ischemia  is  associated  with  an  increase  in  AMP/ATP  and  activation  of 
AMPK through the phosphorylation of Thrl72 (Kudo et al 1995; Baron et al 2005). 
Sakamoto et al studied the role of LKB1 in the activation of AMPK during ischemia 
using transgenic mice  lacking cardiac  expression of LKB1  (Sakamoto  et al 2006). 
The  deletion  of  LKB1  in  the  heart  prevented  the  increase  in  the  Thrl72 
phosphorylation of AMPK in response to ischemia, suggesting that LKB1  mediates 
the activation of AMPK during ischemia (Sakamoto et al 2006). However ischemia 
has been shown to have no effect on the catalytic activity of LKB1, as measured by 
in vitro phosphorylation of recombinant AMPK by LKB1  immunoprecipitated from 
the ischemic heart,  or on the protein abundance of LKB1,  although LKB1  purified 
from the heart is able to phosphorylate a312 (the truncated catalytic subunit which 
can  be  phosphorylated  and  activated  in  the  absence  of  AMP),  confirming  the 
constitutive activity of LKB1  (Sakamoto et al 2006; Altarejos et al 2005). Thus, as 
suggested for the other AMP/ATP-raising conditions, the phosphorylation of Thrl72 
by  LKB1  during  ischemia  is  also  likely to  be  due  to  the  effect  of AMP  to  make 
AMPK a better substrate for LKB 1, rather than a change in LKB 1  catalytic activity.
Recent  studies  suggest  that  in  addition to  LKB1,  the  activation  of AMPK  during 
ischemia  also  involves  some  other AMPKK  which,  unlike  LKB1,  is  activated  by 
ischemia.  In  the  aforementioned  study  by  Sakamoto  et  al,  whereas  the  Thrl72 
phosphorylation  of  a2  AMPK  induced  by  ischemia  was  completely  abolished,
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deficient  hearts  (Sakamoto  et  al  2006).  This  suggests  that  LKB1  is  the  major 
AMPKK mediating the a2 AMPK activation during ischemia but al  AMPK is also 
activated  by  some  other  AMPKK,  as  well  as  by  LKB1  (Sakamoto  et  al  2006). 
Altarejos  et al found that although LKB1  can be  completely precipitated with  5% 
PEG6000 and it is not present in the supernatant, AMPKK activity still remained in 
the supernatant and this AMPKK activity was increased by ischemia (Altarejos et al
2005). Moreover, Baron et al have shown that the total AMPKK activity present in a 
heart  homogenate  is  increased  by  ischemia  (Baron  et al 2005).  Given  that  LKJB1 
activity is  not  increased  by ischemia,  this  result  further  supports  the  idea that the 
activation of AMPK during ischemia involves an AMPKK whose catalytic activity is 
activated  by  ischemia.  Whether  this  AMPKK  is  a  CAMKK  or  a  yet unidentified 
AMPKK  is  unknown.  The  mechanism  by which  ischemia  activates  this  AMPKK 
also remains to be determined. AMP does not appear to activate this AMPKK as the 
total cardiac AMPKK in the study by Baron et al was not directly activated by AMP 
in vitro (Baron et al 2005).
Recent  studies  have  revealed  that  mild  ischemia  or  hypoxia  increases  Thrl72 
phosphorylation  and  AMPK  activity  without  affecting  AMP/ATP  or  Cr/CrP 
(Altarejos  et al 2005;  Frederich  et al 2005).  This  raises  the possibility that during 
severe  ischemia,  AMPK  is  activated by two parallel pathways;  the AMP pathway 
and a pathway which is independent of AMP but dependent on some factors that are 
generated or activated during mild ischemia or hypoxia. Altarejos et al observed that 
the activity of the non-LKBl  AMPKK present in the 5% PEG6000 supernatant was 
increased  by mild  ischemia (Altarejos  et al 2005).  Thus,  this  non-LKBl  AMPKK 
may be responsible  for the activation of AMPK during hypoxia/mild ischemia and 
for  AMP-independent  activation  of AMPK  during  severe  ischemia.  However  the 
involvement  of  LKB1  in  the  AMP-independent  activation  of  AMPK  during 
ischemia/hypoxia  cannot  be  ruled  out  because  it  is  conceivable  that  ‘non-AMP 
factors’  may  stimulate  the  phosphorylation  of AMPK by LKB1  by modifying the 
interaction of AMPK with LKB 1   or by modifying a property of AMPK such as the 
affinity of AMPK for AMP.  Supporting the  latter possibility,  Frederich  et al have 
shown  that  hypoxia  increases  the  sensitivity  of  AMPK  to  stimulation  by  AMP 
(Frederich et al 2005).
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Since the initial report by Moule and Denton that isoproterenol increased Thrl72 and 
AMPK  activity  in  epididymal  fat  cells  (Moule  and  Denton  1998),  several  groups 
have reported the activation of AMPK through adrenergic receptors in the Chinese 
hamster  ovary  cells  (Kishi  et  al  2000),  skeletal  muscle  (Minokoshi  et  al  2002; 
Hutchinson  and  Bengtsson  2006),  white  adipocytes  (Yin  et  al  2003;  Daval  et  al
2005) and brown adipocytes (Inokuma et al 2005; Hutchinson et al 2005). Although 
these  studies  did  not  investigate  the  signalling  mechanism  linking  the  adrenergic 
receptors to AMPK in great detail, the adrenergic activation of AMPK in adipocytes 
was shown to be exclusively mediated by the P receptor and the cAMP pathway (Yin 
et al 2003;  Daval et al 2005;  Hutchinson et al 2005), while that in skeletal muscle 
was shown to be exclusively mediated by the ai receptor (Hutchinson and Bengtsson
2006). The effect of the c l\  adrenergic stimulation on AMPK in skeletal muscle was
also shown to be independent of changes in the AMP/ATP ratio, but it appeared to
2+ involve Ca  (Hutchinson and Bengtsson 2006).  It is not clear whether the effect in 
adipocytes was due to an increase in the AMP/ATP ratio. Inokuma et al reported an 
increase in AMP/ATP after noradrenaline stimulation in brown adipocytes, possibly 
due  to  the  activation  of  the  uncoupling  protein,  UCP1  (Inokuma  et  al  2005). 
However,  a  subsequent  study  by  Hutchinson  et  al  using  UCP1  knock-out  brown 
adipocytes showed UCP1  was not necessary for AMPK activation by noradrenaline, 
although the effect of noradrenaline on AMP/ATP in UCPl-null adipocytes was not 
determined (Hutchinson et al 2005). No measurements of AMP/ATP were made in 
the other studies reporting adrenergic activation of AMPK in adipocytes. The effect 
in  adipocytes  could  also  be  due  to  (3   adrenergic  stimulation  of lipolysis  and  an 
increase in long chain fatty acids which have been shown to activate AMPK (Section 
1.6.5.m).
1.7  The possibility of the  regulation  of AMPK through  adrenergic 
receptors in the heart
Clarifying an effect of adrenergic receptor stimulation on the AMPK activity in the 
heart is important because it may be possible that, given the emerging role of AMPK
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the  biological  effects  of adrenergic  receptor  stimulation  are  mediated  through  the 
regulation  of AMPK.  This  possibility  is  supported  by  the  recent  observations  by 
Hutchinson  and  Bengtsson  that  inhibiting  AMPK  abolished  aj  receptor-mediated 
glucose uptake in skeletal muscle and partially blocked p receptor-mediated glucose 
uptake  in  brown  adipocytes  (Hutchinson  and  Bengtsson  2006;  Hutchinson  et  al
2005).  In the heart,  in  addition to  regulating  glucose uptake  and  fuel  metabolism, 
AMPK is thought to be involved in cardiac hypertrophy and apoptosis, although the 
precise roles of AMPK in these processes are still not clear (Dyck and Lopaschuk
2006).  As  summarised  in  the  Figure  1.4,  the  stimulation  of  cardiac  adrenergic 
receptors  activates  a number of pathways  that could potentially activate  or inhibit 
AMPK activity.  These  include  the  activation of PKA,  PKC  and  Ca2+,  which have 
been shown to activate AMPK in non-cardiac tissues (Sections  1.6.5.g and h),  and 
PKB,  which  has  been  shown to  inhibit AMPK in the  heart  (Section  1.6.5.e).  The 
stimulation of adrenergic receptors also increases cardiac muscle contraction which 
could activate AMPK by the AMP/ATP-dependent pathway. However, An et al have 
reported  that  isoproterenol  has  no  effect  on  AMPK  Thrl72  phosphorylation  in 
perfused hearts or in isolated myocytes (An et al 2005). Moreover, Clark et al have 
shown that  adrenaline  does  not change AMPK  activity in  isolated hearts perfused 
with glucose as a sole substrate (Clark et al 2004). These results suggest that, unlike 
in skeletal muscle and adipocytes, neither a nor (3  receptor stimulation directly alters 
AMPK activity in the heart.
However, the possibility that adrenergic stimulation of contraction activates AMPK 
through an AMP/ATP-dependent pathway under some conditions  can not be ruled 
out.  Studies  with  perfused  hearts  have  reported  different  effects  of  adrenergic 
stimulation on cardiac AMP/ATP. AMP/ATP is unaffected by adrenergic stimulation 
in  some  studies  (Collins-Nakai  et  al  1994;  Goodwin  and  Taegtmeyer  1999)  and 
presumably in the  aforementioned  studies  by An  et al and  Clark et al, while  it  is 
increased in the other studies (Goodwin et al  1998b). This is likely to be due to the 
difference in the intensity of the stimulation, the metabolic substrates included in the 
perfusion media, or the mode of the perfusion (Langendorff vs. working heart mode). 
No  studies  have  directly  correlated  the  increase  in  AMP/ATP  during  adrenergic
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Figure  1.4  The  hypothetical  regulation  of  cardiac  AMPK  by 
adrenergic agonists
Dotted lines indicate hypothetical pathways based on observations in non-cardiac 
tissues, or pathways which are still controversial. See text for details.
72stimulation  to  the  AMPK  activity  in  perfused  hearts.  In  vivo  administration  of 
isoproterenol increased AMPK Thrl72 phsophorylation in the heart possibly due to 
the increased heart contraction, although no measurements of AMP/ATP were made 
(An et al 2005). However, other investigators reported that infusion of dobutamine in 
swine  did  not  cause  activation  of cardiac  AMPK  (King  et al 2005).  Again,  these 
differences in in vivo observations could be due to the difference in the intensity of 
contraction.  In  the  former  study,  the  heart  was  isolated  one  hour  after  the 
isoproterenol  injection whereas the  heart  in the  latter  study was  stimulated  for  15 
minutes. This possibility is supported by the studies by Coven et al and Musi et al 
investigating  the  effect  of  exercise,  which  is  known  to  increase  plasma 
catecholamines (Wadley et al 2006), on the activation of AMPK in the heart.  Low 
intensity exercise  ( 1 0  minutes treadmill running) did not cause activation of cardiac 
AMPK, while moderate (16 minutes running) and high intensity (32 minutes or 30 
minutes running) exercise decreased the cardiac high energy phosphates and caused a 
graded activation of AMPK in the heart (Coven et al 2003; Musi et al 2005).
The finding that long chain fatty acids activate AMPK in the perfused heart and in
neonatal  cardiac  myocytes  (Section  1.6.5.m)  raises  the  possibility  that  in  vivo,
catecholamines  may  activate  cardiac  AMPK  by  increasing  plasma  fatty  acids.
However, in the aforementioned study by Clark et al, it was discovered that although
adrenaline did not affect the AMPK activity in the heart perfused with glucose alone,
it completely abolished the activation of a2 AMPK (the predominant cardiac isoform
(Section  1.6.2))  by palmitate  (Clark et al 2004).  This  finding  implies  that  in  vivo,
most of the activation of cardiac AMPK due to the increased  supply of fatty acids
would be counteracted during adrenergic stimulation. Although detailed information
regarding  the  time-course  of the  effect  of  fatty  acids  to  activate  AMPK  is  not
available, the effect was not found to be transient in both perfused heart and neonatal
myocytes (Clark et al 2004; Hickson-Bick et al 2000). Thus, given that the heart is
constantly exposed to fatty acids, it may be possible that there is a tonic activation of
cardiac AMPK by fatty acids in vivo. If this turned out to be the case, the adrenergic
stimulation in vivo would be expected to not only counteract the activation of AMPK
by the increased fatty acids supply but also decrease the activity of a2 AMPK in the
heart to the level below the unstimulated level. To date, this possibility has not been
conclusively  examined.  Several  in  vivo  studies  have  shown  cardiac  AMPK  is  not
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Musi et al 2005;  An et al 2005;  King et al 2005).  However, the interpretations of 
some  of these  studies  are  complicated  by  activation  of AMPK  secondary  to  an 
increase in AMP/ATP. In addition, the effect of ai-receptor stimulation has not been 
directly examined in vivo (e.g. by infusion of ai agonists).
The  pathway by which  fatty acids  covalently activate  AMPK and  how  adrenaline 
inhibits this effect are unknown.  The observation that adrenaline only inhibited the 
activation  of  a2  AMPK,  despite  the  activation  of  both  al  and  al  AMPK  by 
palmitate, suggests that adrenergic signalling directly acts on the a2 AMPK complex 
or  the  proteins  specifically  associated  with  a2  AMPK,  rather  than  blocking  the 
conversion of fatty acids to the metabolite that activates AMPK.  The activation of 
AMPK by fatty acids was found to be independent of changes in AMP/ATP. It is not 
known whether adrenaline inhibits the activation of AMPK by other conditions that 
are  known  to  activate  AMPK  independently  of AMP/ATP  such  as  hyperosmotic 
stress.  The activation of cardiac AMPK by high intensity exercise may suggest that 
adrenaline  does  not  inhibit  the  activation  of  AMPK  through  an  increase  in 
AMP/ATP, although this needs to be clarified.
1.8  The purpose of the present study
The purpose of the present study was to investigate further the observation made by 
Clark et al (Clark et al 2004) that adrenaline inhibited the increase in AMPK Thrl72 
phosphorylation and activity induced by palmitate in the heart. Specifically, I sought 
to elucidate the adrenergic signalling pathways involved in this effect and get some 
insights  into  the  mechanism  by  which  adrenergic  signalling  prevents  the 
phosphorylation of AMPK Thrl72.  I also tried to determine whether this inhibitory 
effect was  specific  for the  activation  of AMPK by long  chain  fatty  acids,  or  if it 
could also prevent the activation of AMPK by other conditions such as hyperosmotic 
stress and AMP-raising treatments. The use of quiescent cardiac myocytes is suited 
for  this  purpose  for  several  reasons.  First,  it  allows  determination  of whether the 
effect of palmitate and adrenaline observed in perfused hearts was dependent on non­
cardiac  myocytes  (e.g.  endothelial  cells)  in  the  whole  heart.  Second,  because
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effects of different treatments (e.g. inhibitors and activators of adrenergic signalling 
pathways)  on the  effect adrenaline  on AMPK can be more  efficiently investigated 
than in perfused hearts. Lastly, the use of quiescent cardiac myocytes is suited for the 
elucidation  of  the  specific  effects  of  adrenaline  on  different  AMPK-activating 
conditions  because  it  eliminates  the  possibility  of  AMPK  activation  due  to  an 
increase  in  AMP/ATP  that  might  occur  during  adrenergic  stimulation  in  the 
contracting heart.
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2.1  Commercial preparations
All  routinely  used  chemicals  and  chemicals  which  are  not  specified  below  were 
obtained from Sigma-Aldrich or BDH (VWR International).
Purified  water  used  for  cardiac  myocyte  isolation  was  from  BDH  (VWR 
International).
0 2 :CC>2 (95%:5%) cylinders were from BOC Ltd.
Sodium pentobarbitone was from Merial.
Collagenase  Type  2  and  hyaluronidase  were  from  Worthington  Biochemical 
Corporation.
DNase I was from Roche.
(-)-Epinephrine  bitartrate,  (-)-isoproterenol  hydrochloride,  (R)-(-)-phenylephrine 
hydrochloride,  phentolamine  hydrochloride,  (+/-)-propranolol  hydrochloride, 
forskolin,  dibutyryl  cyclic  AMP  sodium  salt,  8-(4-chlorophenylthio)-2’-0- 
methyladenosine 3’, 5’-cyclic monophosphate (8-CPT-2’-0-Me-cAMP) sodium salt, 
insulin,  wortmannin,  D-sorbitol,  phenformin  hydrochloride,  phorbol-12-myristate-
7613-acetate,  BSA (essentially fatty acid  free,  fraction V), palmitic  acid  sodium  salt, 
protein  G-Sepharose  and  bicinchoninic  acid  protein  assay  kit  were  from  Sigma- 
Aldrich.
NEFA C Test kit was from Wako Chemicals Inc.
AICAR, oligomycin, and KN93 were from Calbiochem (Merck Biosciences).
Anti-AMPKal  antibody  (sheep)  was  from  Prof.  David  Carling,  Clinical  Sciences 
Centre, Hammersmith Hospital, Imperial College London.
Anti-AMPKa2 antibody (goat), anti-phospho-Serl6 PLB antibody (rabbit) and anti- 
phospho-Thrl7 PLB antibody (rabbit) were from Santa Cruz Biotechnology Inc.
SAMS peptide was from Cambridge Research Biochemicals.
[y-33P] ATP, [9,10-3H] palmitate, and [U-l4C]-glucose were from N.E.N.
Anti-phospho-Thrl72 AMPKa antibody (rabbit), anti-phospho-Ser485/491  AMPKa 
antibody  (rabbit),  anti-AMPKa  antibody  (rabbit),  anti-phospho-Ser79  ACC1 
antibody  (rabbit),  anti-ACC  antibody (rabbit),  anti-phospho-Thr308  PKB  antibody 
(rabbit),  anti-phospho-Ser473  PKB  antibody  (rabbit),  anti-PKB  antibody  (rabbit), 
HRP-linked  anti-rabbit  secondary  antibody  and  ECL  detection  kit 
(LumiGLO™Reagent and Peroxide) were from Cell Signalling Technology.
IRDye™800-conjugated anti-rabbit secondary antibody was from Rockland.
Odyssey blocking buffer was from Licor.
NuPAGE®  4-12%  Bis-Tris  gels,  PVDF  membranes,  and  buffers  used  for  SDS- 
PAGE  and  western  blotting  (NuPAGE®  LDS  Sample  Buffer,  Sample  Reducing 
Agent,  Antioxidant,  MOPS  SDS  Running  Buffer,  and  Transfer  Buffer)  were  from 
Invitrogen.
772.2  Laboratory preparations
2.2.1 Palmitate bound to albumin
Sodium palmitate was  added  to  a  solution containing  15%  (w/v)  of bovine  serum 
albumin (BSA) and 0.9% (w/v) NaCl (250mg sodium palmitate was added per 50ml 
of the solution). The mixture was sonicated in a sonicating water bath until an even 
mixture was obtained.  The mixture was incubated at 50°C for 30 minutes followed 
by  incubation  at  4°C  overnight.  Undissolved  sodium  palmitate  was  removed  by 
filtration through Whatman No.l  filter paper at 4°C,  followed by centrifugation at 
26,000g  for  30  minutes  at  4°C  in  a  Beckman  Sorvall  RC5-B  centrifuge.  The 
supernatant  was  collected  and  the  pH  was  adjusted  to  7.4  with  NaOH.  After 
determining  the  concentration  of palmitate  bound  to  albumin  (Section  2.13),  the 
preparation was aliquoted and stored at -20°C.
2.2.2 AMPK antibody bound to protein G
0.4ml  of  Protein  G-Sepharose  was  washed  twice  with  Hepes  Buffer  containing 
50mM Hepes pH7.4, 50mM NaF, 5mM Na4P2C > 7,  10% (v/v) glycerol,  ImM EDTA, 
and  ImM  dithiothreitol  (DTT).  lOOpl  of either anti-al  or a2  AMPK antiserum,  or 
pre-immune goat/sheep serum (as controls) was added to 0.8ml of Protein G: Hepes 
Buffer (1:1, v/v) and mixed overnight at 4°C. Protein G-Sepharose bound to AMPK 
antibodies/non-immune  serum  proteins  was  collected  by centrifuging  at  5200g  for 
lmin at 4°C, washed twice with  1ml of Hepes Buffer, resuspended in Hepes Buffer 
(1:1, v/v), and stored at 4°C until used.
2.3  Animals
Animals  used  were  male  Sprague  Dawley  rats  weighing  200-350g  bred  in  the 
Biological  Service Unit at University College London.  Rats were maintained at 20- 
22°C  with  constant  access  to  drinking water and  to  Rat and  Mouse  Breeding Diet 
(Special  Diet  Services,  Witham,  Essex,  UK)  containing 21% protein, 4%  fat,  39% 
starches and sugars. Rats were exposed to 13 hours of light between 0600 and 1900h.
782.4  Heart perfusion
Rats  were  anesthetised  by  an  intraperitoneal  injection  of  sodium  pentobarbitone 
(300mg/Kg).  Hearts  were  removed  and  placed  in  ice-cold  Krebs  Henseleit 
Bicarbonate Buffer (KHB) (25mM NaHC03,  118.5mM NaCl, 4.7mM KC1,  1.2mM 
MgS0 4 ,  1.2mM  KH2PO4,  pH7.4)  containing  5mM  glucose  and  1.3mM  CaCl2, 
followed  by  retrograde  perfusion  through  the  aorta,  as  previously  described 
(Mowbray and Ottaway  1973), with KHB containing 2% (w/v) BSA,  1.3mM CaC^, 
5mM  glucose  with  or  without  palmitate  bound  to  albumin  (Section  2.2.1)  as 
specified. The perfusion medium was constantly gassed with  0 2 :C0 2  (95%:5%) and 
maintained  at  37°C.  The  perfusion  pressure  (preload)  was  70±5cm  H2O  and  the 
perfusion rate was approximately 15ml/min. All hearts were initially perfused for 5 
minutes  in  non-recirculation  mode  to  remove  blood  and  endogenous  hormones. 
Perfusion  was  then  continued  for  further  60  minutes  with  recirculating  perfusate, 
except  for  the  hearts  perfused  with  adrenaline,  which  were  perfused  in  non­
recirculation  mode  for the  entire perfusion period.  At  the  end  of perfusion,  hearts 
were  excised  from  the  cannula  and  freeze-clamped  using  tongs  pre-cooled  to  the 
temperature of liquid N2. Frozen hearts were powdered under liquid N2 and stored in 
liquid N2.
2.5  Adult rat cardiac myocyte isolation
The  buffers  used  in  the  isolation  procedure  were  Buffer  A  consisting  of KHB  + 
lOmM  glucose  +  1.3mM  CaCh,  Buffer  B  consisting  of KHB  +  lOmM  glucose  + 
O.lmM  EGTA,  Buffer  C  consisting  of KHB  +  lOmM  glucose  +  0  to  5pM  added 
CaCb, Wash Buffer consisting of KHB + lOmM glucose + 0.2mM CaCl2 + 2% BSA 
+ 0.5mg/ml DNase I, and Resuspension Buffer consisting of KHB + 1.3mM CaCl2 + 
2% BSA + 5mM glucose with or without 0.5mM palmitate as indicated. All buffers 
were  prepared  with  purified  H2O  with  minimal  contamination  with  Ca  .  Buffers 
(except for ice-cold Buffer A) were maintained at 37°C  and constantly gassed with 
0 2 :CC>2  (95%:5%).  Rats  were  anaesthetised  and  hearts  were  removed  to  ice-cold 
Buffer A, followed by a brief washout perfusion at 37°C with Buffer A as described 
above. After perfusion with recirculating Buffer A for 10 minutes, the perfusate was
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non-recirculating perfusion with approximately  100ml  of Buffer B.  Perfusion with 
Buffer B was continued for a further 5 minutes followed by washing with Buffer C to 
remove  EGTA.  Hearts  were  then  perfused  with  Buffer  C  containing  0.1%  (w/v) 
BSA,  lmg/ml collagenase (type 2), and 0.4mg/ml hyaluronidase for 20 to 30 minutes 
until  the heart became  soft.  The  exact amount of Ca2+  added to  Buffer C  (<5pM) 
depended on the batch of digestive enzymes and the level of Ca2+ contamination, and 
was determined empirically. Myocytes were gently dispersed in Buffer C containing 
0.1% BSA,  lmg/ml collagenase, 0.4mg/ml hyaluronidase, and 0.5mg/ml DNase I by 
shaking in a water bath (37°C) (-150 oscillations/min) for  10 minutes with gassing 
(0 2 iC0 2  (95%:5%)). DNase I was included to minimise the loss of myocytes due to 
clumping  of the  cells  by  DNA  released  from  dead  cells.  The  digested  heart  was 
filtered through nylon mesh and the cells were allowed to settle under gravity for 5 
minutes  at  37°C.  The  supernatant,  which  contained  non-settled  dead  cells,  was 
removed and the cell pellet was resuspended in Wash Buffer. Myocytes were again 
allowed to settle under gravity for 3 minutes. The supernatant was removed and the 
cells  were  resuspended  in  fresh  Wash  Buffer.  The  Ca2+  concentration  was  then 
gradually increased every 2  minutes  (0.4,  0.6,  0.8,  1,  1.3mM) while the cells were 
shaken  gently  at  37°C  with  gassing  (C^iCCh  (95%:5%)).  Finally,  myocytes  were 
allowed to settle under gravity for 5  minutes and the cell pellet was resuspended in 
Resuspension  Buffer  (cells:buffer  1:10  (v/v))  as  a  Cell  Stock.  Except  for 
measurements of glucose and palmitate oxidation, myocytes were incubated in a total 
volume  of  2ml  (0.67ml  of  Cell  Stock  +  1.33ml  of  Resuspension  Buffer)  in 
siliconised  glass  scintillation  vials  at  37°C  with  gentle  shaking  and  gassing  with 
0 2 :C0 2  (95%:5%). At the end of incubation, cells were collected by centrifugation at 
950g at 0°C for 20 seconds. Cells were then quickly washed twice with 0.5ml of ice- 
cold  BSA  free  buffer  (KHB  +  1.3mM  CaCl2  +  5mM  glucose).  This  step  was 
necessary because  BSA  was  found  to  interfere  with  the  detection  of the  AMPKa 
subunit by western blotting. Cells were finally frozen in liquid N2 and stored in liquid 
N2.
802.6  Measurement of cardiac myocyte viability
The viability was determined using a hemocytometer and trypan blue (0.4%) which 
stains  non-viable  cells.  Under  the  light  microscope,  healthy  adult  rat  cardiac 
myocytes  display elongated  (rod-shaped)  morphology with visible  cross  striations. 
Damaged cells appear short (hypercontracted) or spherical. Viability was determined 
as  the  percentage  of  rod-shaped  cells  which  excluded  trypan  blue.  Cells  which 
excluded  trypan  blue  but  were  hypercontracted  or  spherical  were  not  considered 
viable.
2.7 Measurement of glucose oxidation by myocytes
The incubation medium was palmitate-free Resuspension Buffer gassed with O2.CO2 
(95%:5%)  (Section  2.5)  containing  5mM  [U-14C]  glucose  (approximately 
20pCi/mmol).  Myocytes  were  incubated  at  37°C  with  gentle  shaking  in  a  total 
volume  of 2.5ml  (0.5ml  Cell  Stock  +  2ml  buffer)  in  sealed  siliconised  metabolic 
flasks fitted with centre wells. At the end of the indicated incubation period, 0.2ml of 
60% perchloric acid (PCA) and 0.5ml of 1M benzethonium hydroxide were injected 
through the stopper to the outer compartment (containing myocytes) and the centre 
well,  respectively.  After  a further  60  minutes  incubation to  collect  [14C]  CO2,  the 
contents of centre wells were transferred to scintillation vials and 10ml of Ecoscint A 
was added. The radioactivity was measured by scintillation counting (Section 2.14).
2.8 Measurement of palmitate oxidation by myocytes
Myocytes were incubated as above (Section 2.7) except that the incubation medium 
contained  5mM  glucose  and  0.5mM  [9,10-3H]  palmitate  (approximately
18pCi/mmol). At the end of the indicated incubation period, PCA was added to the 
cells as above. [3H] H2O was separated from [9,10-3H] palmitate by the method used 
by  Saddik  and  Lopaschuk  (Saddik  and  Lopaschuk  1991).  0.5ml  of  incubation 
medium  was  mixed  with  1.88ml  of  chloroform:methanol  (1:2,  v/v).  0.625ml  of 
chloroform and 0.625ml of 2M KC1:2M HC1 (v/v) were then added. The mixture was 
vortexed  and  centrifuged  at 2000g  at room temperature.  The  upper aqueous  phasewas  collected  and  0.3ml  of chloroform,  0.3ml  of methanol,  and  0.27ml  of 2M 
KC1:2M HC1  were added. The mixture was vortexed and centrifuged as above. The 
volume  of aqueous  phase  was  measured  and  a  1ml  sample  was  transferred  to  a 
scintillation  vial  and  10ml  Ecoscint  A  was  added  for  scintillation  counting.  The 
efficiency of [3H] H2O extraction with this method was estimated to be 85-90%.
2.9  AMPK activity assay
Frozen  myocytes  were  sonicated  (3X7  seconds)  in  0.5ml  of ice-cold  Sonication 
Buffer containing 50mM Tris/HCl pH 7.5,  ImM EDTA,  ImM EGTA, 50mM NaF, 
5mM  Na4P2C > 7,  10%  glycerol  (v/v),  1%  Triton  X-100  (v/v),  ImM  DTT,  ImM 
phenylmethanesulfonyl  fluoride  (PMSF),  ImM  benzamidine,  and  4pg/ml  soybean 
trypsin inhibitor.  The cell  lysate was centrifuged at  13,000g for  10 minutes  at 4°C 
and 60pl of the supernatant was incubated at 4 °C for 2 hours with either anti-AMPK 
antibody or pre-immune serum prebound to Protein G-Sepharose (Section 2.2.2). The 
volumes of antibody/Protein G Sepharose used for immunoprecipitation were  15 and 
20pl for al  and a2 AMPK, respectively. These volumes were chosen because they 
were  found to  maximally immunoprecipitate AMPK activity from the  supernatant. 
After binding, the immunoprecipitates were collected by centrifugation at 5,200g for 
1   minute at 4°C  and washed once with 200pl of Sonication Buffer and twice with 
AMPK Assay Buffer (40mM Hepes pH7, 80mM NaCl, 0.8mM EDTA,  8 % glycerol 
(v/v), and 800|uM DTT) by centrifuging as above. The immunoprecipitates were then 
incubated  at 37°C  with gentle  shaking in a final  volume of 50pl  of AMPK Assay 
Buffer  which  additionally  contained  200pM  SAMS  peptide 
(HMRSAMSGLHLVKRR), 200pM [y-33P] ATP (100-500 dpm/pmol), 5mM MgCl2, 
and 200pM AMP.  The reaction was  started by addition of [y-33P]  ATP.  The assay 
measures incorporation of 33P to SAMS peptide (Davies et al 1989), which is based 
on the sequence surrounding the AMPK phosphorylation site (Ser79) of ACC1, with 
mutation of Ser77 to alanine to prevent phosphorylation by PKA and addition of two 
arginines to allow recovery of SAMS peptide by ion exchange after the reaction. The 
reaction was stopped after 30 minutes by spotting the reaction mixture onto squares 
of P81  Whatman phosphocellulose ion exchange paper which were then immersed in 
1%  (v/v)  orthophosphoric  acid.  SAMS  peptide  phosphorylated  with  33P  was
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followed by two  washes  in distilled H2O  (10 minutes  each).  The papers  were  air- 
dried and transferred to scintillation vials and  10 ml of Ecoscint A was added before 
radioactivity was counted by a scintillation counter.  Because al  and a2  antibodies 
were  raised  in  sheep  and  goat,  respectively,  activity  immunoprecipitated  with 
sheep/goat pre-immune serum prebound to Protein G-Sepharose was used as a blank 
to account for non-selective binding of AMPK with serum proteins and/or Protein G- 
Sepharose and was subtracted from the activity immunoprecipitated with anti-AMPK 
antibodies. AMPK activity was expressed either as the percentage of AMPK activity 
of myocytes incubated under control conditions (as indicated in the figures/tables) or 
as pmol of ATP incorporated to  SAMS peptide per mg of the  13,000g supernatant 
protein  per  min.  Although  200|nM  AMP  was  always  included  in  the  assay, 
preliminary experiments  confirmed  the  allosteric  activation  of immunoprecipitated 
AMPK by AMP (Figure 2.1). AMPK activity also increased linearly during the assay 
time  (30 minutes)  and  showed  a  good  linear correlation with the  concentration  of 
13,000g supernatant protein within the range of concentrations typically used (Figure 
2.2).
For  heart  samples,  frozen,  powdered  heart  was  weighed  and  homogenised  on  ice 
using an Ultra Turrax tissue disintegrator (lOOmg of tissue/ml)  in Homogenisation 
Buffer  containing  50mM  Tris/HCl  pH7.8,  0.25M  mannitol,  ImM  EDTA,  ImM 
EGTA,  50mM NaF,  5mM  Na4? 2 0 7 ,  ImM DTT,  ImM  PMSF,  ImM benzamidine, 
and  4pg/ml  soybean  trypsin  inhibitor.  The  13,000g  supernatant  was  obtained  and 
AMPK  was  immunoprecipitated  and  assayed  as  above,  except  that  the 
immunoprecipitate  was  washed with  Homogenisation  Buffer instead  of Sonication 
Buffer. AMPK activity of heart samples was expressed as pmol of ATP incorporated 
to SMAS peptide per minute per mg of the 13,000g supernatant protein.
2.10  Western blotting
Myocytes were lysed as above (Section 2.9) and proteins in  15-25pl of the  13,000g 
supernatant  were  separated  by  sodium  dodecylsulphate  polyacrylamide  gel
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Figure  2.1  Time-course  of AMPK  activity  assay  and  the  allosteric 
effect of AMP
a2  AMPK  immunoprecipitated  from  cardiac  myocyte  13,000g  supernatant  was 
assayed  for  the  indicated  time  in  the  presence  or  absence  of  200pM  AMP,  as 
described in Section 2.9. n=4
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Figure  2.2  The  relationship  between  AMPK  activity  and  protein 
concentration of the 13,000g supernatant
Samples of 13,000g supernatant with different protein concentrations were prepared 
from  the  same  myocyte  preparation.  a2  AMPK  was  immunoprecipitated  from  the 
supernatants and AMPK was assayed in the presence of  200pM AMP as described 
in Section 2.9. n=l
85electrophoresis  (SDS-PAGE)  under  denaturing  and  reducing  conditions  on  4-12% 
Bis-Tris  gels,  and  transferred  to  polyvinyldene  difluoride  (PVDF)  membranes. 
Phospho-AMPK  Thrl72,  phospho-AMPK  Ser485/491,  phospho-PKB  Thr308, 
phospho-PKB Ser473, phospho-ACC Ser79/227, total AMPKa, total PKB, and total 
ACC were detected by chemiluminescence (Fujifilm LAS-1000 Image Reader) with 
horseradish peroxidase (HRP)-conjugated secondary antibody and chemiluminescent 
substrate (luminol). For these measurements, primary and secondary antibodies were 
diluted  (1/1000  dilution)  in  Tris  Buffered  Saline  (TBS)  (20mM  Tris/HCl  pH7.6, 
137mM  NaCl)  containing  5%  (w/v)  BSA  and  0.1%  (v/v)  Tween-20.  Secondary 
antibody used for detection of phospho-AMPK Ser485/491  was diluted in the same 
buffer which additionally contained 0.01%  SDS.  5%  (w/v)  milk powder in TBS  + 
0.1%  Tween-20 was  used to block membranes  except for membranes probed with 
anti-phospho-AMPK Ser485/491 antibody, which was blocked with 5% BSA in TBS 
+  0.1%  Tween-20.  Band  intensities  were  quantified  with  Fujifilm  Multi  Gauge 
software.  After measurements of phospho-AMPK, ACC, or PKB, membranes were 
stripped by incubating with 62.5mM Tris/HCl buffer, pH 6.7, containing 0.8% (w/v) 
(3-mercaptoethanol  and  2%  (w/v)  SDS  at  50°C  for 30 minutes,  and  reprobed  with 
antibodies  against total AMPK,  ACC,  or PKB.  Phosphorylation of PLB  Seri6  and 
Thrl7  were  detected  and  quantified  using  secondary  antibody  conjugated  with 
infrared dye (IRDye™800) and an Odyssey infrared imaging system.  For detection 
of PLB  phosphorylation,  membranes  were  blocked  with  Odyssey blocking  buffer. 
Anti-phospho-PLB antibodies and secondary antibody were diluted (1/200 (primary 
antibodies)  and  1/2000  (secondary  antibody))  in  Odyssey blocking  buffer +  0.1% 
Tween-20.
2.11  Measurements of adenine nucleotides and creatine compounds
Adenine  nucleotides  and  creatine  compounds  were  measured  by  ion-pair  reverse 
phase HPLC as described by Sellevold et al (Sellevold et al 1986). The column used 
was a 150 X 4.6mm Nucleosil C18 column with particle size of 5pm and pore size of 
100A. The mobile phase consisted of 215mM KH2PO4, 2.3mM tetrabutylammonium 
hydrogen  sulphate  (TBAHS),  and  3.5%  (v/v)  acetonitrile.  The pH  was  adjusted  to 
6.25  with  10M  KOH.  The  mobile  phase  was  filtered  through  a  0.22pm Millipore
86filter and degassed before use.  200)4,1 of ice-cold 0.21M PCA was added to frozen 
myocytes and the mixture was vortexed.  Following centrifugation at  13,000g for 5 
minutes at 4°C, perchloric ion in  150|xl of the supernatant was precipitated with  1M 
KOH which was added in sufficient amount to precipitate most of the perchloric ion 
in the extract whilst maintaining an acidic pH.  The precise amount was determined 
by  titration  of  a  sample  extract  and  the  usual  amount  was  20-40pl.  Potassium 
perchlorate precipitates  were  removed by centrifuging at  13,000g for 2  minutes  at 
4°C,  and  450)4.1  of the  mobile  phase  was  added  to  50|u,l  of the  supernatant.  The 
samples diluted with the mobile phase were filtered through a 0.22pM filter and 50pl 
was  injected  onto  the  column which was  pre-equilibriated with  the  mobile phase. 
Adenine  nucleotides  and  creatine  compounds  were  eluted  isocratically  at  ambient 
temperature.  The  flow  rate  was  l.Oml/min  and  each  run  lasted  for  20  minutes. 
Elution of creatine compounds and adenine nucleotides was detected by changes in 
absorbance  at  206nm  using  a  Waters  tunable  absorbance  detector,  and the  elution 
profile  was  stored  and  processed  using  Millennium  2010  software.  Peaks  for 
creatine, creatine phosphate, ATP, ADP, and AMP were identified by comparison of 
the retention times with standards (Figure 2.3). In order to ensure that the standards 
had a similar amount of residual PCA as the samples, the standards were prepared in 
0.21M PCA which was partially neutralised with the  same amount of 1M KOH as 
used in the preparation of the samples, and diluted ten times with the mobile phase 
before  injection  onto  the  column.  Amounts  of  adenine  nucleotides  and  creatine 
compounds  were  determined  by  the  comparison  of peak  areas  and  peak  heights, 
respectively, with those of the standards. In order to establish whether this method is 
sensitive enough to accurately measure the small amounts of adenine nucleotides and 
creatine  compounds  present  in  myocyte  samples,  standards  were  prepared  in  the 
range of concentrations similar to those seen in myocyte samples. Peak areas or peak 
heights showed a good linear correlation with the amount of adenine nucleotides or 
creatine  compounds  (Figures  2.4  and  2.5).  Adenine  nucleotides  and  creatine 
compounds in heart samples were determined as above except that 0.2g of powdered 
frozen heart was homogenised on ice (1 minute) in 2ml of 0.21M PCA using an Ultra 
Turrax tissue disintegrator.
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Figure  2.3  A  chromatogram  of  standard  solutions  of ATP,  ADP, 
AMP, creatine, and creatine phosphate1200000  -r
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Figure 2.4 The relationship between the amount of ATP, ADP, and 
AMP with the HPLC peak areas
Standard solutions of ATP, ADP, and AMP were analysed by HPLC as described in 
Section 2.11.  n=l
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Figure  2.5  The  relationship  between  the  amount  of creatine  and 
creatine phosphate with the HPLC peak heights
Standard  solutions  of creatine  and  creatine  phosphate  were  analysed  by HPLC  as 
described in Section 2.11. n=l
902.12  Determination of protein concentration
Protein concentration was determined by a bicinchoninic acid (BCA) method.  This 
method is based on the concentration-dependent reduction of alkaline Cu(II) to Cu(I) 
by proteins, and the chromogenic reaction of BCA with Cu(I).  10pl of samples were 
incubated  at  37°C  for  30  minutes  with  200pi  of  BCAicopper  (II)  sulphate 
pentahydrate 4% solution (50:1, v/v) in a 96 well microtitre plate. After incubation, 
the  absorbance  at  570nm  was  determined  using  a  Dynatech  MR7000 
spectrophotometer. BSA solutions (0.2-lmg/ml) were used as standards.
2.13 Determination of fatty acid concentration
The concentration of free  fatty acids was  assayed using a Wako NEFA  C  test kit. 
This assay is based on the oxidation of fatty acyl-CoA by acyl-CoA oxidase (ACOD) 
to  2,3-trans-enoyl-CoA.  This  reaction  releases  H2O2,  which,  in  the  presence  of 
peroxidase and 4-aminoantipyrine, allows the conversion of 3-methyl-N-ethyl-N-((3- 
hydroxyethyl)-aniline  (MEHA)  to  a  coloured  compound.  lOpl  of  samples  were 
incubated in a 96 well microtitre plate at 37°C for 10 minutes with 67pl of Reagent A 
(50mM phosphate buffer pH6.9 containing 3mM MgCh, 0.3U/ml acyl-Coenzyme A 
synthetase,  3U/ml  ascorbate  oxidase,  3mg/ml  ATP,  0.7mg/ml  Coenzyme  A,  and 
0.3mg/ml 4-aminoantipyrine).  133pl of Reagent B (1.2mM MEHA,  6 .6 U/ml ACOD 
and 7.5U/ml peroxidase) was then added and samples were incubated for further  10 
minutes.  The  absorbance  at  550nm  was  determined  with  a  Dynatech  MR7000 
spectrophotometer. Oleate solutions (0.2-lmg/ml) were used as standards.
2.14 p-Scintillation counting
Radioactivity  of  l4C,  3H,  and  33P  was  measured  using  a  PerkinElmer  Tri-Carb 
2900TR  Liquid  Scintillation  Analyzer,  which  is  equipped  with  software  which 
corrected for quenching and allowed direct calculation of activity in disintegrations 
per minute (dpm).
912.15  Statistical methods
Values  are  given as means ±  S.E.M.  Values  of n indicate numbers of independent 
myocyte  preparations  or  perfused  hearts.  Statistical  significance  was  determined 
using  Students  t-test  for paired  (myocyte  data)  and  unpaired  samples  (heart  data). 
The following symbols were used throughout in figures/tables to indicate statistical 
significance:  a,  P<0.05;  b,  P<0.025;  c,  P<0.01;  d,  P<0.005;  e,  P<0.0005;  NS,  not 
significant  (P>0.05).  Unless  otherwise  specified,  these  symbols  indicate  statistical 
significance of values compared to values of cells incubated under control conditions 
as indicated in legends to figures/tables.
92Chapter 3: Results and Discussion
3.1  Cardiac myocyte isolation
Adult  rat  cardiac  myocytes  were  isolated  by  an  enzymatic  perfusion  method  as 
detailed  in  Section  2.5.  Key  features  of the  procedure  are  (1)  initial  Ca2+-free 
perfusion in the presence of EGTA,  (2)  digestion of hearts  with  a combination of 
collagenase and hyaluronidase in the presence of low Ca2+, (3) mechanical dispersion
of  myocytes  followed  by  stepwise  reintroduction  of  physiological  Ca2+
2_|_
concentration.  As  reported  by  others,  careful  handling  of Ca  concentration  was
found  to  be  crucial  for  successful  isolation  of  cardiac  myocytes.  Myocytes  are
2+
usually isolated under low Ca  to assist their release from intercellular connections
and  extracellular  matrix.  One  potential  problem  associated  with  this  is  the  Ca2+
2 + paradox, that is, the loss of viability due to Ca  overload and hypercontracture when 
Ca2+ is reintroduced to the cells after digestion of hearts under low Ca2+ conditions. It
has  been  reported  previously  that  gradual  reintroduction  of  physiological  Ca2+
0+
concentration  lessens  the  loss  of viability caused  by the  Ca  paradox  (Awan  and 
Saggerson  1993).  However,  despite  this  technique,  initial  attempts  to  isolate 
myocytes in the presence of a low concentration of Ca2+ in the pre-perfusion (5pM) 
and enzyme perfusion (50pM) were unsuccessful. This was unlikely to be due to the
2_j_
Ca  paradox because  cells  were  already non-viable before  the  reintroduction  of a 
physiological concentration of Ca2+.  It was  subsequently found that initial viability 
(before  Ca2+  introduction)  and  the  yield  of  Ca2+-tolerant  myocytes  could  be 
significantly improved if pre-perfusion and enzyme-perfusion were performed in the 
absence  of added  Ca2+.  There  are  several  explanations  for  this  observation.  It  is
932+ possible that too much Ca  during enzyme perfusion may damage myocytes due to 
excessive enzyme activity because collagenase and possibly other proteases present
in  commercially  available  collagenase  preparations  are  activated  by  Ca2+.  Many
2+
investigators have also found that a short period of Ca  -free perfusion is necessary 
for  isolation  of viable  cells  (Tytgat  1994;  Mitra  and  Morad  1985).  This  may  be
9+
related  to  Ca  -dependent  loosening  of the  extracellular  matrix  (Mitra  and  Morad 
1985)  and intercellular connections (Wittenberg et al  1986).  Wittenberg et al have
9-1-
reported  that  the  concentration  of Ca  has  to  be  reduced  to  5-14pM  in  order  to 
dissociate  the  intercellular  connections  (Wittenberg  et  al  1986).  A  higher
9_i
concentration of Ca  increased the proportion of the cells still attached to each other 
at the  intercalated disc,  and this was associated with a significant loss of viability, 
possibly because cells attached firmly to each other are vulnerable to a shearing force 
of  dissociation  which  forcedly  tears  apart  the  cells  causing  membrane  damage.
2_j_
Although hearts in the initial isolation attempts were exposed to Ca  concentration
as  low as 5pM,  it is possible that the actual concentration of Ca2+ was higher than
that  required  for  gentle  separation  of  intercellular  connections  because  of
contamination  from  blood,  chemicals,  and  the  perfusion  apparatus.  Although  the
absence of added Ca2+ during the perfusion step could improve viability, over a time,
this method showed a considerable variation in the cell viability which ranged from
0-90% even with the same enzyme batches. This was likely to be due to variation in
Ca2+ contamination. In order to circumvent this problem, EGTA was included during
the  perfusion  step.  Addition  of  EGTA  was  generally  found  to  improve  initial
viability  and  consistency.  However,  it  was  noted  that  in  the  presence  of EGTA,
hearts  could  not  be  satisfactorily  digested  due  to  inhibition  of the  activity  of the
dissociation enzymes.  The mechanical dispersion of the inadequately digested heart
still  yielded  viable  cells  but  it  was  observed  that  these  cells  were  shorter
(hypercontracted) than the healthy cells and soon became spherical, possibly due to
the damage caused by forced separation of the cells,  and that the cells which were
not  immediately  exposed  to  the  buffer  during  mechanical  dispersion  became
ischemic.  Thus,  a precise balance of beneficial and detrimental  effects of Ca2+ was
required. Based on these observations, in the final method, hearts were first perfused
with Ca2+-free buffer in the presence of EGTA, followed by enzyme perfusion in the
presence of a small amount of added Ca2+ but in the absence of EGTA.  The initial
perfusion with EGTA ensured that that heart was exposed to sufficiently low Ca2+.
94Omitting  EGTA  and  adding  a  small  amount  of Ca2+  (<5pM)  during  the  enzyme 
perfusion  ensured  adequate  digestion  of the  heart  and  the  gentle  release  of the 
myocytes  without  causing  overdigestion.  During  enzyme  perfusion,  hyaluronidase 
was also used in combination with collagenase to facilitate the action of collagenase 
since heart collagen fibres are coated with a layer of glycoprotein. Addition of Ca2+
during  enzyme  perfusion,  however,  was  not  usually  found  to  be  required  for
2+
adequate digestion of hearts, probably due to the presence of Ca  in the preparations
2+ of digestive enzymes. Appropriate amounts of Ca  were added when underdigestion 
of the  heart  was  apparent.  Consistent  isolation  of myocytes  with  reasonably high 
viability (60-80%) could be achieved with this method.
To  assess  the  metabolic  performance  of isolated  myocytes,  glucose  and  palmitate 
oxidation  by  myocytes  was  determined.  Linearity  of  the  rates  of  glucose  and 
palmitate oxidation for at least  1 hour indicated that the cells are metabolically active 
and there is no significant loss of viability during this period (Figures 3.1  and 3.2). 
The  values  for the  rate  of oxidation of glucose  and palmitate  were  roughly in the 
range  of  values  reported  by  other  investigators.  Montini  et  al  reported  glucose 
(5mM) and palmitate (0.4mM palmitate, 3% BSA) oxidation rates of approximately 
1.4 and 0.7nmol/min/mg protein, respectively (Montini et al 1981). Bums and Reddy 
reported  glucose  (5mM)  oxidation  rate  of approximately  0.7nmol/min/mg  protein 
(Bums  and  Reddy  1977).  The  rates  of glucose (5mM)  and palmitate  (0.5mM,  2% 
BSA)  oxidation  obtained  in  the  present  study  were  approximately  0.8  and 
0.3nmol/min/mg protein, respectively.
3.2  The effect of adrenaline on cardiac AMPK activity
A previous  study by Clark  et al with perfused  hearts  found  that  adrenaline  could 
antagonise  activation  of  a2  AMPK  by  palmitate  (Clark  et  al  2004).  Because 
activation of the al isoform by palmitate was not affected by adrenaline (Clark et al
2004),  it  appeared  likely  that  the  inhibitory  effect  of  adrenaline  on  a2  AMPK 
involved  a  direct  modification  of the  a2  AMPK  complex  or proteins  specifically 
associated  with  this  isoform.  In  order  to  investigate  this  effect  further,  it  was
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Figure 3.1 Glucose oxidation by cardiac myocytes
Cardiac myocytes were incubated for indicated time in the presence of 5mM [U-I4C] 
glucose. Glucose oxidation was estimated from  14C0 2  production. n=3
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Figure 3.2 Exogenous palmitate oxidation by cardiac myocytes
Cardiac myocytes were incubated for indicated time in the presence of 5mM glucose 
and 0.5mM [9,11-3H] palmitate (2% BSA). Palmitate oxidation was estimated from 
3H20  production. n=3
97examined  whether  the  effect  could  be  reproduced  in  cardiac  myocytes,  an 
experimental  system  which  is  well-suited  for  dose/time-response  analysis  and  for 
investigation of signalling pathways. As shown in Figure 3.3, incubation of myocytes 
with  5mM  glucose  and  0.5mM  palmitate  for  1   hour caused  a  significant  2.5-fold 
increase in a2 AMPK activity compared to incubation with 5mM glucose alone. The 
extent  of activation  of AMPK  by  0.5mM  palmitate  seen  in  this  experiment  was 
comparable to that observed previously in perfused hearts. In the presence of glucose 
and palmitate, adrenaline (>0.5pM) decreased a2 AMPK activity by approximately 
50% (or inhibited the activation of a2 AMPK by palmitate by approximately 70%) 
(Figure  3.3).  The  half maximal  effect  of this  inhibitory  effect  (IC50)  was  seen  at 
approximately 0.1 pM adrenaline. However, in contrast to the observation in perfused 
hearts  that  adrenaline  did  not  affect  AMPK  activity  in  the  absence  of palmitate 
(Clark et al 2004),  in cardiac  myocytes,  it was  observed that adrenaline decreased 
AMPK  activity  to  a  similar  extent  (-40-50%)  even  in  the  absence  of palmitate 
(Figures 3.4 and 3.16) or in myocytes which did not show a significant activation of 
AMPK  by palmitate  (Figure  3.4).  Although  2-  to  3-fold  activation  of AMPK  by 
palmitate was consistently observed in the early stage of the present study when the 
experiment presented in Figure 3.3 was carried out, this marked activation of AMPK 
by palmitate could not be reproduced in the later experiments. The reason for this is 
unknown.  Because the activation of AMPK by palmitate was  found to be a rather 
slow process in the previous study with perfused hearts (the activation was apparent 
only  after  1  hour  of perfusion),  it  was  examined  whether  extending  the  time  of 
incubation  from  1   hour  to  2  hours  could  enhance  the  activation  of AMPK  by 
palmitate  in  the  later  myocyte  preparations  (Figure  3.4).  Linearity  of palmitate 
oxidation  indicated  myocytes  were  metabolising  palmitate  and  that  there  was  no 
marked  loss  of  viability  during  this  extended  incubation  period.  However,  no 
significant effect of palmitate on AMPK activity was  observed even after 2 hours. 
Nonetheless,  adrenaline  still  significantly  decreased  AMPK  activity  by  -50%  in 
these  cells  in  the  presence  of palmitate.  These  results  suggest  a  direct  inhibitory 
effect  of adrenaline  on  cardiac  AMPK  activity,  at  least  in  isolated  myocytes.  The 
effect  of adrenaline  in  cardiac  myocytes  was  not  dependent  on  the  presence  of 
glucose.  Under conditions  where palmitate  had  little  or no  effect on AMPK,  2pM 
adrenaline  still  decreased  a2  AMPK  activity  of myocytes  incubated  with  0.5mM
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Figure  3.3  The  effect  of palmitate  on  a2  AMPK  activity  and  the 
dose-response  curve  of the  inhibition  of AMPK  by  adrenaline  in 
cardiac myocytes
Cardiac myocytes were incubated for 1   hour with 5mM glucose alone or with 5mM 
glucose  +  0.5mM  palmitate  in  the  absence  or  presence  of  the  indicated 
concentrations  of adrenaline.  a2  AMPK  activity  was  assayed  in  the  presence  of 
200fiM  AMP.  The  results  are  expressed  as  percentage  of AMPK  activity  of cells 
incubated with 5mM glucose alone (without adrenaline).  The letters above the data 
points indicate statistical significance compared to AMPK activity of cells incubated 
with  5mM  glucose  alone  (without  adrenaline).  The  letters  below  the  data  points 
indicate statistical  significance compared to AMPK activity of cells incubated with 
5mM glucose + 0.5mM palmitate in the absence of adrenaline.  n=7-16
99NS
Figure 3.4 The presence of palmitate is not essential for the effect of 
adrenaline to decrease AMPK activity
Cardiac myocytes were incubated for 2 hour with 5mM glucose alone (G) or 5mM 
glucose + 0.5mM palmitate (G+P) in the absence (open bar) or presence (filled bar) 
of 2pM adrenaline. a2AMPK activity was assayed in the presence of 200|iiM AMP. 
The  results  are  expressed  as  percentage  of AMPK activity of cells  incubated with 
5mM glucose alone in the absence of adrenaline. n=3
100palmitate  alone  by  41±4%  (P<0.005,  n=4)  after  1   hour.  In  the  same  myocytes 
preparations  adrenaline decreased  a2  AMPK activity of cells  incubated with 5mM 
glucose  and  0.5mM  palmitate  by  37±6%  (PO.Ol,  n=4).  In  the  rest  of  the 
experiments presented here,  myocytes  were  normally incubated  in the presence  of 
both  5mM  glucose  and  0.5mM palmitate  to  ensure  adequate  fuelling  of the  cells. 
However,  because  these  experiments  were  performed  under  conditions  where 
palmitate  had  little  or  no  effect  on  AMPK  activity,  these  experiments  effectively 
investigated the direct inhibitory effect1   of adrenaline on AMPK activity in cardiac 
myocytes.  At present, the possibility cannot be ruled out that this  direct inhibitory 
effect is mechanistically distinct from the effect of adrenaline to block activation of 
AMPK  by  palmitate  observed  previously  in  perfused  hearts  and  in  the  results 
presented  in  Figure  3.3.  In  contrast to  the  inhibitory effect  of adrenaline  reported 
previously in perfused hearts, which was restricted to a2 AMPK, the direct effect of 
adrenaline  on AMPK  in  cardiac  myocytes was  seen  for both  al  and  a2  isoforms, 
although the effect was greater for a2 AMPK (Figure 3.5).
In order to re-investigate the possibility of a direct inhibitory effect of adrenaline on 
AMPK activity in perfused hearts and to check if the loss of the effect of palmitate to 
activate AMPK was due to the myocyte isolation procedure, hearts were perfused for 
1   hour with  5mM  glucose or 5mM  glucose + 0.5mM palmitate  in the presence  or 
absence  of 2pM  adrenaline  (Figure  3.6).  Palmitate  did  not  activate  a2  AMPK  in 
perfused hearts, indicating the lack of the effect of palmitate in myocytes was not due 
to cell damage caused during the isolation procedure.  In contrast to the observation 
in  myocytes,  adrenaline  did  not  affect  a2  AMPK  activity  in  hearts  perfused  with 
glucose alone or glucose and palmitate, the observation consistent with the lack of a 
direct  effect  of adrenaline  in  perfused  hearts  reported  previously  by  Clark  et  al. 
Therefore, the possibility was considered that the apparently direct inhibitory effect 
of adrenaline  seen  in myocytes  in  the present  study was  an  experimental  artefact. 
While  screening for different conditions to activate AMPK in cardiac myocytes,  it 
was found that incubation of cells with 0.5mM H2O2 for 1   hour increased al AMPK 
activity to 227.5±40.4% relative to control (P<0.05) (n=4), but apparently decreased
1   The  expression  ‘direct  inhibitory  effect’  is  used  here  simply  to  distinguish  an  inhibitory  effect  of 
adrenaline  on  AMPK  activity  under  basal  conditions  from  that  seen  when  AMPK  is  activated  by 
palmitate.  It does not necessarily mean that the effect of adrenaline on AMPK under basal conditions 
is mechanistically direct.
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Figure 3.5 The effect of adrenaline on al and a2 AMPK activity
Cardiac  myocytes  were  incubated  for  1  hour  with  5mM  glucose  and  0.5mM 
palmitate in the absence (C) or presence of 2pM adrenaline (filled bars). Following 
immunoprecipitation  using  anti-al  or  a2  AMPK  antibody,  AMPK  activity  was 
assayed in the presence of 200juM AMP. The results are expressed as percentage of 
al or a2 AMPK activity of cells incubated in the absence of adrenaline. n=4
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Figure  3.6  The  effect  of palmitate  and  adrenaline  on  a2  AMPK 
activity in perfused hearts
Hearts  were  perfused  for  1   hour  with  5mM  glucose  alone  (G),  5mM  glucose  + 
0.5mM palmitate (G+P), 5mM glucose + 2pM adrenaline (G+A), or 5mM glucose + 
0.5mM palmitate  + 2pM  adrenaline  (G+P+A).  AMPK activity was  assayed  in the 
presence of 200pM AMP.  n=4-6
103a2 AMPK activity to 27.0±7.0% (P<0.005) (n=6). It has been previously reported in 
skeletal  muscle  that  H2O2  activates  al  AMPK  but  it  does  not  affect  a2  AMPK 
activity  (Toyoda  et al 2004).  The  apparent  inhibition  of a2  AMPK was  due  to  a 
reduction in cell viability to approximately 26% (n=2) of the untreated cells and loss 
of  AMPK  protein  which  was  decreased  to  40.0±7.2%  (P<0.005)  (n=4). 
Unphysiologically high concentrations of adrenaline as used in this study (pM) have 
been reported to damage the heart as evidenced by release of lactate dehydrogenase 
after  10  minutes  of perfusion  with  adrenaline  (Horak  and  Opie  1983).  Prolonged 
adrenergic stimulation is also known to cause apoptosis in cardiac myocytes (Zhu et 
al 2003). However, the decrease in AMPK activity by adrenaline seen in the present 
study was unlikely to be due to such toxic effects of adrenaline because adrenaline 
treatment  did  not  significantly  affect  the  viability  of myocytes  (initial  viability: 
71±5%;  viability after  1   hour incubation:  65±3%;  viability after  1   hour incubation 
with 2pM  adrenaline:  67±2%;  n=6).  Moreover,  the decrease  in AMPK  activity by 
adrenaline was accompanied by a corresponding decrease in Thrl72 phosphorylation 
in the AMPK a subunit (Figure 3.7) without affecting the a subunit protein amount 
(100±12.5%  relative  to  untreated;  n=4).  Adrenaline  also  caused  a  significant 
decrease  in  Ser227  (Ser79  in  ACC1)  phosphorylation  of ACC2  (the  predominant 
cardiac isoform) (Figure 3.8), a well-established downstream target of AMPK, again 
without affecting the  total  ACC  amount  (107.0±14.9%  relative  to  untreated,  n=4). 
Therefore, it appears that adrenaline has a genuine direct inhibitory effect on AMPK 
in cardiac myocytes.
Figure  3.9  shows  a time-course  of the  effect  of adrenaline  to  decrease  a2  AMPK 
activity in cardiac myocytes. This and all subsequent experiments focussed on the a2 
isoform because of the greater effect of adrenaline on this isoform (Figure 3.5) and 
because a2 AMPK is the predominant isoform in the heart (Cheung et al 2000). The 
effect of adrenaline was rapid with the half-maximal effect seen at approximately 4 
minutes,  and  the  effect  was  sustained  after  1   hour  (Figure  3.9)  or  2  hours  of 
incubation (Figure 3.4).
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Figure  3.7  The  effect  of  adrenaline  on  AMPK  Thrl72 
phosphorylation in cardiac myocytes.
Cardiac  myocytes  were  incubated  for  1   hour  with  5mM  glucose  and  0.5mM 
palmitate in the absence (C) or presence of 2pM adrenaline (A).  The  figure shows 
the results from three myocyte preparations.  Band quantification is given in Figure 
3.19.
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Figure  3.8  The  effect  of  adrenaline  on  ACC  Ser79  (Ser227) 
phosphorylation in cardiac myocytes.
(a)  Cardiac  myocytes  were  incubated  for  1   hour  with  5mM  glucose  and  0.5mM 
palmitate  in  the  absence  (C)  or  presence  of  2pM  adrenaline  (A).  ACC 
phosphorylation  was  detected using an  anti-phospho-Ser79  ACC1  antibody,  which 
also  reacts  with  the  equivalent  residue  (Ser227)  in  ACC2  (predominant  cardiac 
isoform).  The  figure  shows  the  results  from  three  myocyte  preparations,  (b) 
Quantification  of band  intensity,  expressed  as  percentage  of  phospho-ACC/total 
ACC of cells incubated without adrenaline, is shown. n=4
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Figure 3.9 Time-course of inhibition of AMPK by adrenaline
Cardiac myocytes were incubated for indicated time with 5mM glucose and 0.5mM 
palmitate  in  the  absence  or  presence  of 2pM  adrenaline.  a2  AMPK  activity was 
assayed in the presence of 200pM AMP. The results are expressed as percentage of 
AMPK activity of cells incubated in the absence of adrenaline. n=5
1073.3  The  effect  of  adrenaline  is  independent  of  changes  in  total 
cellular high energy phosphates
Adrenergic  stimulation  increases  cardiac  energy  production  to  meet  an  increased 
demand  for  energy  which  accompanies  an  increased  contractile  activity.  Because 
cardiac myocytes  are quiescent,  it is  conceivable that adrenaline  stimulation in the 
cardiac  myocytes  increases  the  energy  production  and  cellular  high  energy 
phosphates without significantly increasing the energy utilisation and consequently 
decreases  AMPK  activity.  This  may  account  for  the  inhibition  of  AMPK  by 
adrenaline in myocytes but not in perfused hearts. In order to test this possibility, the 
total  cellular  high  energy  phosphate  contents  were  analysed  by  HPLC  after 
incubating the cells in the presence or absence of 2pM adrenaline for 20 minutes. No 
significant difference in the total amount of AMP, ADP, ATP, or the AMP/ATP ratio 
was  observed  despite  a  significant  inhibition  of the  AMPK  activity by adrenaline 
(Table 3.1). The direct regulation of AMPK by Cr and CrP is questioned by a recent 
study (Taylor et al 2005). Nevertheless, the Cr/CrP ratio is a more sensitive indicator 
of cellular energy state than the AMP/ATP ratio (Neumann et al 2002). Adrenaline 
did not affect the cellular contents of Cr,  CrP,  or the Cr/CrP ratio.  The AMP/ATP 
ratio was also not affected by adrenaline after 1  hour incubation despite a decrease in 
AMPK activity to 61.1±4.2% (n=8) (P<0.0005). The AMP/ATP ratios of control and 
adrenaline-treated cells after 1   hour were 0.045±0.011  (n=8) and 0.040±0.009 (n=8), 
respectively.  There  was  no  significant  difference  between  the  AMP/ATP  ratios 
between  20  and  60  minutes.  Therefore,  it  appears  that  the  effect  of adrenaline  to 
inhibit AMPK in myocytes is not due to increased energy production, and there may 
be a novel pathway linking the adrenergic receptors to the AMPK system in cardiac 
myocytes.
3.4  The  effect  of  adrenaline  is  mediated  by  both  ai  and  p 
adrenoreceptors
The  effect  of  2pM  adrenaline  to  inhibit  AMPK  was  partially  abolished  in  the 
presence of either 2pM propranolol (a selective p blocker) or 2pM phentolamine (a 
selective ai blocker), while the effect was essentially abolished when both blockers
108Control (20 min)  +adrenaline (20 min)
Cr (nmol/mg protein) 9.3 ±1.3 10.0 ± 0.9N S
CrP (nmol/mg protein) 13.6 ± 1.2 13.1 ± 1.8N S
AMP (nmol/mg protein) 0.398 ±0.114 0.372 ± 0.058N S
ADP (nmol/mg protein) 3.55 ±0.41 3.31 ±0.49N S
ATP (nmol/mg protein) 10.3 ±0.9 10.3 ± 1.0N S
AMP+ADP+ATP 14.28 ± 1.25 14.03 ± 1.43N S
(nmol/mg protein)
Cr/CrP 0.69 ± 0.09 0.79 ± 0.07N S
AMP/ATP 0.039 ±0.011 0.036 ± 0.005N S
AMPK activity (%) 100 72.5 ± 1.8e
Table  3.1  The  effect  of  adrenaline  on  adenine  nucleotides  and 
creatine compounds
Cardiac  myocytes  were  incubated  for  20  minutes  with  5mM  glucose  and  0.5mM 
palmitate  in the  absence  or presence  of 2pM  adrenaline.  Adenine nucleotides  and 
creatine compounds were measured by HPLC following PCA extraction. The effect 
of  adrenaline  on  AMPK  activity  in  the  same  myocytes  preparations  was  also 
determined in parallel.  n=4
109were present (Figure 3.10). The effect of adrenaline could be completely mimicked 
by  the  (3   agonist  isoproterenol  (IC50~40nM)  (Figure  3.11).  The  ai  agonist 
phenylephrine did not significantly inhibit AMPK at 2pM, but higher concentrations 
(10  or  1  OOpM)  of phenylephrine  completely  mimicked  the  effect  of  adrenaline 
(IC5o~4pM)  (Figure  3.12).  Both  isoproterenol  (2pM)  and  phenylephrine  (lOOpM) 
also  decreased  AMPK  Thrl72  phosphorylation.  Because  a  high  concentration  of 
phenylephrine (lOOpM) is known to cause cross-stimulation of (3  receptors (Valks et 
al  2002),  cells  were  incubated  with  phenylephrine  in  combination  with  2pM 
propranolol  in  these  experiments.  The  lack of cross-stimulation  of (3   receptors  by 
phenylephrine  was  supported  by  a  lack  of detectable  phosphorylation  of PLB  at 
Seri 6  (the site phosphorylated  exclusively by PKA (Wegener et al  1989))  in cells 
treated  with  2,  10,  or  lOOpM  phenylephrine  (Figure  3.13).  As  expected, 
phosphorylation of PLB  Seri 6  was  increased by both adrenaline and  isoproterenol 
(Kuschel  et  al  1999).  As  a  precaution,  isoproterenol  was  given  to  the  cells  in 
combination  with  2pM  phentolamine.  Although  the  possibility  of  the  cross­
stimulation of the ai receptor by isoproterenol cannot be completely ruled out in the 
present study, it is unlikely that the effect of isoproterenol on AMPK was mediated 
by  the  ai  receptor  because  it  was  seen  with  low  concentrations  of the  agonist 
(0.5pM)  despite the presence of 2pM phentolamine.  These results indicate that the 
effect  of  adrenaline  is  mediated  by  both  ai  and  p  receptors.  Several  signalling 
components such as PI3K, Ca2+ signalling, and MAPKs are known to be activated by 
both adrenergic receptors, and it is possible that the effect of adrenaline involves one 
of these signalling components common to both receptors. However, these results do 
not rule out the possibility of the two distinct mechanisms to inhibit AMPK by ai 
and p receptors.
3.5  The effect of adrenaline is not mediated through the PI3K/PKB 
pathway
In perfused hearts, insulin has been shown to decrease basal AMPK activity as well 
as the activation of AMPK by ischemia by an incompletely understood mechanism 
(Beauloye  et al 2001).  The  effect of insulin has been reported to be dependent on
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Figure  3.10  The  effect  of ai  and  p  adrenergic  antagonists  on  the 
effect of adrenaline on AMPK
Cardiac  myocytes  were  incubated  for  1   hour  with  5mM  glucose  and  0.5mM 
palmitate  in  the  absence  (control)  or presence  of 2pM  adrenaline  and  adrenergic 
antagonists  (2pM  propranolol  and  2pM  phentolamine)  as  indicated.  a2  AMPK 
activity was assayed in the presence of 200pM AMP.  The results are expressed as 
percentage  of AMPK  activity  of control  cells.  The  letters  directly  above  the  bars 
indicate statistical significance compared to control.  n=8
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Figure  3.11  The  effect  of  isoproterenol  on  AMPK  activity  and 
Thrl72 phosphorylation
(a) Cardiac myocytes were incubated with 5mM glucose and 0.5mM palmitate for 1  
hour  in  the  absence  (control)  or  presence  of  the  indicated  concentrations  of 
isoproterenol.  Isoproterenol  was  given  to  the  cells  in  combination  with  2pM 
phentolamine. a2 AMPK activity was assayed in the presence of 200pM AMP. The 
results  are  expressed as  percentage  of AMPK  activity of control  cells.  n=4-10  (b) 
shows band intensity of phospho-Thrl72  from cells treated with 2pM isoproterenol 
(ISO) corrected for total AMPKa amount and expressed as percentage of the value of 
control cells (C). n=3
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Figure  3.12  The  effect  of  phenylephrine  on  AMPK  activity  and 
Thrl72 phosphorylation
(a) Cardiac myocytes were incubated with 5mM glucose and 0.5mM palmitate for 1  
hour  in  the  absence  (control)  or  presence  of  the  indicated  concentrations  of 
phenylephrine.  Phenylephrine  was  given  to  the  cells  in  combination  with  2pM 
propranolol.  a2  AMPK activity was  assayed  in the presence of 200pM  AMP.  The 
results are expressed as percentage of AMPK activity of control cells. n=6 (b) shows 
band intensity of phospho-Thrl72 from cells treated with 100pM phenylephrine (PE) 
corrected  for  total  AMPKa  amount  and  expressed  as  percentage  of the  value  of 
control cells (C). n=4
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Figure  3.13  The  effect  of  adrenergic  agonists  on  PLB  Serl6 
phosphorylation
Phosphorylation of PLB Seri 6 was examined after incubating cardiac myocytes with 
5mM glucose and 0.5mM palmitate for 1  hour in the absence (C) or presence of 2pM 
adrenaline  (A),  2|l iM  isoproterenol  +  2pM  phentolamine  (ISO),  or  the  indicated 
concentrations  of PE  +  2pM  propranolol  (PE).  The  figures  show the  results  from 
three myocyte preparations.
114PI3K  activity,  but  independent  of  changes  in  the  AMP/ATP  or  Cr/CrP  ratios 
(Beauloye et al 2001). Kovacic et al have shown that the effect of insulin to inhibit 
AMPK  is  mimicked  by  over-expressing  constitutively  active  PKB,  suggesting  an 
involvement of PI3K-PKB pathway (Kovacic et al 2003). PI3K has been shown to 
be  downstream of both  ai  and  (3   adrenergic receptors  in the heart (Section  1.5.5). 
Although the identity of the P13K isoform activated by these receptors has not been 
conclusively elucidated, the activation of the class IB PI3K (P13Ky) through the Gpy  
dimer (Oudit et al 2004), as well as the possibility of the activation of the class LA 
PI3Ks (the isoforms activated by insulin) through increased tyrosine kinase activity 
have  been  suggested  (Morisco  et  al  2000).  Activation  of  PI3K  is  not  always 
associated with activation of PKB (Till et al 2000). However, at least stimulation of 
the  p  receptor  has  been  shown  to  cause  activation  of PKB  in  cardiac  myocytes 
through  PI3K  (Zhu  et  al  2001).  Therefore,  it  seemed  possible  that  adrenaline 
inhibited AMPK through the PI3K-PKB pathway. The fact that the effect of insulin 
is  seen  in  perfused  hearts  whereas  that  of adrenaline  is  not  does  not  necessarily 
exclude  this  possibility  because  unlike  insulin,  adrenaline  stimulates  contractile 
activity  in  perfused  hearts  which  could  potentially  activate  AMPK  by  increasing 
AMP. Consistent with this, several studies have reported an increase in AMP during 
adrenergic stimulation in perfused or in vivo hearts (Goodwin et al  1998b;  Ingwall 
2002). The simultaneous effects of adrenaline to activate AMPK by increased energy 
expenditure  while  inhibiting  AMPK  through  the  PI3K-PKB  pathway  may  be 
responsible  for the  apparent  lack  of significant  changes  in  the  AMPK activity by 
adrenaline in perfused hearts. The possibility of an involvement of PI3K in the effect 
of adrenaline was investigated using wortmannin, an inhibitor of both class LA and 
IB  PI3Ks  (Figure  3.14).  While  wortmannin  (3pM)  abolished  the  small  significant 
decrease  in  AMPK  activity  by  insulin  and  slightly  increased  the  basal  activity, 
possibly due to removal of some tonic inhibition by PI3K, it did not affect the effect 
of  adrenaline,  indicating  that  PI3K  is  not  involved  in  the  effect  of  adrenaline. 
Moreover,  in contrast to the observations by other investigators,  no increase in the 
phosphorylation of PKB at Thr308 or Ser473 was detected after 1  hour of incubation 
with adrenaline (Figure 3.15), suggesting that the PI3K-PKB pathway is not relevant 
to the effect of adrenaline. As expected, insulin increased phosphorylation of PKB at 
both Thr308 and Ser473. However, these results do not rule out the involvement of a
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Figure 3.14 The effect of wortmannin on the effect of adrenaline on 
AMPK
Cardiac  myocytes  were  incubated  for  1   hour  with  5mM  glucose  and  0.5mM 
palmitate alone (control) or with insulin (lOnM) or adrenaline (2pM), in the presence 
(filled  bar)  or  absence  (open  bar)  of  3pM  wortmannin.  a2  AMPK  activity  was 
assayed in the presence of 200pM AMP. The results are expressed as percentage of 
AMPK activity of cells  incubated  without  insulin,  adrenaline  or wortmannin.  The 
letters  direct  above  the  bars  indicate  statistical  significance  compared  to  control 
without adrenaline.  n=3-5
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Figure 3.15 The effect of adrenaline on PKB phosphorylation
Phosphorylation of PKB Thr308 and Ser473 was examined after incubating cardiac 
myocytes for  1   hour with 5mM glucose and 0.5mM palmitate in the absence (C) or 
presence of 2pM  adrenaline (A).  The  figures  show the results  from three myocyte 
preparations.  As a positive control,  PKB  phosphorylation  was  also  examined after 
incubating  cells  for  1   hour with  5mM  glucose  in  the  absence  (G)  or presence  of 
lOnM insulin (I).
117transient  activation  of PKB  by  adrenaline  through  a  PI3K-independent  pathway. 
Morisco  et  al  reported  that  isoproterenol  caused  a  PI3K-independent  increase  in 
Thr308 phosphorylation which returned to the basal level after 1  hour (Morisco et al
2005). However, because the effect of adrenaline on AMPK was sustained for up to 
2  hours,  a  transient  activation  of PKB  is  unlikely  to  account  for  the  effect  of 
adrenaline.  Consistent  with  the  idea  that  adrenaline  and  insulin  inhibit  AMPK 
through distinct pathways, the effect of insulin was found to be additive to that of 
adrenaline (Figure 3.16).  Insulin (lOnM) caused an approximately 20% decrease in 
AMPK activity.  The  inhibitory effect was  slightly higher (-30%)  if palmitate was 
omitted  from  the  incubation,  possibly  due  to  inhibition  of insulin  signalling  by 
palmitate (Soltys et al 2002).  In the presence of 2pM adrenaline, the concentration 
which  gave  the  maximal  effect  of adrenaline  (Figure  3.3),  insulin  still  decreased 
AMPK activity by -20% (in the presence of palmitate) or -30% (in the absence of 
palmitate) (Figure 3.16).
3.6  The effect of adrenaline on AMPK phosphorylation other than 
Thrl72
Recently, Horman et al have shown that the AMPK a subunit is phosphorylated at 
Ser485  (al)  or  Ser491  (a2)  by PKB  in  vitro  or in response to  insulin  in perfused 
hearts (Horman et al 2006). The phosphorylation of Ser485/491 was shown to inhibit 
phosphorylation of Thrl72  and this  was  suggested to be the mechanism by which 
insulin inhibits AMPK (Horman et al 2006).  Ser485/491  is also phosphorylated by 
PKA in vitro (personal communication from Richard Heath and David Carling). This 
may explain the inhibitory effect of adrenaline seen in the present study, at least for 
the  effect  of the  (3   receptor.  Therefore,  the  effect  of  adrenaline  on  Ser485/491 
phosphorylation  was  investigated  using  a  commercially  available  antibody against 
this  phosphorylation.  This  antibody was  previously used  successfully to  detect  an 
increase  in  Ser485/491  phosphorylation by PKB  (Soltys  et al 2006).  It was  found 
adrenaline  did  not  significantly  increase  the  phosphorylation  of  Ser485/491  in 
cardiac myocytes (Figure 3.17). In addition to Thrl72 and Ser485/491, AMPK a and 
(3  subunits are known to be phosphorylated at multiple other sites (Section 1.6.4) and 
the effect of adrenaline may involve phosphorylation of a site other than Ser485/491.
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Figure  3.16  The  additivity  of inhibitory  effects  of adrenaline  and 
insulin on AMPK
a)  Cardiac  myocytes  were  incubated  for  1   hour  with  5mM  glucose  and  0.5mM 
palmitate in the absence or presence of insulin (lOnM), adrenaline (2pM), or insulin 
+ adrenaline.  a2 AMPK activity was assayed in the presence of 200pM AMP.  The 
results  are  expressed  as  percentage  of AMPK  activity  of cells  incubated  without 
insulin  or  adrenaline.  n=5  (b)  Cardiac  myocytes  were  incubated  under  similar 
conditions to (a) except that palmitate was omitted from the incubation medium. n=4
119(a)
P-Ser485/491
Total AMPK
(b)
CL
CO
l?5
go
'S < D if)
O sz
Cl < /) O
160
NS
140
120
100
80
60
40
20
Figure  3.17  The  effect  of  adrenaline  on  AMPK  Ser485/491 
phosphorylation
(a)  Phosphorylation  of AMPK  Ser485/491  was  examined  after  incubating  cardiac 
myocytes for 1  hour with 5mM glucose and 0.5mM palmitate in the presence (A) or 
absence  of 2pM  adrenaline  (C).  The  figure  shows  the  results  from  four myocyte 
preparations,  (b)  shows  band  intensity  of phospho-Ser485/491  corrected  for  total 
AMPKa amount and expressed as percentage of the value of cells incubated without 
adrenaline. n= 8
120This  possibility  was  investigated  in  collaboration  with  Richard  Heath  and  David 
Carling  from  MRC  Clinical  Sciences  Centre,  Hammersmith  Hospital,  Imperial 
College  London.  Cell  lysates of myocytes treated with or without adrenaline were 
incubated with recombinant catalytically inactive AMPK (alplyl) in the presence of 
radioactive  ATP.  The  autoradiograph  (Figure  3.18)  revealed  that  the  AMPK  pi 
subunit was more heavily phosphorylated in the lysate of the adrenaline-treated cells 
compared to the  non-treated cells,  suggesting that some kinase  downstream of the 
adrenergic receptor phosphorylates the AMPK pi  subunit. Apart from  Ser485/491, 
PKA  phosphorylates  the  pi  subunit  at  Ser24  in  vitro  (Richard  Heath  and  David 
Carling, unpublished work). However, phosphorylation of pi  Ser24 was found not to 
be increased by adrenaline (Figure 3.18).
3.7  Adrenaline selectively attenuates activation of AMPK by sorbitol 
and palmitate
As shown in Figure 3.3, under conditions where palmitate activated AMPK by 2.5- 
fold,  adrenaline  still  decreased  AMPK activity by the  same proportion  (-50%)  as 
seen under basal  conditions  (i.e.  cells  incubated  without  palmitate)  (Figure  3.16). 
Palmitate has  been reported  to  activate  AMPK without a detectable  change  in  the 
AMP/ATP ratio and is believed to activate AMPK by a pathway distinct from that 
used by AMP-raising conditions  (Clark et al 2004,  Watt et al 2006).  Therefore,  it 
was  investigated  whether  the  effect  of  adrenaline  could  be  maintained  under 
conditions  where  AMPK  was  activated  by  other  AMPK-activating  stimuli  i.e. 
AICAR  (a precursor of the  AMP  mimetic  ZMP),  oligomycin  (an  inhibitor  of the 
FjFo-ATPase), phenformin (an inhibitor of complex I of the respiratory chain), and 
sorbitol  (induces  hyperosmotic  stress).  Sorbitol-induced  hyperosmolarity  has  been 
reported to  activate AMPK by an unidentified mechanism that does  not  involve  a 
change in the AMP/ATP ratio (Fryer et al 2002). In this study lOOmM sorbitol was 
used  instead  of 500mM,  which  is  commonly  used  to  induce  hyperosmotic  stress 
(Fryer et al 2002),  because this  concentration was  found  to  be  sufficient to  cause 
activation of AMPK and because incubation of the cells with 500mM sorbitol for 1  
hour caused a significant loss of myocyte viability. Concentrations of sorbitol similar 
to  lOOmM  have  been  previously  shown  to  cause  AMPK  activation  or  other
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Figure  3.18  The  effect  of  adrenaline  on  AMPK  p-subunit 
phosphorylation
(a)  Cardiac  myocytes  were  incubated  for  1   hour  with  5mM  glucose  and  0.5mM 
palmitate in the presence (A) or absence (C) of 2|iiM  adrenaline.  Cell  lysates were 
incubated  with  recombinant  catalytically  inactive  AMPK  aipiyl  complex  and 
phosphorylation of AMPK was detected by autoradiography.  Only phosphorylation 
of pi  subunit was increased by incubation with cell lysates,  (b) shows western blot 
analysis  of Ser24  phosphorylation  of AMPKp  subunit  with  cell  lysates  from  cells 
treated with or without adrenaline. The figures show the results from four (a) or three
(b)  myocyte  preparations.  The  in  vitro  phosphorylation  experiment  and  western 
blotting  were  performed  by  Richard  Heath,  MRC  Clinical  Sciences  Centre, 
Hammersmith Hospital, Imperial College London.
122hyperosmotic  responses  in  skeletal  muscle  and  endothelial  cells  (Fujii  et al 2005, 
Ochi  et  al  2002).  As  shown  in  Figure  3.19,  AICAR,  oligomycin,  sorbitol  and 
phenformin  all  activated  AMPK  to  a  similar  extent  (3-  to  4-fold).  The  inhibitory 
effects  of adrenaline  on  AMPK  activity  and  Thrl72  phosphorylation  were  either 
greatly diminished or became  statistically insignificant in the presence of AICAR, 
oligomycin or phenformin.  In contrast,  in the presence  of sorbitol,  adrenaline  still 
markedly decreased AMPK activity and Thrl72 phosphorylation by approximately 
50%, the observation similar to that seen in the presence of palmitate. These results 
suggest that adrenaline may selectively attenuate activation of AMPK by palmitate 
and  hyperosmolar  stress.  However,  as  mentioned  above,  the  possibility cannot be 
ruled out that the effect of adrenaline to attenuate the activation of AMPK by these 
conditions is mechanistically distinct from the effect of adrenaline seen under basal 
conditions.
3.8  Adrenergic  signalling  components  mediating  the  effect  of 
adrenaline
In  order to  gain more  insight  into  the  signalling pathway mediating the  inhibitory 
effect  of  adrenaline  on  AMPK  activity  (under  basal  conditions),  the  possible 
involvement  of  several  well-recognised  adrenergic  signalling  components  was 
examined.  Incubation  of  the  cells  with  forskolin  or  the  cell  permeable  cAMP 
analogue dibutyryl cAMP did not significantly affect AMPK activity (Figures  3.20 
and  3.21).  Forskolin  and  dibutyryl  cAMP  activated  PKA  as  evidenced  by  the 
increased  PKA-driven  phosphorylation  of  PLB  Seri 6 .  AMPK  activity  was  also 
unaffected by 8-CPT-2’-0-Me-cAMP,  a selective activator of Epac  (Enserink et al
2002).  These  results  exclude  the  involvement  of cAMP  signalling  or  PKA  in  the 
effect of adrenaline.
CAMKII  has  been  shown  to  be  activated  by  the  p  receptor  in  quiescent  cardiac 
myoctes through a PKA-independent activation of the L-type Ca2+ channel, possibly 
by direct activation of the Ca2+ channel by Gs (Zhu et al 2003). Because CAMKII is 
also known to be activated by the ai receptor (Wang et al 2001), the involvement of
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Figure  3.19  The  effect  of  adrenaline  on  activation  of AMPK  by 
different conditions
a2  AMPK  activity  (a)  and  Thrl72  phosphorylation  (b)  were  measured  after 
incubating  cardiac  myocytes  for  1   hour with  5mM  glucose  and  0.5mM palmitate 
alone (control), or with  ImM AICAR, 5pM oligomycin,  lOOmM sorbitol, or  lOmM 
phenformin,  in the presence  (filled bar)  or absence  (open bar)  of 2pM  adrenaline. 
AMPK activity was assayed in the presence of 200pM AMP.  The band intensity of 
Thrl72  phosphorylation  was  quantified  and  corrected  for  total  AMPKa.  AMPK 
activity and  Thrl72  phosphorylation  are  expressed  as  percentage  of the  values  of 
cells incubated without adrenaline and AMPK-activating agents. AMPK activity of 
control cells was 29.8±12.3pmol/min/mg protein. n=4
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Figure 3.20 The effect of forskolin on AMPK activity
(a) a2 AMPK activity was assayed in the presence of 200pM AMP after incubating 
cardiac myocytes for 1  hour with 5mM glucose and 0.5mM palmitate alone (control) 
or with 2pM adrenaline or  lOpM forskolin. The results are expressed as percentage 
of AMPK activity of cells incubated without adrenaline or forskolin. n=4 (b) Activity 
of PKA in control cells (C), adrenaline-treated cells (A),  and forskolin-treated cells 
(F) were checked with phosphorylation of PLB Seri6 .  The figure shows the results 
from two myocyte preparations.
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Figure 3.21 The effect of cAMP analogues on AMPK activity
(a)  a2 AMPK activity was assayed in the presence of 200pM AMP after incubating 
cardiac myocytes for 1  hour with 5mM glucose and 0.5mM palmitate alone (control) 
or with 2pM  adrenaline,  ImM dybutyryl cAMP,  or 50pM  8-CPT-2’-0-Me-cAMP. 
The results are expressed as percentage of AMPK activity of cells incubated without 
adrenaline  or  cAMP  analogues.  n=4  (b)  Activity  of  PKA  in  control  cells  (C), 
adrenaline-treated cells (A), and cells treated with dybutyryl cAMP (dbcAMP) were 
checked with phosphorylation of PLB Serl6 . The figure shows the results from two 
myocyte preparations.
126this  enzyme  in the  effect of adrenaline was  investigated.  The  effect of adrenaline, 
isoproterenol,  or phenylephrine on AMPK activity was unaffected by  lOpM KN93 
(Figure 3.22). In order to check that this concentration of the inhibitor was sufficient 
to block CAMKII  activation, the  effect of the  inhibitor on posphorylation of PLB 
Thrl7  (the  site  exclusively phosphorylated by CAMKII  (Wegener et al  1989))  by 
adrenergic agonists was investigated. As expected, both adrenaline and isoproterenol 
(Kuschel  et al  1999),  but not phenylephrine caused  an increase  in the PLB  Thrl7 
phosphorylation. Although the lack of phosphorylation of PLB by phenylephrine has 
been  observed  previously  (Lindemann  et  al  1986),  it  was  observed  that 
phenylephrine actually decreased PLB  Thrl7 phosphorylation in the present study. 
The  increase  in  PLB  Thrl7  phosphorylation  with  adrenaline  was  completely 
inhibited by KN93 while that by isoproterenol was partially inhibited. The fact that 
the effect of adrenaline on AMPK activity was seen despite the blockade of CAMKII 
rules out the involvement of this enzyme.
A possible involvement of PKC was examined using a phorbol ester which activates 
the DAG-dependent isoforms of PKC (conventional and novel PKCs). Incubation of 
myocytes  with  lpM  PMA  completely  mimicked  the  effect  of adrenaline  (Figure 
3.23), suggesting the possibility that PKC mediates the effect of adrenaline.
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Figure 3.22 The effect of KN93 on the effect of adrenaline on AMPK
(a) Cardiac myocytes were pre-incubated with 5mM glucose and 0.5mM palmitate in 
the  presence  (filled  bar)  or  absence  (open  bar)  of  lOpM  KN93  for  30  minutes 
followed by further 30 minutes incubation under control condition (no addition), or 
with  2pM  adrenaline,  2pM  isoproterenol  +  2pM  phentolamine,  or  lOOpM 
phenylephrine + 2pM propranolol. a2 AMPK activity was assayed in the presence of 
200pM AMP  and results  were  expressed  as percentage  of AMPK activity of cells 
incubated without KN93 or adrenergic agonists. n=3-4 (b) The effects of adrenaline 
(A), isoproterenol (ISO), phenylephrine (PE), and KN93 on phosphorylation of PLB 
Thrl7 are shown. n=3
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Figure 3.23 The effect of PMA on AMPK activity
Cardiac  myocytes  were  incubated  for  1   hour  with  5mM  glucose  and  0.5mM 
palmitate alone (control) or with 2pM adrenaline or  1  juM PMA.  a2 AMPK activity 
was  assayed  in  the  presence  of 200pM  AMP  and  the  results  were  expressed  as 
percentage of AMPK activity of cells incubated without adrenaline or PMA. n=3
1293.9  General Discussion
A previous study with perfused hearts found that adrenaline could decrease AMPK 
activity only when AMPK was activated by palmitate, suggesting an indirect effect 
of adrenaline  on cardiac  AMPK (Clark et al 2004).  The  lack of a direct  effect of 
adrenaline on AMPK activity in perfused hearts was confirmed in the present study. 
However,  in isolated  cardiac myocytes,  adrenaline unexpectedly decreased AMPK 
activity and Thrl72 phosphorylation even in the absence of palmitate. This effect is 
unlikely to be an experimental artefact caused by toxic effects of adrenaline,  since 
the decrease in AMPK activity was not associated with a decrease in viability, total 
AMPK  and  ACC  protein  amount,  or the  total  amount  of adenine  nucleotides  and 
creatine compounds. As discussed below, there are several potential explanations for 
this direct inhibitory effect of adrenaline on AMPK in myocytes and the lack of this 
effect in perfused hearts.
1.  While  adrenaline  stimulates  both  energy  production  and  contractile  activity  in 
perfused  hearts,  in  quiescent  myocytes,  adrenaline  is  likely  to  increase  energy 
production without significantly increasing energy expenditure.  Thus,  it is possible 
that  adrenaline  inactivates  AMPK  in  quiescent  myocytes  by  decreasing  the 
AMP/ATP ratio. This effect may be more pronounced if myocytes are suffering from 
low cellular levels of ATP and CrP, possibly due to cell damage sustained during the 
isolation procedure or due to other conditions of the incubation (e.g. hypoxia), and if 
AMPK activity is already significantly activated under basal conditions. The values 
of ATP and CrP in myocytes obtained in this study (~10nmol/mg proteins) are rather 
low compared to ~20nmol/mg protein reported by other investigators (Geisbuhler et 
al 1984; Ladilov et al 2003). However, the AMP/ATP ratio obtained in myocytes in 
this  study  is  comparable  to  values  obtained  by  other  investigators  (Luiken  et  al
2003).  In the present study,  in order to obtain clearly visible peaks  (especially for 
AMP) by HPLC, concentrated samples were prepared by extracting the cells with a 
minimal  volume  of  0.21M  PCA.  It  was  found  difficult  to  obtain  concentrated 
neutralised extracts in sufficient amount with higher concentrations of PCA because 
of increased  precipitation.  However,  this  concentration  of PCA  is  lower  than  the 
concentrations commonly used to extract cells, and a previous study measuring the
130high  energy  phosphates  using  the  same  method  as  used  in  this  study  reported 
incomplete  extraction  of ATP  by 0.21M  PCA  (Sellevold  et al  1986).  It  was  also 
found in the present study that values of adenine nucleotides in the perfused hearts 
measured in the extracts prepared by 0.21M PCA were also approximately half of the 
values  obtained  previously  using  a  different  method,  despite  the  comparable 
AMP/ATP  and ATP/ADP ratios.  Thus, the low amount of high energy phosphates 
seen  in  the  myocytes  in  this  study  probably  reflects  an  incomplete  extraction  of 
adenine  nucleotides  and  creatine  compounds  rather than energy-deprivation  of the 
myocytes. Whether the myocytes were energy-depleted or not, the observations that 
both AMP/ATP and Cr/CrP ratios were unaltered by adrenaline seems to exclude the 
possibility that adrenaline decreases AMPK activity by increasing ATP production. 
The incomplete extraction of the adenine nucleotides  and creatine  compounds  is  a 
systematic  error  and  would  be  unlikely  to  affect  this  conclusion.  However,  the 
possibility that adrenaline  caused  a  small  or localised change  in  free  AMP  and/or 
ATP which could not be detected with the method used in the present study cannot 
be  ruled  out.  In  vitro,  AMPK  has  been  reported  to  be  allosterically  activated  or 
inhibited by NAD+  or NADH,  respectively (Rafaeloff-Phail  et al 2004).  Thus, the 
effect of adrenaline might also involve a change in NAD+/NADH, although the effect 
of NAD+/NADH on AMPK Thrl72 phosphorylation is unknown.
2.  Adrenaline increases contractile activity in perfused heart. It is possible that there
is a direct inhibitory effect of adrenaline on AMPK in cardiac myocytes (isolated or
in the whole heart),  but in perfused hearts, this  effect may be  suppressed by some
signalling  process  which  is  induced  by  contraction.  For  example,  one  possible
signalling process which might be antagonistic to the inhibitory effect of adrenaline
is PI3K, which has been reported to be activated by electrically-induced contraction
in cardiac myocytes (Till et al 2000). This contraction-activated PI3K is likely to be
different  from  the  PI3K  isoform  or  the  pool  of PI3K  which  is  involved  in  the
inactivation  of  AMPK  by  insulin  because  its  activation  is  not  associated  with
activation  of PKB  (Till  et al  2000).  In  endothelial  cells,  activation  of AMPK by
metformin appears to be mediated by peroxynitrite which activates the cSrc-PI3K-
PDKl-PKC^ pathway and increases  association of LKB1  with AMPK, possibly by
PKC(^ phosphorylation of LKB1  (Section  1.6.5.g).  In the heart, metformin has also
been  reported to  increase  the  association  of AMPK with  LKB1  (Zou  et al 2004).
131Moreover, it has been shown peroxynitrite activates AMPK in cardiac myocytes and 
the  effect of metformin  on AMPK in cardiac  myocytes  is  abolished by  inhibiting 
peroxynitrite (Zou et al 2004).  Taken together, these results suggest the possibility 
that in cardiac myocytes, there are two pools/isoforms of PI3K which have opposite 
effects  on  AMPK.  One  of these  is  inhibitory,  involves  PKB,  and  is  activated  by 
insulin. The other has an activating effect, does not involve PKB, and is activated by 
peroxynitrite.  It is possible that the isoform/pool of PI3K which activates AMPK is 
activated by contraction and this may counter the inhibitory effect of adrenaline on 
AMPK.
3.  It was observed that adrenaline could decrease AMPK activity to the same extent 
as seen under basal conditions when AMPK was activated by palmitate or sorbitol. 
In  contrast,  the  inhibitory  effect  of adrenaline  was  either markedly diminished  or 
became  statistically insignificant under conditions  where  AMPK was  activated by 
AICAR,  oligomycin,  or  phenformin,  the  conditions  which  activate  AMPK  by the 
AMP-pathway.  These  results  raise  the  possibility  that  the  inhibitory  effect  of 
adrenaline  seen  under  basal  conditions  in  myocytes  is  due  to  blockade  of tonic 
activation  of  AMPK  through  the  pathway  which  is  activated  by  palmitate  or 
hyperosmotic stress. Both palmitate and sorbitol-induced hyperosmolarity have been 
reported to activate AMPK by a pathway distinct from the AMP-raising conditions 
(Fryer et al 2002; Daniel and Carling 2002b; Clark et al 2004; Watt et al 2006). It is 
not known whether these two  conditions  activate AMPK by the  same mechanism, 
although the present observation that adrenaline selectively attenuated activation of 
AMPK by these conditions  support this possibility.  The tonic activation of AMPK 
through  the  pathway  which  is  activated  by  palmitate/hyperosmolarity  would  be 
expected to  be  dwarfed  under conditions  where  AMPK  is  activated through other 
pathways  (e.g.  the  AMP-pathway),  explaining  the  observation  that  the  inhibitory 
effect  of  adrenaline  was  blunted  in  the  presence  of  AICAR,  oligomycin,  or 
phenformin.  Although  oligomycin  and  phenformin  have  been  shown  to  increase 
cellular  AMP  (Luiken  et  al  2003;  Hawley  et  al  2005),  the  possibility  that  these 
agents  activated  AMPK  without  increasing  AMP  cannot  be  ruled  out,  given  the 
reports  that  hypoxia  in  perfused  hearts  and  metformin  (a  compound  related  to 
phenformin)  activate  AMPK  by  AMP-independent  mechanisms  (Altarejos  et  al 
2005; Frederich et al 2005; Hawley et al 2002; Fryer et al 2002; Zou et al 2003 and
1322004).  However,  it is  still possible that the AMP-independent activation of AMPK 
by oligomycin and phenformin is mechanistically distinct from activation of AMPK 
by palmitate or sorbitol and is not blocked by adrenaline.  It was observed that the 
AMP/ATP ratio  in perfused hearts was significantly higher (P<0.05, unpaired test) 
than that in myocytes (the AMP/ATP ratios of perfused hearts and myocytes fuelled 
with  5mM  glucose  and  0.5mM palmitate  for  1   hour were  0.087±0.002  (n=4)  and
0.045±0.010  (n=8),  respectively).  This  observation  has  been  made  by  other 
investigators (Geisbuhler et al 1984) and it is probably due to the lack of contractile 
activity  in  myocytes.  Supporting  this,  Luiken  et  al  have  shown  that  electrically- 
induced  contraction  in  quiescent  cardiac  myocytes  caused  an  approximately  60% 
increase in AMP (Luiken et al 2003). The lack of the significant inhibitory effect of 
adrenaline in perfused heart under basal conditions may be explained by the higher 
AMP/ATP ratio and the basal activation of AMPK through the AMP pathway which 
masks  the  effect  of  adrenaline  on  the  tonic  activation  of  AMPK  though  the 
palmitate/sorbitol pathway.
4.  Lastly,  the  inhibitory  effect of adrenaline  on basal  AMPK activity in myocytes 
may be due to blockade of activation of AMPK by some unknown condition during 
the incubation that activated AMPK through the same pathway as sorbitol/palmitate 
or through other pathways which are also inhibited by adrenaline.
Whatever the actual reason for the lack of a direct inhibitory effect of adrenaline in 
perfused  hearts,  the  present  data  at  least  suggest  the  possibility  of an  adrenergic 
signalling pathway that directly regulates AMPK in cardiac myocytes.
The effect of adrenaline was found to be mediated by both aj and p adrenoreceptors. 
In  contrast  to  this  finding,  An  et al have  reported  no  significant  effect  of  10pM 
isoproterenol  on  AMPK  Thrl72  phosphorylation  in  cardiac  myocytes  (An  et  al
2005). The reason for this discrepancy is not clear. The involvement of both receptor
types  in  an  effect  of  adrenaline  is  not  unprecedented.  Several  signalling  or
downstream  effects  of adrenaline,  such  as  Ca2+  signalling,  MAPK  activation,  and
glucose transport,  have been reported to be  stimulated by both receptors  (Sections
1.5.3,  1.5.9, and  1.4.2). Although glucose has been reported to inactivate AMPK by
an unknown mechanism that  does  not  involve  a change  in  the  AMP/ATP ratio  in
133skeletal muscle (Itani et al 2003; Halse et al 2003), the inhibitory effect of adrenaline 
observed in the present study is unlikely to be secondary to adrenergic stimulation of 
glucose uptake/metabolism because the effect of adrenaline on AMPK was  seen in 
the  absence  of glucose.  Cardiac  myocytes  express  several  subtypes  of ai  and  p 
receptors including aiA, am, aiD, pi, P2 and P3 receptors (Section 1.2). While the pi 
receptor  is  exclusively coupled  to  the  Gs-cAMP  pathway,  the  P2  and  possibly  P3 
receptors are additionally coupled to Gj signalling (Section  1.3). Although the three 
ai  receptor  subtypes  are  all  coupled  to  Gq,  stimulation  of  different  ai  receptor 
subtypes  has  been  reported  to  cause  distinct  downstream  effects,  possibly  due  to 
coupling  to  additional  G  proteins  and  compartmentalisation  of  the  receptors 
(Sectionl.4.3).  Further  study  is  required  to  determine  the  adrenergic  receptor 
subtypes and G proteins involved in the effect of adrenaline.
Insulin  has  been  reported  to  inhibit  cardiac  AMPK  via  the  PI3K-PKB  pathway
(Beauloye et al 2001; Kovacic et al 2003). Because PI3K has also been reported to
be activated by cardiac  adrenergic receptors, PI3K-PKB became a likely candidate
for  the  pathway  responsible  for  the  inhibitory  effect  of adrenaline.  However,  the
observations that PKB was not activated by adrenaline and the effect of adrenaline
was unaffected by PI3K inhibition excluded this possibility. The inhibitory effect of
insulin has recently been reported to be due to PKB phosphorylation of Ser485/491
of AMPK  a  subunit,  which  prevents  phosphorylation  of  Thrl72  by  LKB1  and
possibly by other AMPKKs  (Horman et al 2006;  Soltys et al 2006).  Recently, this
site has been reported to be also phosphorylated by PKA in vitro (Hurley et al 2006).
However,  Ser485/491  phosphorylation  was  not  increased  by  adrenaline  in  cardiac
myocytes,  indicating  this  phosphorylation  is  not  responsible  for  the  effect  of
adrenaline. The effect of adrenaline also does not involve cAMP signalling, PKA, or
CAMKII. The observation that the effect of adrenaline was mimicked by PMA may
suggest  the  involvement  of  PKC.  PKC  is  a  well-established  component  of  ai
adrenergic signalling. Activation of PKC in response to stimulation of the p receptor
has also been reported in adult rat cardiac myocytes (Shizukuda and Buttrick 2001),
although the mechanism by which the p receptor activates PKC is unknown.  Thus,
PKC may be involved in both ai- and  p-mediated effects of adrenaline on AMPK.
Adult rat cardiac myocytes appear to express at least PKCs and PKC^, and possibly
PKCa, PKCp, and PKCS (Malhotra et al 2001b; Bogoyevitch et al 1993; Puceat et al
1341994).  However,  stimulation  of  cardiac  ai  or  p  receptors  has  been  reported  to 
selectively  activate  PKCe  and  possibly  PKCS  (novel  PKCs)  without  affecting 
conventional  and atypical PKCs  (Puceat et al  1999;  Clerk et al  1994;  Wang et al 
2003;  Deng et al  1998;  Shizukuda and Buttrick et al 2001).  In contrast,  in cardiac 
myocytes,  PMA  (a DAG  analogue) has been  shown to  activate both  conventional 
(PKCa) and novel PKCs (PKCe and PKCS) (Puceat et al 1994).  Phorbol esters are 
also known to activate other enzymes such as PKDs, which are also DAG dependent, 
PI3K and PLD  (van Lint  1995;  Farese 2002).  Therefore,  although the finding that 
PMA decreased AMPK activity in cardiac myocytes is an interesting observation and 
warrants  further  research,  involvement  of PKC  in  ai  and  P  mediated  effect  of 
adrenaline needs to be examined using selective PKC inhibitors.
At  present,  how  adrenaline  signalling  brings  about  a  decrease  in  Thrl72 
phosphorylation  is  unknown.  In  principle,  the  effect  of adrenaline  could  involve 
inhibition of AMPKKs or stimulation of dephosphorylation by protein phosphatases. 
The  heart  expresses  LKB1,  CAMKKp  (but  not  a)  and  possibly  other,  as  yet 
unidentified AMPKKs  (Sakamoto et al 2006;  Allard et al 2006;  Baron et al 2005; 
Altarejos et al 2005). Further study is necessary to determine if adrenaline affects the 
activities  of any of these  AMPKKs.  Alternatively,  adrenaline  could  affect Thrl72 
phosphorylation  by  a  direct  covalent  modification  of AMPKKs  or AMPK,  which 
prevents Thrl72 phosphorylation by a mechanism other than reduction in AMPKK 
catalytic activity. For example, adrenaline could decrease Thrl72 phosphorylation by 
preventing  the  association  of AMPK  with  AMPKKs,  by  making  AMPK  a  better 
substrate for a protein phosphatase, or by increasing affinity of AMPK for ATP. In 
this regard, it is of note that adrenaline increased phosphorylation of the AMPK pi 
subunit.  Further study is required to  identify the residue(s) phosphorylated and the 
role of this phosphorylation in the inactivation of AMPK by adrenaline. A number of 
phosphorylation sites have been identified on the pi  subunit including Ser24, Ser25, 
Ser96, SerlOl, Serl08, and Seri82 (Mitchelhill et al 1997; Woods et al 2003; Chen 
et  al  1999).  It  was  found  adrenaline  did  not  increase  phosphorylation  of  Ser24. 
Preliminary experiments  by Richard  Heath  also  suggested  that phosphorylation of 
Seri08  and  Seri82  were  not  increased  by  adrenaline.  Thus,  adrenaline  might 
increase phosphorylation at Ser25,  Ser96,  SerlOl, or an other yet unidentified site.
135The  pi  subunit contains  21  serine residues  and  15  threonine  residues  (Chen  et al 
1999) which could be potentially phosphorylated.
Although  one  potential  clue  to  understanding  the  mechanism  of  the  effect  of 
adrenaline  is  the  observation  that  the  increase  in  AMPK  activity  and  Thrl72 
phosphorylation  induced  by  sorbitol  or  palmitate  was  markedly  inhibited  by 
adrenaline,  at  present,  very  little  is  known  about  how  these  conditions  increase 
Thrl72 phosphorylation. It has been reported in cultured cells that although LKB1  is 
required  for  phosphorylation  of Thrl72  by  hyperosmolarity,  catalytic  activity  of 
LKB1  is  unaffected  (Woods  et  al  2003,  Shaw  et  al  2003).  Thus,  like  AMP, 
hyperosmolarity also appears to increase Thrl72 phosphorylation by making AMPK 
a better substrate for LKB1. The facilitation of Thrl72 phosphorylation by AMP is 
thought to be due to a conformational change of the AMPK complex which exposes 
Thrl72  (Cheung  et  al  2000).  It  is  possible  that  activation  of  AMPK  by 
hyperosmolarity involves a similar conformational change of AMPK or, as suggested 
for  activation  of  AMPK  by  metformin  (Zou  et  al  2004),  it  involves  increased 
association  of LKB1  with  AMPK.  The  mechanism  by  which  fatty  acids  activate 
AMPK also does not appear to involve stimulation of LKB1  catalytic activity (Watt 
et  al  2006),  and  might  also  involve  making  Thrl72  a  better  substrate  and/or 
activation of other AMPKKs.
It appears there is considerable tissue-specific difference in adrenergic signalling and
AMPK regulation.  In contrast to the present finding that adrenaline inhibits AMPK
in  cardiac  myocytes,  adrenergic  agents  have  been  reported  to  increase  AMPK
activity  and/or  Thrl72  phosphorylation  in  skeletal  muscle  cells  and  adipocytes
(Section  1.6.5.p).  It has  been  shown that the  activation of AMPK in adipocytes  is
mediated by the (3  receptor and is mimicked by cAMP-raising treatments (Yin et al
2003;  Daval  et al 2005;  Hutchinson et al 2005).  The mechanism by which cAMP
signalling activates  AMPK in  adipocytes  is unknown.  However,  in  liver,  glucagon
has  been  shown  to  increase  AMPK  Thrl72  phosphorylation  and  this  has  been
suggested  to  be  due  to  PKA  phosphorylation  of LKB1  at  Ser428  (Kimball  et al
2004). Phosphorylation of this site has been implicated in the increased association
of LKB1  with AMPK (Xie et al 2006).  Thus,  P receptor stimulation in adipocytes
may  also  involve  PKA  phosphorylation  of  LKB1.  However,  in  contrast  to
136adipocytes, stimulation of the p receptor does not activate AMPK in skeletal muscle, 
indicating cAMP/PKA does not regulate AMPK in skeletal muscle (Minokoshi et al 
2002).  Moreover,  a  very  recent  study  has  reported  that  cAMP-raising  conditions 
decrease AMPK activity and Thrl72 phosphorylation in INS-1, MEF, and COS cells 
(Hurley  et  al  2006).  This  effect  has  been  reported  to  be  due  to  inhibition  of the 
catalytic  activity  of  CAMKKa  and  P  and  to  PKA  phosphorylation  of  AMPK 
Ser485/491 (Hurley et al 2006). CAMKKp is also expressed in the heart (Allard et al
2006).  However,  cAMP-raising  agents  did  not  affect  AMPK  activity  in  cardiac 
myocytes.  Ser485/491  phosphorylation  was  also  found  not  to  be  increased  by 
adrenaline despite activation of PKA as evidenced by increased phosphorylation of 
PLB  Seri 6 . The activation of AMPK in skeletal muscle by noradrenaline has been 
reported  to  be  mediated  by the  ai  receptor  (Hutchinson  and  Bengtsson  2006).  ai 
receptor-mediated Ca2+ signalling has been implicated in the activation of AMPK in
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this tissue because the  effect was mimicked by a Ca  ionophore (Hutchinson and
Bengtsson  2006).  Activation  of  AMPK  by  Ca2+-raising  treatments,  including
stimulation of Gq coupled receptors has been observed in several other cell types and
it is likely to be due to activation of CAMKKs (Section 1.6.5.h). However, it appears
that raising Ca2+ does not activate AMPK in cardiac myocytes. Although Ca2+ was
not  measured  in  the  present  study,  adrenaline  increased  activity  of  CAMKII,
indicating activation of Ca2+ signalling. In the present study, phorbol ester was found
to inhibit AMPK activity. However, phorbol ester has been reported to have no effect
on AMPK in skeletal  muscle  (Hutchinson and  Bengtsson 2006),  while it has been
shown to activate AMPK in endothelial cells (Xie et al 2006). The effect of phorbol
ester  in  endothelial  cells  was  probably  due  to  activation  of PKC^,  possibly  via
activation of PI3K and PDK1  (Farese 2002), as it was abolished by an inhibitor for
PKC^. As mentioned above, there is the possibility that PKC^ also activates AMPK
in cardiac myocytes. Although the present observation that PMA inhibited AMPK in
cardiac  myocytes  apparently  contradicts  this  possibility,  phorbol  ester  has  been
reported to have no effect on the activation of PKC^ in cardiac myocytes (Puceat et
al  1994).  The  reason  for  these  tissue-specific  effects  of adrenergic  signalling  on
AMPK is unknown, but it may be partly due to difference in expression pattern of
AKAPs,  PKC  anchoring  proteins,  or  different  compartmentalisation  of  Ca2+
signalling.  It could also be due to differences in expression of AMPKKs and other
AMPK-associated  proteins.  The  tissue  specificity  of the  hormonal  regulation  of
137AMPK is not unique to adrenergic agents. Both leptin and ghrelin have been shown 
to have different effects on AMPK in different tissues (Sections 1.6.5.i and j).
It is not clear whether adrenaline decreases cardiac AMPK activity in vivo. Although
adrenaline appears to have a direct inhibitory effect on AMPK in cardiac myocytes,
the  observations  in perfused hearts made  in the present  study and  in the previous
study by Clark et al suggest that the activation of AMPK by palmitate is essential for
the effect of adrenaline to inactivate AMPK in perfused hearts. However, because the
heart  is  normally  exposed  to  long  chain  fatty  acids  in  vivo,  it  is  possible  that
adrenaline decreases cardiac AMPK activity in vivo. However, at present, there is a
considerable controversy in the literature over the effect of long chain fatty acids to
activate  AMPK.  Apart  from  the  previous  study  by  Clark  et  al,  the  activation  of
AMPK  by  long  chain  fatty  acids  has  been  reported  in  cultured  neonatal  cardiac
myocytes and in skeletal muscle cells (Hickson-Bick et al 2000; Fediuc et al 2006;
Watt et al 2006).  However,  other investigators have  failed to  see  an activation  of
AMPK by long chain fatty acids in perfused hearts or in rat skeletal muscle (Crozier
et al 2005;  Folmes  et al 2006;  Olsen and  Hansen  2002).  Crozier et al have  even
reported  a  decrease  in  AMPK  Thrl72  phosphorylation  in  hearts  perfused  with
palmitate compared to hearts perfused with glucose alone (Crozier et al 2005). An in
vivo study showed that dietary polyunsaturated fatty acids decreased the extent of a
decrease  in  rat  hepatic  AMPK  Thrl72  phosphorylation  and  activity  seen  during
fasting/refeeding (Suchankova et al 2005), implying activating effect of fatty acids.
In contrast, a study by Dobrzyn et al in mice  showed that dietary polyunsaturated
fatty  acids  did  not  cause  any  change  in  AMPK  Thrl72  phosphorylation  in  liver,
skeletal muscle, and heart (Dobrzyn et al 2005). The lack of the effect of fatty acids
to  activate  AMPK  may  explain  the  observation  by  King  et  al  that  infusion  of
dobutamine did not decrease cardiac AMPK activity in vivo (King et al 2005). In the
present study, although a significant 2- to 3- fold activation of AMPK by palmitate
was observed in cardiac myocytes in the early stage of the study, this marked effect
was subsequently lost for unknown reasons. Palmitate also did not activate AMPK in
perfused hearts indicating the loss of the effect is not related to myocyte isolation. It
is  still  possible  that  hearts  perfused  with  glucose  alone  were  energetically
compromised,  and  the  AMPK-activating  effect  of  palmitate  was  blunted  by  a
simultaneous effect of palmitate to increase ATP production and so inhibit AMPK.
138However,  this  is  unlikely because  HPLC  analysis  of the  total  adenine  nucleotides 
showed  that  the  AMP/ATP  ratio  in  the  hearts  perfused  with  glucose  alone 
(0.067±0.02,  n=4)  was  not  significantly  different  from  that  in  the  hearts  perfused 
with palmitate (0.087±0.02, n=4).
The  observation  that  adrenaline  inhibited  activation  of  AMPK  by  sorbitol  in 
myocytes  suggests  that  adrenaline  may  inhibit  cardiac  AMPK  in  vivo  during 
hyperosmotic situations.  However, it is not known whether this  inhibitory effect of 
adrenaline on hyperosmolarity-induced activation of AMPK holds in the heart, and 
whether relatively small physiological fluctuations in blood osmolarity affect cardiac 
AMPK activity significantly.
Studies  in  cardiac  myocytes  and  skeletal  muscle have  suggested that  activation  of 
AMPK attenuates protein translation through activation of eEF2 kinase and through 
inhibition of the mTOR-p70  S6  kinase pathway (Chan and Dyck 2005).  Moreover, 
activation  of  AMPK  by  AICAR  or  adiponectin  has  been  shown  to  inhibit  ai 
adrenergic  receptor-induced hypertrophic response in cardiac myocytes (Chan et al 
2004;  Shibata et al 2004).  Therefore, the  inhibition of AMPK by adrenaline could 
potentially play a role  in the development of hypertrophy by prolonged  adrenergic 
stimulation. It appears that AMPK has an anti-apoptotic role in the heart (Terai et al 
2005; An et al 2006). Thus, the effect of adrenaline to inhibit AMPK might also be 
involved  in  adrenergic  stimulation  of  apoptosis.  Both  AMPK  and  adrenergic 
stimulation  regulate  some  of the  key  enzymes/processes  involved  in  glucose  and 
fatty acid catabolism, namely glucose uptake, PFK2, and ACC2. Cardiac ACC2 has 
been  shown  to  be  phosphorylated  and  inactivated  by  PKA  and  AMPK  in  vitro 
(Boone et al  1999).  Although phosphorylation of ACC has been shown to occur in 
cardiac  myocytes  in  response  to  isoproterenol  (Boone  et  al  1999),  it  has  been 
reported that adrenaline does not change ACC activity in perfused hearts (Goodwin 
and  Taegtmeyer  1999).  This  observation  may  be  explained  by  the  inhibition  of 
AMPK  activity  by  adrenaline.  In  hearts  exposed  to  fatty  acids  (e.g.  in  the  above 
study by Goodwin and Taegtmeyer and in vivo hearts), it is possible that there is high 
basal phosphorylation of ACC2 by AMPK due to activation of AMPK by fatty acids. 
Adrenergic  stimulation  increases  PKA-driven phosphorylation of ACC2,  but at the
same time removes the inhibitory effect of ACC2 by AMPK by inactivating AMPK.
139This  might result in no  net change  in ACC2  activity.  The  inhibition of AMPK by 
adrenaline  is  contradictory  to  the  effect  of  the  hormone  to  stimulate  glucose 
catabolism in the heart.  Similar paradoxical effects are also seen for insulin, which 
has been reported to inactivate cardiac AMPK but is also known to stimulate glucose 
uptake  and  glycolysis  (Folmes  et al 2006).  It  may be  possible  that  the  activating 
effect  of adrenaline  on  glucose  catabolism  (e.g.  through  PKA  and  Ca  -dependent 
mechanisms)  dominates  over the  inhibitory effect due to removal  of the activating 
effect  of AMPK.  Alternatively,  there  may  be  mechanisms  to  ensure  that  glucose 
catabolism is increased by adrenaline despite inhibition of AMPK. For example, the 
pool of AMPK that regulates glucose uptake and glycolysis may not be inhibited by 
adrenaline  due  to  compartmentalisation  of  adrenergic  signalling.  The  effect  of 
adrenaline  to  inhibit  AMPK  may  actually  be  a  mechanism  to  fine-tune  fuel 
catabolism  according  to  the  energy  demand  of  the  heart.  During  adrenergic 
stimulation,  contractile  activity  is  stimulated,  increasing  the  demand  for  energy. 
Normally,  this  increase  in  demand  for  energy  is  adequately  met  by  adrenergic 
stimulation of fuel catabolism (e.g. through PKA and Ca2+-dependent mechanisms), 
so adrenaline turns off AMPK to prevent over-stimulation of catabolism.  However, 
the energy demand  arising  from more  intense contractile activity is not adequately 
met  by  adrenergic  stimulation  of  catabolism,  and  under  these  conditions  the 
AMP/ATP ratio begins to rise. This increase in the AMP/ATP ratio turns on AMPK. 
The  present  result  shows  that  the  inhibitory  effect  of  adrenaline  on  AMPK  is 
markedly blunted when AMPK is activated by the AMP-pathway. Thus, under these 
conditions, AMPK and adrenergic stimulation synergistically stimulate catabolism to 
meet the extra demand for energy.
1403.10  Conclusion
The  original  aim  of the  present  study was  to  investigate  the  adrenergic  signalling 
pathway responsible for the effect of adrenaline to inhibit palmitate-induced AMPK 
activation.  The  present results  suggest that,  in  addition to  activation  of AMPK by 
palmitate,  adrenaline  may  also  inhibit  activation  of  AMPK  by  sorbitol-induced 
hyperosmolarity.  In  contrast  to  the  observation  in perfused  hearts,  adrenaline  also 
showed  an  apparently  direct  inhibitory  effect  on  AMPK.  Because  the  effect  of 
palmitate to  activate AMPK was  lost during the present study,  this direct effect of 
adrenaline  on  AMPK  was  investigated.  The  present  data,  particularly  the 
observations that ( 1) the effect of adrenaline was independent of a detectable change 
in  the  AMP/ATP  ratio,  (2)  the  effect  was  mimicked  by  PMA,  (3)  adrenaline 
increased phosphorylation of the AMPK |31 subunit suggest the possibility of a novel 
signalling/mechanism  which  regulates  AMPK.  The  results  from  the  present  study 
also highlight the tissue specificity of adrenergic signalling and AMPK regulation.
1413.11  Suggestions for further study
1.  Investigation  of  whether  a  change  in  NAD+/NADH  is  responsible  for  the 
inhibitory effect of adrenaline on AMPK.
2.  Investigation  of  the  effect  of  adrenaline  with  electrically  stimulated  cardiac 
myocytes  to  determine  if contraction  is  responsible  for  the  lack  of the  effect  of 
adrenaline in perfused hearts.
3. Characterisation of the inhibitory effect of adrenaline on AMPK in the presence of 
sorbitol to clarify if the inhibitory effect seen when AMPK is activated by sorbitol is 
mechanistically identical to the effect of adrenaline under basal conditions.
3.  Investigation  of the  effect  of hyperosmolarity  on  AMPK  activation  in perfused 
hearts and the effect of adrenaline on hyperosmolarity-induced AMPK activation.
4.  Investigation  of the  effect  of adrenaline  on  the  AMP-independent  activation  of 
AMPK by hypoxia and metformin.
5.  Investigation  of the  adrenoreceptor  subtypes  mediating  the  effect  of adrenaline 
using selective agonists and antagonists.
6 .  Investigation of G proteins involved in the effect of adrenaline using CTX, PTX, 
and a Gq inhibitor.
7.  Determination  of the  effect  of selective  PKC  inhibitors  on  ai  and  (3   mediated 
effect.
8 .  AMPKK  activity  assay  using  recombinant  AMPK  with  total  cell  lysates  or 
CAMKK0  and  LKB1  immunoprecipitated  from  cardiac  myocytes  treated  with  or 
without adrenaline.
9. Investigation of the effect of adrenaline on association of AMPK with AMPKKs.
10.  Investigation  of the  effect  of adrenaline  on  phosphorylation  of the  AMPK  02 
subunit.
11.  Identification  of  the  site  on  01  subunit  phosphorylated  by  adrenaline  and 
investigation  of the  role  of this  site  in  the  effect  of adrenaline  by  site  directed 
mutagenesis.
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